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ABSTRACT 
Identification of suitable biomarkers is growing increasingly important for the treatment of 
rheumatoid arthritis (RA). They can be measured in a number of different biological materials 
and can provide clinical information regarding prediction, diagnosis, and prognosis of disease, 
as well as response to therapeutics.  
In this thesis, I utilised synovial biopsies collected from patients enrolled in the Birmingham 
Early Inflammatory Arthritis Cohort (BEACON) to test the hypothesis that detection of 
expression of CXCL4 and CXCL7 may be used to predict progression of early stage synovitis 
to RA. I found that these two chemokines, CXCL4 and CXCL7, were predominantly 
expressed on macrophages within the synovium of patients presenting with early synovitis. 
Increased CXCL4 and CXCL7 was observed in patients with early RA compared to those 
with a resolving disease course. However, this increase was transient as expression in 
treatment naive established RA patients (>12 weeks duration, <3 years duration) was 
comparable to uninflamed controls.  
Moreover, I identified expression of a variant of CXCL4, CXCL4L1 in the rheumatoid 
synovium. Expression of this potent inhibitor of angiogenesis was evident in the lining layer 
of the synovium.  
These data highlight CXCL4 and CXCL7 as potential predictors of disease outcome in 
patients presenting with early synovitis.  
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1 INTRODUCTION 
 
1.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic, debilitating inflammatory disease that affects 
approximately 1% of the world’s population. The onset of disease occurs most commonly in 
the fifth decade of life, with increased numbers of cases being reported in females rather than 
males. It manifests as symmetrical painful, reddened, swollen joints (Gorman and Cope, 
2008, Iwamoto et al, 2008). The joints commonly affected by RA include the wrists, knees, 
fingers and toes (Smolen and Redlich, 2014). Chronic joint inflammation ultimately leads to 
bone and cartilage degradation, deformity and disability. Further complications can arise in 
patients suffering from RA including cardiovascular, respiratory, musculoskeletal and 
neurological problems. Patients with RA are more likely to develop premature atherosclerosis 
and myocardial infarction than those unaffected (Karatoprak et al, 2012).  
 
Due to the presence of autoantibodies to citrullinated proteins (ACPA) and/or Rheumatoid 
Factor (RF) in a large proportion of patients, RA is considered an autoimmune disease 
(Gorman and Cope, 2008). ACPA target proteins that have undergone post translational 
modification of amino acid side chains from arginine to citrulline by peptidylarginine 
deiminase (PAD) enzymes (Figure 1.1). Proteins that may be subject to this post translational 
modification include collagen, α-enolase, vimentin, and fibrin (Smolen and Redlich, 2014). 
RF is directed towards the Fc domain of IgG antibodies. It is present in approximately 75% of 
RA patients, but it is not specific for RA as it is reported in other autoimmune diseases as well 
as in 5% of the healthy population (Nijenhuis et al, 2004). The presence of both 
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autoantibodies can be found a number of years prior to the onset of clinically apparent 
disease. In addition to ACPA and RF, antibodies directed against carbamylated proteins (anti-
CarP antibodies) may be useful predictors of RA as their presence also predates the onset of 
clinical symptoms (Shi et al, 2013). Carbamylation is a post translational modification 
involving cyanate. It results in a modification of lysine to homocitrulline (Figure 1.1) (Shi et 
al, 2013). Under normal conditions, cyanate is maintained in equilibrium with urea. Cyanate 
levels may also increase during inflammation due to the release of hydrogen peroxide and 
myeloperoxidase from neutrophils which drive the loss of equilibrium between thiocyanate 
and cyanate. A shift towards an increase in cyanate results in subsequent protein 
carbamylation (Trouw et al, 2013). Anti-carbamylated protein antibodies have been identified 
in both ACPA positive RA (49-73%) and ACPA negative RA (8-14%) patients (Jiang et al, 
2014). They have also been identified in patients suffering from arthralgia (Shi et al, 2013) 
and juvenile idiopathic arthritis (Hissink Muller et al, 2013).  
 
 
Figure 1.1 Citrullination and Carbamylation: Two post translational modifications 
recognised by autoantibodies.  Figure from Trouw et al, 2013. 
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Although the exact aetiology of RA is unknown, there is strong evidence linking genetic 
factors, such as HLA-DR and PTPN22 (Bowes and Barton, 2008, Silman and Pearson, 2002), 
gender, and environmental factors, such as cigarette smoking and infectious diseases (Epstein-
Barr virus, Porphyrymonas gingivalis, Proteus and Mycoplasma), to the pathogenesis of RA 
(Silman and Pearson, 2002). Pregnancy and the use of the oral contraceptive pill may be 
associated with a decreased risk of RA, whilst the postpartum period following pregnancy and 
breast feeding after the first pregnancy poses an increased risk to the development of RA 
(Silman and Pearson, 2002). This may indicate a role for hormones in the development of RA. 
Overall, the contribution of genetic factors to the risk of developing RA is approximately 60% 
(Bowes and Barton, 2008), whereas 40% is attributed to environmental risk factors.  
 
Part of the heritability of RA and its association with the HLA-DR positioned on chromosome 
6 (6p21.3) can be explained by the ‘shared epitope’ hypothesis. The ‘shared epitope’ is 
encoded by a number of different susceptibility alleles; HLA-DR4 (DRB1*0401, *0404, and 
*0405), HLA-DR1 (DRB1*0101 and *0102), and HLA-DR10 (DRB1*1010). In the 
Caucasian population the HLA-DRB1*0401 and *0404 alleles are associated with the greatest 
risk of RA (De Almeida et al, 2011, Gregersen et al, 1987, Pratesi et al, 2013). Individuals 
who are heterozygous for HLA-DRB1*0401/*0404 have been associated with suffering early 
onset disease that is far more severe (Bowes and Barton, 2008). Furthermore the combination 
of cigarette smoking and the ‘shared epitope’ genes further increases the risk of developing 
RA (Lee et al, 2007). In the Asian population, the allele associated with the greatest risk of 
RA is HLA-DRB1*0405. These alleles encode an amino acid sequence from position 70 to 74 
(70QRRAA74, 70KRRAA74, or 70RRRAA74) in the third hypervariable region (HVR3) of 
the first domain of the HLA-DRβ1 chain. Alleles that offer protection against RA or that lead 
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to a less erosive form of RA have also been identified; HLA-DRB1*0103, *0402, *1102, 
*1103, *1301, *1302, and *1304. These alleles encode an amino acid sequence with a 
negatively charged aspartic acid residue at position 70 or encode the sequence 70DERAA74 
(Pratesi et al, 2013). The ‘shared epitope’ amino acid sequences are found in the MHC class II 
peptide binding groove and therefore may influence antigen presentation in RA. 
 
The protein tyrosine phosphatase, non-receptor type 22 (PTPN22) gene located on 
chromosome 1p13 has also been associated with RA as well as in other autoimmune diseases 
such as type I diabetes mellitus, Hashimoto’s thyroiditis, Addison’s disease and systemic 
lupus erythematosus (SLE). A single nucleotide polymorphism (SNP) in the PTPN22 gene 
(Rs2476601, 1858C>T, R620W), is evident in 13.8% of RA patients compared to 8.8% of 
controls (Begovich et al, 2004).  PTPN22 encodes a 110 kDa cytoplasmic protein lymphoid 
tyrosine phosphatase, known as Lyp. Lyp functions as a down regulator of effector T cell and 
memory T cell receptor signalling pathways through its association with the SH3 domain of 
Csk. Therefore the PTPN22 polymorphism may be associated with RA due to the inability of 
the variant Lyp phosphatase to bind Csk and down-regulate T cell activation (Begovich et al, 
2004). 
 
Although the HLA-DRB1 alleles and the PTPN22 polymorphism account for a large 
proportion of the genetic susceptibility to RA, several other genes have been associated with 
the development and severity of RA including PADI4, STAT4, PRKCQ, TRAF1/C5, CTLA4 
and the 6q23 region (Bowes and Barton, 2008, Okada et al, 2014).  
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1.2 Early rheumatoid arthritis 
With an estimated cost to the UK economy of £3.8-4.75 billion per year, RA is considered a 
major economic burden (NICE, UK). It is therefore essential to diagnose patients as early as 
possible and target expensive therapeutics to those who are most likely to respond. There is 
evidence to support a ‘window of opportunity’ hypothesis in early RA whereby patients 
diagnosed within 3 months of disease onset (Early RA) are more likely to benefit from 
treatment with disease modifying anti-rheumatic drugs (DMARDs) and various biological 
agents such as rituximab and etanercept than patients diagnosed later in disease (Cush, 2007). 
Early treatment appears to result in reduced disease activity score and the achievement of 
clinical remission (Demoruelle and Deane, 2012). The psychosocial consequences of disease 
such as work place disability leading to loss of employment as well as patient fatigue, pain 
and emotional stress may also be prevented by earlier treatment.  
 
1.3 The classification of rheumatoid arthritis 
The American Rheumatism Association (ARA) derived the 1987 criteria for the classification 
of RA. The revised criteria were drawn up based on the previous 1958 ARA criteria with the 
aim of simplifying and improving the specificity and sensitivity of the classification. 
Although classification criteria are predominantly used in clinical trials to standardise the 
enrolled participants, they may also be used within the clinic to aid in the routine diagnosis of 
RA (Cornec et al, 2012). In order to reach a diagnosis of RA using the ARA 1987 
classification criteria, at least 4 out of the 7 criteria must be present and criteria 1-4 must be 
evident for at least 6 weeks. The criteria included morning stiffness of at least 1 hour before 
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improvement, arthritis of 3 or more joints, symmetric arthritis and the presence of serum 
rheumatoid factor (Table 1.1).  
 
In 2010, the American College of Rheumatology / European League against Rheumatism 
(ACR/EULAR) collaborative group reassessed the classification criteria for RA. This was 
done, as the previous 1987 classification criteria were deemed too insensitive for the 
diagnosis of early RA. The 2010 ACR/EULAR criteria is split into 4 domains; joint 
involvement, serology, acute-phase reactants, and duration of symptoms. Each domain is 
assessed and given a score (Table 1.2). The scores from each individual domain are then 
combined and a classification is given. A score of ≥6/10 is regarded as ‘definite’ RA. An 
advantage of the 2010 ACR/EULAR criteria over the ARA 1987 classification criteria is the 
ability to identify patients at an earlier stage of disease rather than at the established stage.   
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Criterion Definition 
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 
hour before maximal improvement 
2. Arthritis of 3 or more joint 
areas 
At least 3 joint areas simultaneously have had soft tisse 
swelling or fluid (not bony overgrowth alone) observed by a 
physician. The 14 possible areas are right or left PIP, MCP, 
wrist, elbow, knee, ankle, and MTP joints 
3. Arthritis of hand joints At least 1 area swollen (as defined above) in a wrist, MCP, or 
PIP joint 
4. Symmetric arthritis Simultaneous involvement of the same joint areas (as defined 
in 2) on both sides of the body (bilateral involvement of PIPs, 
MCPs, or MTPs is acceptable without absolute symmetry)  
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxtaarticular regions, observed by a physician 
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been positive in 
<5% of normal control subjects 
7. Radiographic changes Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must 
inclide erosions or unequivocal bony decalcification localized 
in or most marker adjacent to the involved joints 
(osteoarthritis changes alone do not qualify) 
 
*For classification purposes, a patient shall be said to have rheumatoid arthritis if he/she has 
satisfied at least 4 of these 7 criteria. Criteria 1 through 4 must have been present for at least 6 
weeks. Patients with 2 clinical diagnoses are not excluded. Table from Arnett et al, 1988.  
Table 1.1 The American Rheumatism Association 1987 criteria for the classification of 
rheumatoid arthritis 
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 Score 
A. Joint involvement 
1 large joint 
2-10 large joints 
1-3 small joints (with or without involvement of large joints) 
4-10 small joints (with or without involvement of large joints) 
>10 joints (at least 1 small joint) 
 
0 
1 
2 
3 
5 
B. Serology (at least 1 test result is needed for classification) 
Negative RF and negative ACPA 
Low-positive RF or low-positive ACPA 
High-positive RF or high-positive ACPA 
 
0 
2 
3 
C. Acute-phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR 
 
0 
1 
D. Duration of symptoms 
<6 weeks 
≥6 weeks 
 
0 
1 
  
*Classification criteria for the diagnosis of rheumatoid arthritis. For a patient to be diagnosed 
with ‘definite’ RA a total score of ≥6/10 must be achieved. Table from Aletaha et al, 2010. 
Table 1.2 The 2010 American College of Rheumatology/European League Against 
Rheumatism classification criteria for rheumatoid arthritis. 
 
1.4 The synovium 
The synovium is a thin membrane that lines the joint cavity. It is the site of synovial fluid 
production which acts to lubricate, maintain mobility, and provide nutrition to the 
cartilaginous surfaces.  The synovium is divided into two regions termed; the synovial lining 
layer and the synovial sublining layer. The synovial lining is approximately 2-3 cell layers 
thick and consists of two different cell types; type A macrophage-like synoviocytes, and the 
type B fibroblast-like synoviocytes. In the normal synovium, the macrophage-like 
synoviocytes account for 10-20% of the lining layer.  
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The type A macrophage-like synoviocytes can be characterised by their expression of the 
surface markers; CD11b, CD14, CD16α, CD68, and CD163. They also express MHC class II 
molecules, as well as neuron-specific esterase and the cathepsins B, D, and L (Pap et al, 
2000). Type A macrophage-like synoviocytes may play an important role in the presentation 
of antigen as well as removal of cellular debris from the joint by phagocytosis. Type B 
fibroblast-like synoviocytes express uridine diphosphoglucose dehydrogenase (UDPGD) 
required for the synthesis of hyaluronic acid, and CD55. Furthermore they express vascular 
cell adhesion molecule (VCAM-1), intracellular adhesion molecule (ICAM-1), β1 integrins 
and cadherin-11. The type B fibroblast-like synoviocytes synthesise a number of 
glycoproteins including lubricin, fibronectin and laminin, and furthermore during 
inflammation they produce a large number of inflammatory mediators including cytokines, 
matrix metalloproteinases and prostaglandins (Bartok and Firestein, 2010).  
 
The synovial sublining layer is highly vascularised with a rich network of arterioles, venules 
and capillaries (Haywood and Walsh, 2001). It can be split into three different tissue 
subtypes; adipose, areolar and fibrous. The adipose tissue is largely characterised by the 
presence of adipocytes. Areolar tissue is the most common tissue type and is often found in 
larger joints. It is folded in appearance into villous projections. The fibrous sublining is poorly 
vascularised and often resembles fibrocartilage. The normal synovial sublining contains very 
few inflammatory cells. Those that are present may include CD4+ and CD8+ T cells and B 
cells.  
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Figure 1.2 The synovium in early rheumatoid arthritis. Haematoxylin and Eosin stained 
synovial tissue biopsy from an early RA patient enrolled in the BEACON cohort (BX115). A 
large number of blood vessels surrounded by inflammatory infiltrate is evident in the 
sublining. Images were taken using the Nikon Eclipse E400 microscope at A) x200 total 
magnification and, B) x400 total magnification by Nichola Adlard and Dagmar Scheel-
Toellner. 
 
 
In RA, the main site of inflammation is the synovium with evidence of synovial lining 
hyperplasia accompanied by an infiltrate of inflammatory cells into the synovium, including T 
cells, B cells, plasma cells, dendritic cells (DCs), macrophages, mast cells and neutrophils 
(Kraan et al, 1999).  The synovial lining that was once 2-3 cells layers thick can expand up to 
10-20 cell layers thick (Figure 1.2). This expansion is a result of an increase in the number of 
both type A macrophage-like and type B fibroblast-like synoviocytes (Bartok and Firestein, 
2010). In the sublining, T cells, which are predominantly CD4+CD45RO+ memory cells, are 
accountable for 30-50% of the infiltrating cells. CD8+ T cells are also evident and are often 
found scattered throughout the synovium (Pratts et al, 2009). B cells numbers vary 
considerably between patients and may be involved in autoantibody production (Bartok and 
Firestein, 2010). The synovial fluid is also rich in inflammatory cells during RA, with mostly 
neutrophils present (Iwamoto et al, 2008). Pannus tissue, which is characteristic of RA 
pathology, acts like a locally invasive tumour. It is rich in type B fibroblast-like synoviocytes, 
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macrophages, and osteoclasts. Osteoclasts play an important role in the pathogenesis of RA 
by degrading bone via the production of matrix metalloproteinases (MMPs), hydrochloric 
acid and cathepsin K (Väänänen et al, 2000). Osteoclastogenesis is driven by the expression 
of RANKL and MCSF in the synovium. RANKL is expressed by synovial fibroblasts, B cells 
and T cells. The type B fibroblast-like synoviocytes also play a role in the degradation of 
cartilage via the release of a number of proteases including MMPs. Both resident and 
infiltrating inflammatory cells are a rich source of chemokines and cytokines, including 
TNFα, IL-1, IL-6, IL-17 and IL-23 (Gorman and Cope, 2008, McInnes and Schett, 2007).  
 
1.5 Macrophages 
Macrophages and monocytes belong to the mononuclear phagocytic system (Chow et al, 
2011). Monocytes are small (12-20 µm in diameter) cells with kidney shaped nuclei. They are 
accountable for 2-8% of peripheral blood mononuclear cells. Monocytes differentiate from 
common myeloid progenitor cells within the bone marrow and are subsequently released into 
the blood whereby they circulate for 12-32 hours before migrating into tissues. Monocytes 
may be classified into three different subsets based on cell surface marker and chemokine 
receptor expression; classical, intermediate, and non-classical (Chow et al, 2011). Classical 
monocytes (90-95% of circulating monocytes) are CD14hi, CD16-, CD64+, CD62L+, CCR2hi, 
and CX3CR1low. They possess phagocytic and anti-microbial functions. Intermediate 
monocytes (2-11% of circulating monocytes) are pro-inflammatory cells that express CD14hi, 
CD16+, CD64+, CCR2low, and CX3CR1hi (Yang et al, 2014). They produce high levels of 
TNFα, IL-1β and IL-6. Non-classical monocytes (5-10% of circulating monocytes) are anti-
inflammatory cells that produce IL-1RA. They express CD14low, CD16hi, CD64-, CCR2low, 
and CX3CR1hi. As for murine monocytes, they are also classified into classical (60% 
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circulating monocytes), intermediate and non-classical groups (40% circulating monocytes). 
Murine monocyte cell surface markers differ from their human counterparts. They are 
grouped based on Ly6C, CD43, and CD11b expression. Murine monocytes do, however, 
express the same chemokine receptors, CCR2 and CX3CR1 (Chow et al, 2011).  
 
Once in the tissue, monocytes differentiate into macrophages. Macrophages are much larger 
(25-50 µm in diameter) and reside in the tissue for 2-4 months. Within the tissues, 
macrophages are subdivided into different subpopulations based on their anatomical location. 
For example, macrophages within the liver are referred to as Kupffer cells, in the bone; 
osteoclasts, and within the central nervous system; microglia (Murray and Wynn, 2011, Zhou 
et al, 2014). Macrophages play an important role in both the innate and adaptive immune 
system. They are professional phagocytic cells that can engulf invading pathogens as well as 
cellular debris and apoptotic cells. Macrophages can also present processed antigen to T cells 
in the context of MHC class II (Gordon, 2014, Mosser, 2003).  
 
Similar to the classification of T cells into Th1/Th2/Th17/Treg subsets, macrophages have 
been loosely grouped into two subsets referred to as M1 macrophages and M2 macrophages, 
although their phenotypes probably represent extremes of a continuous spectrum seen in 
humans in vivo. M1 macrophages, also described as classically activated macrophages, have a 
pro-inflammatory phenotype (Murray and Wynn, 2011). They can be induced by IFNγ, LPS, 
GM-CSF and TNF-α, and as a result M1 macrophages secrete a large number of pro-
inflammatory mediators including cytokines; IL-1, IL-6, TNFα, IL-12, and IL-23, and 
chemokines; CXCL9, CXCL10 and CXCL11 (Koh and DiPietro, 2011, Li et al, 2012). M1 
  
13 
 
macrophages are extremely effective at killing intracellular pathogens through the production 
of reactive oxygen species (ROS) and have an enhanced ability in presenting antigen in the 
context of MHC class II (Cassetta et al, 2011, Mosser, 2003). M2 macrophages, or 
alternatively activated macrophages, are poor killers of intracellular pathogens and are also 
not as effective as M1 ‘classically activated’ macrophages at presenting antigen in the context 
of MHC class II. M2 macrophages demonstrate an anti-inflammatory regulatory phenotype. 
Therefore they play important roles in the dampening of the inflammatory response, tissue 
repair through the release of extracellular matrix components, and in the resolution of 
inflammation (Murray and Wynn, 2011).  M2 macrophages are induced by IL-4, IL-10, IL-
13, TGF-β, M-CSF, immune complexes and glucocorticoids (Cassetta et al, 2011, Koh and 
DiPietro, 2011, Mosser, 2003).  M2 macrophages express increased levels of cytokines; IL-4 
and IL-10, and chemokines; CCL16, CCL17, CCL18, CCL22, CCL24. They also express the 
scavenger receptor CD163 and the mannose receptor CD206 (Li et al, 2012, Murray and 
Wynn, 2011). Due to the restrictive nature of the M1 and M2 classification system, 
macrophages may also be grouped based on their function; classically activated macrophages, 
wound healing macrophages and immune regulatory macrophages.  
 
In 2012, Schulz et al described an alternative origin for tissue-resident macrophages. It is well 
documented that renewal of haematopoietic cells arise from the differentiation of 
haematopoietic stem cells (HSCs). However, in this study, it was reported that tissue 
macrophages in the brain, lung, liver, and epidermis in the adult mouse originate from yolk 
sac derived erythro-myeloid progenitors (EMPs). It was reported that yolk sac derived 
macrophages may co-exist with macrophages derived from HSCs. Moreover Hashimoto et al 
(2013) reported that tissue resident macrophages repopulate independently of monocytes. 
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1.5.1 Macrophages in rheumatoid arthritis 
In RA, macrophages play a fundamental role in the pathogenesis of disease (Kennedy et al, 
2011, Li et al, 2012). They have been found in abundance in the rheumatoid synovium and at 
the cartilage-pannus junction, and account for 30-40% of the cellular infiltrate (Burmester et 
al, 1997, Kennedy et al, 2011, Kraan et al, 1999). Although within the rheumatoid synovium, 
synovial macrophages have neither been classified as M1 or M2, it has been reported that 
both pro- and anti- inflammatory macrophages are present. However, there is an imbalance 
towards the pro-inflammatory phenotype rather than the anti-inflammatory phenotype (Li et 
al, 2012). Synovial macrophages have been shown to secrete a large variety of 
proinflammatory mediators that drive inflammation and exacerbate joint destruction including 
IL-1, IL-6, TNFα, and IL-23 as well as a host of chemokines including CXCL5, CXCL7, 
CXCL8, CXCL9, CXCL10, CCL2, CCL3, CCL5 and CCL18, and ROS (Li et al, 2012, 
Szekanecz et al, 2007). In contrast, synovial macrophages have also been shown to release a 
variety of anti-inflammatory mediators including IL-10, TGF-β, soluble TNF-R, and IL-1Ra 
(Li et al, 2012). Synovial macrophages have also been shown to release matrix 
metalloproteinases -1, -2 and -9 (MMP-1, MMP-2 and MMP-9) which degrade articular 
cartilage and bone, tissue inhibitors of matrix metalloproteinases -1 and -2 (TIMP-1 and 
TIMP-2), and cathepsins B, L, S and K. Synovial macrophages play a role in supporting 
prolonged B cell activation via the secretion of B cell stimulating factor, BLys, and the 
proliferation-inducing ligand, APRIL (Szekanecz et al, 2007). They also drive T cell 
activation via the presentation of antigen in context with MHC class II and drive Th1 cell 
polarisation via the release of IL-12.  
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Synovial macrophages have been validated as a biomarker in RA with the number of CD68+ 
synovial macrophages in the synovial sublining being indicative of disease severity. 
Furthermore an increased number of macrophages have been observed in clinically affected 
joints as opposed to non-affected joints and the number of macrophages has been shown to 
correlate with radiographic progression (Burmester et al, 1997, Kennedy et al, 2011). 
Moreover, a reduction in the number of synovial macrophages may indicate a good response 
to therapy and has been reported to correlate with clinical improvement (Bresnihan et al, 
2007, Haringman et al, 2005, Wijbrandts et al, 2007). 
 
1.6 Plasmacytoid dendritic cells 
In the human, there are two main populations of dendritic cell (DC); myeloid and 
plasmacytoid. They play an important role in the induction of the innate and adaptive immune 
response, induction of tolerance, and establishment of immunological memory (Mclellan and 
Kämpgen, 2000). Myeloid DCs, or conventional DCs as they are often described, are a 
population of professional antigen presenting cells (APC). They originate in the bone marrow 
and subsequently migrate to the non-lymphoid tissues where they are referred to as immature 
DCs. It is within the non-lymphoid tissues where they encounter foreign pathogens. DCs 
phagocytose pathogens and migrate to the lymphoid tissue whereby they present processed 
antigen to both CD4+ and CD8+ T cells in the context of major histocompatibility molecules 
(MHC) (Banchereau et al, 2000). Plasmacytoid dendritic cells (pDCs) are a small population 
(0.3-0.5% of peripheral blood mononuclear cells) of professional antigen presenting cells that 
are Lineage-, MHC class II+, CD4+, CD45RA+, CD123+/IL-3Rα+, ILT3+, ILT1-, 
CD303+/BDCA-2+ and CD304+/BDCA-4+ (Colonna et al, 2004, Guéry and Hugues, 2013, 
Reizis et al, 2011). Human pDCs can be distinguished from myeloid dendritic cells (mDCs) in 
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that they do not express CD11c (Guéry and Hugues, 2013). However, murine pDCs do 
express low levels of CD11c (Swiecki and Colonna, 2010). Murine pDCs also differ from 
human pDCs in that they do not express the human specific pDC markers; BDCA-2, BDCA-
4, ILT-7 and CD123 but instead express Siglec-H, BST-2, Ly6C and Ly49Q (Reizis et al, 
2011, Swiecki and Colonna, 2010). Murine pDCs also express CD8 which may serve as a 
maturation and activation marker. Plasmacytoid dendritic cells were initially referred to as 
plasmacytoid T cells and later as plasmacytoid monocytes due to the expression of both 
lymphoid; CD4, and myeloid cell markers; CD68 and CD123/IL-3Rα (Swiecki and Colonna, 
2010). However, in the 1990s they were finally described as plasmacytoid dendritic cells 
(pDCs) after it was observed that isolated cells could differentiate to dendritic cells in the 
presence of IL-3 or IL-3 and CD40L. Plasmacytoid DCs are key players in antiviral immunity 
due to their ability to produce IFNα in response to viral infection (Mclellan and Kämpgen, 
2000). 
 
Plasmacytoid dendritic cells have been identified in the foetal thymus, liver and bone marrow 
(Colonna et al, 2004).  In the adult, pDCs are produced in the bone marrow and subsequently 
released into the blood (Guéry and Hugues, 2013). They arise from common dendritic cell 
progenitors that express CD115/M-CSFR, CD117/c-kit, and CD155/Flt3 (Guéry and Hugues, 
2013). When released, they migrate to the thymus and secondary lymphoid tissues including 
the mucosal associated lymphoid tissue, spleen, tonsil and lymph nodes (Colonna et al, 2004). 
They enter the lymph nodes via the high endothelial venules (HEVs) and largely reside in 
areas rich in T cells (Colonna et al, 2004). Plasmacytoid dendritic cells are also recruited to 
sites of infection and inflammation, as well as tumours.  
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Plasmacytoid dendritic cells are a predominant source of type I interferons (IFNs). Type I 
IFNs play an important role in host defence against viral challenge (Mathan et al, 2013). They 
induce apoptosis in virally infected cells, prevent protein synthesis and trigger RNA 
degradation. Type I IFNs can also activate and recruit T cells, B cells, NK cells and mDCs 
(Colonna et al, 2004, Mathan et al, 2013). Furthermore, pDCs secrete a large number of 
cytokines; TNFα, IL-6, IL-12 and IL-10 and chemokines; CCL3, CCL4, CCL5, CXCL9, and 
CXCL10 (Swiecki and Colonna, 2010). Plasmacytoid dendritic cells also express the 
receptors for a number of chemokines including CCR1, CCR2, CCR5, CCR7, CXCR3, and 
CXCR4 (Colonna et al, 2004). Therefore, as well as promoting inflammation by the release of 
type I IFNs and cytokines such as TNFα, pDCs may also have a tolerogenic phenotype by 
inducing the expansion and differentiation of IL-10 secreting T regs (Kavousanki et al, 2010). 
Additionally pDCs produce and respond to the type III interferons: IFN λ1, λ2 and λ3 
following viral challenge. The type III IFNs, like the type I IFNs, play an important role in the 
anti-viral response. They may also promote survival of pDCs (Yin et al, 2013).   
 
In order for pDCs to become activated and produce type I IFNs and numerous cytokines, they 
must first recognise pathogen associated molecular patterns (PAMPs) expressed by the 
invading pathogen via the use of pattern recognition receptors (PRRs). Plasmacytoid dendritic 
cells express Toll-like receptor 7 (TLR7) and Toll-like receptor 9 (TLR9) (Mathan et al, 
2013). Both of these are expressed intracellularly within the endosomes. Myeloid DCs do not 
express TLR7 and TLR9. TLR7 recognises viral uridine- or guanosine- rich single stranded 
RNA and synthetic compounds including imidazoquinoline, whereas TLR9 recognises 
unmethylated CpG motifs in single stranded DNA. Recognition of PAMPs by TLR7 and/or 
TLR9 leads to downstream signalling through the MyD88 adaptor protein and Btk, IRAK-4 
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and TRAF-6. This leads to phosphorylation and translocation of IRF-7 to the nucleus and the 
subsequent transcription of IFN-I. Signalling through TRAF-6 also results in cytokine and 
chemokine transcription via the NFκB and MAPK pathways (Guéry and Hugues, 2013).  
 
Prior to activation pDCs are in an immature state and as a result express only low levels of 
MHC class II and co-stimulatory molecules, CD80 and CD86. It is at this stage where pDCs 
may induce anergy (Goubier et al, 2008, Guéry and Hugues, 2013, Steinman and 
Nussenzweig, 2002). However, upon activation pDCs upregulate MHC class II and co-
stimulatory molecule expression. Plasmacytoid dendritic cells can process and present antigen 
to CD4+ T cells. Plasmacytoid dendritic cells may also present antigen by MHC class I 
leading to the activation of cytotoxic CD8+ T cells (Mathan et al, 2013). Furthermore, pDCs 
may support the differentiation of B cells to plasma cells.  
 
1.6.1 Plasmacytoid dendritic cells in rheumatoid arthritis 
In RA, pDCs have been reported in the synovial tissue nearby small and large lymphoid 
aggregates. They have also been reportedly found in close proximity to perivenular sites 
(Takakubo et al, 2008). Lande et al (2004) reported the presence of CD123+, BDCA-2+ pDCs 
by immunohistochemistry in the synovial tissue of RA and psoriatic arthritis (PsA) patients as 
well as immature pDCs in the RA and PsA synovial fluid. Plasmacytoid dendritic cells were 
absent in samples collected from patients with osteoarthritis (OA). In this study, pDCs within 
the synovial tissue expressed increased levels of CD123 compared to BDCA-2. It was 
suggested that the reduction of BDCA-2 staining on pDCs within the RA synovium was 
indicative of a mature pDC phenotype.  Furthermore, Cavanagh et al (2005) identified pDCs 
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in synovial tissue biopsies taken from patients with RA but not in biopsies taken from healthy 
individuals. It was reported that pDCs were accountable for 30% of the dendritic cells within 
RA synovial tissue and that the numbers of pDCs were higher in the RA tissue than the 
synovial fluid and peripheral blood. Plasmacytoid dendritic cells express the chemerin 
receptor, ChemR23 (Mathan et al, 2013). Both ligand and receptor have been identified in the 
RA synovium, particularly the synovial lining and sublining. In a study by Kaneko et al 
(2011), chemerin was found to stimulate IL-6, MMP-3 and CCL2 production from fibroblast-
like synoviocytes and therefore may play an important role in RA pathogenesis. The presence 
of chemerin in RA may also act to chemoattract pDCs to the synovium.  
 
Richez et al (2009) identified pDCs and mDCs in the peripheral blood of RA patients who 
responded and failed to respond when treated with infliximab over a 14 week time period. It 
was shown, that both mDCs and pDCs were reduced in the peripheral blood of patients with 
active RA, suggesting that both mDCs and pDCs may leave the peripheral blood and reside in 
the synovium during inflammation. The patients that responded to infliximab treatment had 
increased number of mDCs in the peripheral blood. As for non-responders, the number of 
mDCs and pDCs in the peripheral blood did not change.  
 
More recently, the production of tolerogenic DCs (TolDCs) are becoming an increasingly 
attractive therapeutic option in RA with a number of phase I clinical trials in process, 
including the Autologous Tolerogenic Dendritic Cells for RA trial (AUTODECRA TRIAL, 
clinicaltrials.gov reference NCT01352858) (Hilkens and Isaacs, 2013). TolDCs have been 
shown to induce anergy in antigen primed memory T cells, drive naïve T cells towards an 
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anti-inflammatory phenotype and in animal models of arthritis TolDCs have been shown to 
reduce the severity and progression of the arthritis when pulsed with type II collagen before 
administration (Hilkens and Isaacs, 2013). Moreover, in a phase I study carried out by 
Thomas et al (2011), the administration of TolDCs pulsed with four citrullinated peptide 
antigens to 18 RA patients was shown to be well tolerated. Harry et al (2010) have described 
a protocol for the generation of TolDCs using ex vivo monocytes taken from patients with 
established RA and healthy controls using dexamethasone, vitamin D3 and a TLR4 agonist. 
The TolDCs were reported to express high MHC class II and produce high levels of IL-10 and 
TGFβ but low levels of IL-12, IL-23 and TNFα. They were also shown to express low levels 
of co-stimulatory molecules. 
 
1.7 Platelets 
Platelets are small (2µm), anucleate disc shaped vesicles that are produced by 
megakaryocytes within the bone marrow (Semple et al, 2011). There are approximately 
150,000-500,000 platelets per μl/blood and they have a typical life span of 7-10 days. 
Platelets express a number of surface receptors including P-selectin (CD62P), Fc receptors 
(FcγRIIA, FcεRI, and FcαRI), GPIIb/IIIa (CD41), glycoprotein VI (GPVI) and C-type lectin-
like receptor 2 (CLEC-2). Platelets contain α-granules, dense granules and lysosomes which 
are a rich source of different inflammatory mediators and immune modulators. Platelet α-
granules (200-500nm) are the most abundant granule with approximately 50-80 granules per 
platelet (Blair and Flaumenhaft, 2009). The α-granules are a source of over 250 biologically 
active mediators. Molecules that play an important role in the coagulation cascade, 
endothelial cell repair, and adhesion have been described (Blair and Flaumenhaft, 2009, 
Semple et al, 2011). Numerous chemokines and cytokines are also stored and released from α-
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granules upon activation. These include, amongst many others, CXCL4, CXCL7, CCL5, 
TGF-β, IL-1β, IL-6 and IL-8. Additionally platelets also express the chemokine receptors; 
CCR1, CCR3, CCR4 and CXCR4 (Clemetson et al, 2000). Dense granules (150nm), 3-8 per 
platelet, contain a number of low molecular weight molecules that enhance platelet activation 
(Blair and Flaumenhaft, 2009). These include histamine, calcium, serotonin, adenosine 
diphosphate (ADP) and adenosine triphosphate (ATP) (Blair and Flaumenhaft, 2009). Platelet 
lysosomes contain hydrolases and are far less abundant than α- and dense granules (Nurden, 
2011, Zarbock et al, 2007). 
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 Factor Stored or 
synthesised 
Reported Immune 
Target cells 
Pleiotropic 
inflammatory and 
immune modulators 
Histamine 
 
5-HT (serotonin) 
Stored 
 
Stored 
EC, M, PMN, NK, 
TC, BC, E 
M, MΦ 
Lipid mediators TxA2 
 
PAF 
 
 
SIP 
Synthesised 
 
Synthesised 
 
 
Synthesised 
Platelets, TC, and 
MΦ subsets 
Platelets, PMN, M, 
MΦ and lymphocyte 
subsets 
EC, TC, BC, DC, 
NK, MΦ 
Growth factors PDGF 
TGF-β 
Stored 
Stored 
M, MΦ, TC 
M, MΦ, TC, BC 
Chemokines NAP2 (CXCL7) and 
related β-TG variants 
PF4 (CXCL4) 
GRO-α (CXCL1) 
ENA-78 (CXCL5) 
MIP-1α (CCL3) 
 
MCP-3 (CCL7) 
Proteolytic cleavage 
of stored precursors 
Stored 
Stored 
Stored 
Stored 
 
Stored 
PMN 
 
PMN 
PMN 
PMN 
M, E, B, NK, TC, 
and DC subsets 
M, B, NK cell , and 
DC subsets 
Cytokines IL-1β 
 
HMGB1 
Synthesised 
 
Stored 
M, EC, DC, and MΦ 
subsets 
MΦ, PMN, EC 
*Abbreviations: Factors: β-TG, β-thromboglobulin; ENA-78, epithelial neutrophil activation protein-78; GRO-α, 
growth-regulating oncogene-α; 5-HT, 5 hydroxytryptamine (serotonin); HMGB1, high mobility group box 1; IL-
1β, interleukin-1β; MCP-3, monocyte chemotactic protein-3; MIP-1α, macrophage inflammatory protein-1α; 
NAP2, neutrophil activating peptide 2; PAF, platelet-activating factor; PDGF, platelet-derived growth factor; 
PF4, platelet factor 4; SIP, sphingosine 1-phosphate; TGF-β, transforming growth factor β; TxA2, thromboxane 
A2. Target cells: B, basophil; BC, B lymphocyte; DC, dendritic cell; E, eosinophil; EC, endothelial cell; M, 
monocyte; MΦ, macrophage; NK, natural killer cell; PMN, polymorphonuclear leukocyte (neutrophil); TC, T 
lymphocyte. 
Table 1.3 Inflammatory mediators and immune modulators released from activated 
platelets. A number of mediators are released from activated platelets including chemokines, 
cytokines and growth factors. This is not an exhaustive list as the platelet proteome consists of 
over 300 different mediators and modulators. Table from Bergmeier and Wagner, 2007.  
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1.7.1 Soluble Glycoprotein VI 
Glycoprotein VI (GPVI) is a 60-65kDa type 1 transmembrane glycoprotein receptor 
expressed by platelets and megakaryocytes. GPVI is a receptor for collagen and laminin, both 
of which are exposed within the vessel wall upon damage. GPVI can exist as both a monomer 
and a dimer within the platelet plasma membrane. The GPVI monomer binds with low 
affinity to a specific glycine-proline-hydroxyl within collagen, whereas the dimer binds with 
high affinity (Al-Tamimi et al, 2011).  As a result of GPVI binding to collagen, the platelet 
becomes activated and releases its granular contents. In order to carry out its function, GPVI 
is covalently linked to the Fc-receptor γ (FcRγ) chain within the platelet plasma membrane. 
This association is necessary as the FcRγ chain is responsible for initiation of the downstream 
signalling pathways upon ligand binding (Al-Tamimi et al, 2011). Patients with reduced or 
absent platelet GPVI may present with epistaxis, ecchymosis, gingival bleeding and 
menorrhagia (Moroi et al, 1989). Their platelets lack the ability to aggregate in the response to 
collagen.  
 
GPVI is also found within the plasma. Soluble GPVI (sGPVI) is a marker of platelet 
activation. GPVI is cleaved from the plasma membrane by a disintegrin and metalloproteinase 
domain 10 (ADAM10) within minutes of ligand binding (Gardiner et al, 2007). Further 
ligands associated with the shedding of GPVI have, also, been identified. These include 
collagen, collagen related peptide (CRP), N-ethylmaleamide (NEM), coagulation factor X and 
snake toxin (Al-Tamimi et al, 2011, Wijeyewickrema et al, 2007). High shear stress may also 
lead to cleavage of GPVI from the plasma membrane.  
 
  
24 
 
GPVI has been studied as a potential diagnostic biomarker in patients with acute coronary 
syndrome (ACS). An increase in GPVI has been associated with poor clinical outcome in 
patients presenting with chest pain (Bigalke et al, 2010). Similarly an increase in GPVI has 
also been associated with a poor outcome in stoke patients. In contrast sGPVI is decreased in 
stroke patients (Wurster et al, 2013). Regulation of sGPVI has also been reported in 
Alzheimer’s disease. Here, a decrease in sGPVI and a corresponding lower platelet count was 
observed in Alzheimer’s disease patients when compared to healthy (Laske et al, 2008).  In 
this study, another platelet activation marker was studied, β-thromboglobulin (β-TG). β-TG is 
a precursor molecule to CXCL7. Levels of β-TG were not found to be significantly different 
between patients and healthy controls. 
 
1.7.2 A role for platelets in the immune response 
Platelets not only play an important role in haemostasis and wound repair but are also 
important mediations of inflammation. They are now considered to be key immune cells with 
roles overlapping both innate and adaptive immune responses (Semple et al, 2011). Platelets 
express a number of different Toll-like receptors (TLRs) that are capable of recognising 
pathogen associated molecular patterns (PAMPs) and danger associated molecular patterns 
(DAMPs). A study by Cognasse et al (2005) identified the expression of a number of TLRs 
by platelets including TLR2, TLR4 and TLR9 that were found to be upregulated upon platelet 
activation. Platelets, therefore, have the ability to act as ‘sentinels’ of the immune system and 
are capable of responding to bacterial, viral, fungal and protozoal infection. Platelets can 
capture pathogens and influence killing via the release of thrombocidins and ROS. A study by 
Krijgsveld et al (2000) identified two thrombocidins; Thrombocidin-1 (TC-1) and 
Thrombocidin-2 (TC-2) are both released from the α-granules of thrombin stimulated 
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platelets. They were identified as C-terminal amino acid truncated forms of neutrophil 
activating peptide-2 (NAP-2) and connective tissue-activating peptide III (CTAP-III). Both 
were shown to have bactericidal effects on Gram positive and Gram negative bacteria as well 
as activity against the fungi, Cryptococcus neoformans. Platelets can form complexes with 
neutrophils which result in the enhancement of neutrophil chemotaxis, phagocytosis and 
production of ROS. Additionally, in response to infection, platelets can trigger neutrophil 
extracellular trap (NET) release through their expression of TLR4. This leads to the 
entrapment of bacteria within a complex of extracellular DNA and histones (Semple et al, 
2011, Vieira-de-Abreu et al, 2012).  Platelets can also play an important role in leukocyte 
recruitment to the site of infection/inflammation through the release of a number of different 
chemokines.  
 
CD40 and CD40L belong to the TNFR/TNF superfamilies of molecules. The interaction of 
CD40 on a B cell with CD40L on a T cell is a necessary trigger for B cell proliferation, Ig 
production, isotype class switching and germinal centre formation (Renshaw et al, 1994, 
Splawski et al, 1993). Both CD40 and CD40L are also expressed by cells other than B cells 
and T cells, respectively. CD40 is expressed on monocytes/macrophages, DCs, endothelial 
cells, fibroblasts and neutrophils, and CD40L is expressed on basophils and mast cells 
(Gauchat et al, 1993).  Expression of both CD40 and CD40L has also been reported on 
platelets (Elzey et al, 2011, Henn et al, 1998).  Hence, platelets may be capable of influencing 
the adaptive immune response (Henn et al, 2001). Inwald et al (2003) reported the expression 
of CD40 on resting and activated platelets. CD40L is stored within platelet α-granules and is 
rapidly translocated within seconds to the platelet surface upon activation with thrombin 
(Henn et al, 1998). Hence, CD40L is considered a marker of platelet activation. Platelet 
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CD40L can also be cleaved from the platelet surface and circulate as soluble CD40L 
(sCD40L). Increased sCD40L has been identified in the plasma of patients with systemic 
lupus erythematosus (SLE), primary Sjögren’s Syndrome (pSS) and RA (Sellam et al, 2009). 
Platelet CD40L has been shown to play a role in DC maturation, B cell isotype switching 
(IgM/IgD to IgG) and germinal centre formation. Platelet CD40L may also trigger endothelial 
cells to upregulate their expression of adhesion markers and enhance chemokine release, thus 
potentiating leukocyte recruitment.    
 
Hamzeh-Cognasse et al (2008) reported a role for platelets in DC maturation. Dendritic cells 
cultured with platelets in a filter separated co-culture system led to an increase in DC 
maturation markers; CD80, CD83 and CD86 and an overexpression of IL-12 (p70). 
Interestingly, platelets cultured in direct contact with DCs did not lead to an upregulation of 
DC maturation markers or IL-12 (p70). It was suggested that platelets may release soluble 
mediators that trigger DC maturation. Platelets have the ability to provide the necessary co-
stimulation signal to T cells through the expression of CD86 and can also influence CD4+ 
differentiation and T cell trafficking. Zhu et al (2014) reported that platelets co-cultured with 
anti-CD3/CD28 stimulated CD4+ T cells led to Th1, Th17 and Treg differentiation. 
Furthermore, Gerdes et al (2011) identified an increase in Th1 but not Th2 cytokine release 
when platelets were co-cultured with anti-CD3/CD28 CD4+ T cells. This study also identified 
an increase in IL-10 and IL-17 production in the co-cultured cells. Platelets can also present 
antigen to CD8+ cytotoxic T cells in the context of MHC class I (Chapmen et al, 2012).  
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1.7.3 Platelets in rheumatoid arthritis 
In RA, increased levels of activated platelets have been reported in the blood as well as in the 
synovial fluid. High platelet counts have been observed in inflamed joints (Farr et al, 1983). 
Platelet-leukocyte complexes have also been observed in patients with RA, thus suggesting 
that platelets may aid in the recruitment and activation of leukocytes within the inflamed joint 
(Joseph et al, 2001).  In a study by Pamuk et al (2008), blood from RA patients was shown to 
have increased levels of CD62P, sCD40L and circulating platelet-monocyte complexes as 
compared to healthy controls. In a K/BxN serum transfer model of inflammatory arthritis, 
mice deficient in >95% platelets were shown to have limited arthritis.  
 
A role for platelet microparticles in the pathogenesis of RA has recently been elucidated. 
Pivotal work by Boilard et al (2010) used flow cytometry to demonstrate CD41+ platelet 
microparticles in synovial fluid from RA patients. The platelet microparticles were absent in 
95% of fluid samples taken from patients with OA. Likewise, Sellam et al (2009) identified 
platelet microparticles in the plasma of patients with pSS, SLE and RA. The numbers of 
platelet microparticles were shown to be significantly higher in the three different disease 
groups compared to healthy controls. Platelet microparticles are small vesicles (0.2-1µm) that 
bud off from the existing platelet. They contain an abundance of inflammatory mediators as 
well as a large number of platelet surface receptors including CD41, CD62P, CD40L and 
CXCR4. In a K/BxN serum transfer model of inflammatory arthritis, platelet microparticle 
release was shown to be triggered via the GPVI receptor. GPVI is a receptor for collagen. 
Moreover, platelet microparticles have been reported to exacerbate the inflammatory process 
by triggering fibroblast-like synoviocytes to release pro-inflammatory cytokines, namely IL-1. 
Likewise, fibroblast-like synoviocytes have also been found to trigger the release of platelet 
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microparticles thus creating a vicious cycle (Boilard et al, 2010, Zimmerman and Weyrich, 
2010).    
 
1.8 Chemokines  
The chemokine family are a collection of small chemotactic proteins (8-15kDa) that play an 
important role in immune cell recruitment, activation and retention at sites of inflammation. 
Furthermore, chemokines are also involved in angiogenesis, tumour growth and metastasis 
(Lei and Takahama, 2011). To date there are approximately 50 known chemokine ligands that 
can be subdivided into four families based on the position of conserved terminal cysteine 
residues (Pease and Williams, 2006). For the purpose of nomenclature, the chemokine ligands 
are referred to as CCL, CXCL, XCL and CX3CL, and their corresponding receptors are CCR, 
CXCR, XCR, and CX3CR respectively. The two larger subfamilies are the CC chemokines, 
clustered on chromosome 17q, in which the cysteine residues are adjacent to one another, and 
the CXC chemokines clustered on chromosome 4q, in which the cysteine residues are 
separated by a single amino acid residue (Figure 1.3). CC chemokines are largely responsible 
for the chemoattraction of monocytes, DCs, lymphocytes, NK cells, basophils and eosinophils 
(Martier et al, 2011, Szekanecz and Koch, 2001). CXC chemokines can be subdivided into 
two groups based on the presence or absence of an ELR peptide motif (Glutamic acid-
Leucine-Arginine). Those that are ELR+ chemoattract neutrophils via the CXCR2 receptor, 
whilst ELR- chemokines (CXCL9 and CXCL10) predominantly bind to the CXCR3 receptor 
and chemoattract monocytes and lymphocytes. Exceptions to this rule include CXCL4, an 
ELR- chemokine that has been reported to lack the ability to chemoattract monocytes, and 
CXCL13, an ELR- chemokine that does not bind the CXCR3 receptor but instead recruits B 
cells via the CXCR5 receptor.  
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ELR+ and ELR- CXC chemokines also differ in their angiogenic/angiostatic properties, with 
ELR+ chemokines promoting angiogenesis and ELR- inhibiting angiogenesis. One exception 
to this rule is CXCL12. It is an ELR- chemokine, but promotes angiogenesis (Szekanecz and 
Koch, 2001, Szekanecz et al, 2003).  
 
The smaller subfamilies are comprised of two chemokines that make up the XC family and a 
single chemokine, Fractalkine, which belongs to the CX3C family. The XC family contain 
one cysteine residue, whereas the cysteine residues in Fractalkine are separated by three 
amino acids (Figure 1.3). Fractalkine is a unique chemokine in that it can exist in soluble or 
membrane bound forms. The XC family of chemokines chemoattract only lymphocytes, 
whereas the CX3C member chemoattracts both lymphocytes and monocytes.  
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Figure 1.3 Chemokine structure. An image adapted from Wallace et al (2004) depicting the 
four chemokine families and their terminal cysteine residues. The mucin-like domain enables 
Fractalkine and, also, CXCL16 to exist as membrane bound forms.  It can be cleaved from the 
membrane by MMPs.  
 
 
Chemokines may also be subdivided into two groups based on their functional role; 
inflammatory or homeostatic. However, this sub-categorisation is not entirely consistent as 
some chemokines may have both homeostatic and inflammatory roles. Inflammatory 
chemokines act on cells of the innate and adaptive immune system. They play an important 
role in leukocyte recruitment during inflammation, cancer and autoimmune disease. 
Homeostatic chemokines are expressed at constitutively active levels and are largely confined 
to the thymus and lymphoid tissue whereby they play an important role in immune 
surveillance and cell trafficking during haematopoiesis. They also have a role in the initiation 
of the adaptive immune response within the lymph nodes, spleen and Peyer’s patches (Moser 
et al, 2004).   
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1.9 Leukocyte trafficking 
The trafficking of leukocytes from the circulation into the tissue occurs in four stages; (1) 
leukocyte rolling, (2) activation of integrins on leukocytes, (3) firm adhesion to endothelial 
cells, and (4) diapedesis (Springer, 1994, Tarrant and Patel, 2006). 
 
Leukocyte rolling is mediated by selectins on the endothelium. Selectins are a family of C-
type lectin, carbohydrate binding molecules of which there are three major classes; Platelet- 
or P-selectin (CD62P), Leukocyte- or L-selectin (CD62L), and Endothelial- or E-selectin 
(CD62E) (Ley, 2003). They facilitate the interactions of leukocytes with platelets and 
leukocytes with the endothelium (Rosen and Bertozzi, 1994). P-Selectin is evident in platelet 
α-granules and megakaryocytes, as well as in Weibel-Palade bodies of endothelial cells 
(Springer, 1994). P-selectin is not expressed on the cell surface in the resting state. However, 
upon activation with mediators such as thrombin, histamine or various cytokines e.g. TNFα, 
P-selectin is targeted to the plasma membrane whereby it functions as a cell adhesion 
molecule (Rosen and Bertozzi, 1994). Within minutes following an inflammatory stimulus, P-
selectin is cleaved from the cell surface via proteolytic enzymes (Tarrant and Patel, 2006). E-
selectin is expressed by activated endothelial cells within a few hours after the initial 
inflammatory stimulus (Rosen and Bertozzi, 1994). It is upregulated in the RA synovium and 
is thought to play an important role in inflammatory cell recruitment (Tarrant and Patel, 
2005). L-selectin is expressed on the tips of the microvilli on all leukocytes apart from a 
particular subset of memory T cells (Schmidt et al, 2013). It plays an important role in the 
attachment of leukocytes to the endothelium and lymphocyte homing to the secondary 
lymphoid tissue via the high endothelial venules (HEVs). Upon cellular activation, like P-
selectin, L-selectin is rapidly cleaved from the cell surface. The chemokine, Fractalkine, can 
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also serve as a selectin-like adhesion molecule. Fractalkine is an atypical chemokine since it 
can exist as both a soluble and a cell-bound form. It is capable of rapid capturing of 
leukocytes from the circulation. The interaction of leukocytes with selectins initiates cell 
rolling across the endothelium. As the leukocyte rolls, chemokines presented by 
glycosaminoglycans on the endothelial surface bind to their receptors on the surface of the 
leukocyte. This triggers the cell to stop and adhere. Chemokines not only trigger the cell to 
stop and adhere, but also lead to the activation of integrins on the leukocyte surface.  
 
The integrins are a family of transmembrane receptors that are formed of two subunits; α and 
β. Thus far, there are 18 known α-subunits and 8 β-subunits which have given rise to at least 
24 known α-β combinations (van der Flier and Sonnenberg, 2001). Integrins that contain a β2 
subunit are largely involved in cell-cell interactions and play an important role in leukocyte 
function including leukocyte trafficking and phagocytosis. Whereas, those that contain a β1 
subunit are involved in cell-extracellular matrix interactions and function as receptors for 
collagen, fibronectin (α5β1) and laminin (α6β1). Integrins on the leukocyte bind to their 
ligands on the endothelium and lead to firm adhesion. The integrin ligands on the 
endothelium include the intercellular adhesion molecules (ICAM), mucosal addressin cell 
adhesion molecule-1 (MAdCAM-1), platelet-endothelial cell adhesion molecule-1 (PECAM-
1) and vascular cell adhesion molecule-1 (VCAM-1) (Tarrant and Patel, 2005). Integrins on 
leukocytes that interact with ICAM-1 and ICAM-2 include the β2 integrins, leukocyte 
functional antigen-1 (LFA-1) (CD11a/CD18), complement receptor type-3 (CR3, 
CD11b/CD18, MAC-1) and p150/95 (CD11c/CD18) (Plow et al, 2000). ICAM-1 is 
upregulated during inflammation whereas ICAM-2 is constitutively expressed and therefore 
plays a role in homeostatic leukocyte trafficking (Springer, 1994).  
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Following firm adhesion to the endothelium, the leukocytes migrate across the endothelial 
monolayer and basement membrane by a process of diapedesis, or transendothelial migration. 
This can occur within 90 seconds (Mamdouh et al, 2003). Predominantly, diapedesis occurs at 
the endothelial junctions/borders and is known as paracellular transmigration. However, it has 
been observed that leukocytes can also transmigrate through the endothelial cell itself by a 
process known as transcellular migration. Although the exact process of diapedesis has yet to 
be fully elucidated, it does involve the molecules PECAM-1 (CD31) and CD99 which are 
expressed on the leukocytes as well as the endothelial cell junctions (Mamdouh et al, 2003). 
Furthermore, the transmembrane immunoglobulins poliovirus receptor (CD155) and DNAX 
associated molecule-1 (DNAM-1/CD226) have also been shown to play a role in diapedesis 
(Sullivan et al, 2013). In a study by Mamdouh et al (2003), PECAM-1 was shown to recycle 
from the endothelial junctions to a compartment below the surface known as the 
‘subjunctional reticulum’. When monocytes were included in the experiments, PECAM-1 was 
shown to surround the monocytes during diapedesis. When monocyte PECAM-1 was 
blocked, the cells were unable to migrate.  
 
More recently, novel insight into the trafficking of T cells across the endothelium has been 
described. Chimen et al (2015) demonstrated that B cells were able to negatively regulate the 
trafficking of T cells across the endothelium during inflammation and that this process was 
dampened in autoimmune diseases such as type 1 diabetes and RA. In response to adiponectin 
release and its subsequent binding to its targeted receptors, adiponectin receptor 1 (AdipoR1) 
and adiponectin receptor 2 (AdipoR2), B cells were shown to produce a novel 14 amino acid 
peptide derived from the proteolytic cleavage of 14.3.3.ζδ  known as PEPtide Inhibitor of 
Trans-Endothelial migration or PEPITEM. Once released, PEPITEM was shown to bind to 
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cadherin-15 (CDH15) on the surface of the endothelium. Within the cytosol of the endothelial 
cells, sphingosine was subsequently phosphorylated by sphingosine kinases to produce 
sphingosine-1-phosphate. Sphinogsine-1-phosphate was then transported from the endothelial 
cell whereby it was reported to bind to sphingosine-1-phosphate receptors 1 and 4 on the 
surface of T cells. As a result, T cell trafficking across the endothelium was inhibited. In the 
context of type 1 diabetes and RA, the expression of AdipoR1 and AdipoR2 was shown to be 
decreased on the surface of the B cells and as a result PEPITEM release was subsequently 
decreased. Therefore, this led to uncontrolled trafficking of T cells into the tissues and 
exacerbation of disease. 
 
1.10 Chemokine receptors in cellular trafficking 
In order to exert their function, chemokines must bind to receptors. Predominantly 
chemokines signal via G-Protein coupled receptors (Figure 1.4). However, they may also bind 
and interact with glycosaminoglycans and a number of atypical decoy chemokine receptors. 
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Figure 1.4 G-Protein coupled receptors. The G-protein coupled receptors are composed of a central region of seven transmembrane 
spanning α helices (labelled 1-7). The extracellular region consists of the N-terminus and three extracellular loops, whereas the intracellular 
region consists of the C-terminus and three intracellular loops. The G-protein, which is comprised of a Gα subunit and a Gβγ subunit is also 
found intracellularly in close proximity to the C-terminus. In its inactive form, the Gα subunit is tightly associated with GDP.   
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1.10.1 G-Protein coupled receptors 
The G-Protein coupled receptors (GPCRs) are a large group of serpentine seven 
transmembrane spanning proteins coupled to heterotrimeric G proteins (Figure 1.4). The 
heterotrimeric G proteins are comprised a Gα subunit and a dimer of Gβ and Gγ subunits 
(Gβγ). In the inactive stage, the Gα subunit is associated with the Gβγ subunit. A single 
molecule of ADP is also bound to the Gα subunit. Upon chemokine ligand coupling to the 
GPCR, GDP is exchanged for GTP. This results in a conformational shape change and the 
dissociation of the Gα from the Gβγ subunits.  The subunits are then free to modulate the 
activation of downstream signalling pathways. Hydrolysis of GTP to GDP by the Gα subunits 
GTPase activity leads to the termination of the signal and reassociation of the Gα and Gβγ 
subunits (Borroni et al, 2010, Kobilka, 2007, Neumann et al, 2014).  
 
To date there are approximately 20 known G-coupled protein receptors that mediate 
chemokine signalling. They are grouped into CCR, CXCR, XCR and CX3CR- type receptors. 
Chemokines are described as being highly promiscuous as they may bind more than one 
chemokine receptor. For example the inflammatory chemokine CCL5 (RANTES) is capable 
of binding to three different receptors; CCR1, CCR3 and CCR5 (Table 1.4). Likewise, the 
chemokine receptor CCR3 is capable of binding five different chemokine ligands; CCL5, 
CCL7, CCL8, CCL13, and CCL15 (Table 1.4). However, those chemokines described as 
homeostatic; CCL19, CCL21, CCL25, and CXCL13, tend to be far more restrictive in the 
receptors they bind.  
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1.10.2 Chemokine interaction with Glycosaminoglycans 
Chemokines not only interact with G-Protein coupled receptors but also bind to 
glycosaminoglycans (GAGs) with varying affinities (Comerford and Nibbs, 2005). 
Glycosaminoglycans are negatively charged macromolecules formed of long chains of 
repeating disaccharide subunits (1-25,000 subunits) (Johnson et al, 2005). Each disaccharide 
subunit may consist of a hexosamine and a hexose or hexuronic acid (Laguri et al, 2008). 
They are extremely diverse macromolecules as they can undergo extensive modifications 
including sulphation and acetylation.  The GAGs may be subdivided into six groups; 
chondroitin sulphate, dermatan sulphate, keratan sulphate, heparin, heparan sulphate, and 
hyaluronic acid. Both heparin and hyaluronic acid are soluble glycosaminoglycans, whereas 
the remaining GAGs are ubiquitously expressed on the cell surface and extracellular matrix 
attached to a protein core. When GAGs form structures with proteins, they are known as 
proteoglycans (Johnson et al, 2005).  
 
Glycosaminoglycans play an important role in retaining chemokines at their site of release 
and prevent chemokines from being washed away by the flow of blood (Nibbs et al, 2003). 
This is extremely important for the recruitment of leukocytes, as the loss of GAGs can lead to 
the inability of chemokines to recruit leukocytes in vivo. They may also regulate the 
presentation of chemokines to their appropriate ligands. For example, GAGs on endothelial 
cells may present chemokines to circulating leukocytes, thus enabling cell trafficking 
(Comerford and Nibbs, 2005).  GAGs may also prevent chemokines from undergoing 
proteolytic degradation (Laguri et al, 2008). 
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1.10.3 The Duffy Antigen Receptor for Chemokines 
The Duffy Antigen Receptor for Chemokines (DARC), or Fy antigen, was first described in 
1950 after antibodies to the DARC antigen were discovered in a haemophiliac patient 
(Cutbush et al, 1950). DARC was initially reported as a receptor for Plasmodium vivax and 
Plasmodium knowlesi on the erythrocyte surface (Miller et al, 1975, Miller et al, 1976, Nibbs 
et al, 2003). Furthermore, it is known to be expressed by vascular endothelial cells, high 
endothelial venules (HEVs) of the lymph nodes and sinusoids within the spleen. Whilst in 
pathology, DARC has been observed in inflamed tissues such as the RA synovium (Smith et 
al, 2008) and psoriatic skin. In RA, DARC positivity has been observed on endothelial cells 
of post capillary venules but not arterioles (Patterson et al, 2002, Gardner et al, 2006). 
Moreover, an increase in expression of DARC was evident in patients with early RA (disease 
duration of <7 months) compared to those with established disease of >8.8 years.  
 
DARC is capable of binding inflammatory chemokines, but not homeostatic chemokines, of 
both CC and CXC subfamilies with varying affinities (Comerford and Nibbs, 2005). 
Furthermore, DARC is known to bind ELR+ angiogenic chemokines but not ELR- angiostatic 
chemokines. The interaction of chemokines with DARC does not result in downstream 
signalling as it lacks the DRYLAIV motif on the second intracellular loop. Therefore, DARC 
may act to dampen the inflammatory response by acting as a chemokine decoy receptor. 
DARC expression on erythrocytes may also serve as a chemokine ‘sink’ or ‘reservoir’, thus 
regulating chemokine levels in the blood (Rot, 2005). Furthermore, DARC may play an 
important role in chemokine transport across the endothelial barrier (Lee et al, 2003). In a 
study by Lee et al (2003), CXCL1 and CXCL8 were shown to traffic across endothelial 
monolayers in the presence of Duffy antigen. Additionally, neutrophil recruitment was 
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enhanced in monolayers expressing Duffy antigen compared to those negative for Duffy 
antigen. In a later study by Smith et al (2008) DARC blockade was shown to inhibit the 
adhesion of neutrophils to endothelial cells co-cultured with RA synovial fibroblasts.  
 
1.10.4 The D6 receptor 
The D6 receptor, located on chromosome 3p21.3, was first cloned from placenta and 
haematopoietic stem cells in 1997 (Bonini et al, 1997, Graham et al, 2012). D6 is expressed 
by endothelial cells of lymphatic afferent vessels in the gut, lungs, skin and placenta. 
Moreover, D6 expressed has also been reported on pDCs and mDCs as well as particular 
subsets of B cells (Graham et al, 2012). The D6 receptor functions as a decoy and scavenging 
receptor by binding to a large number of inflammatory chemokines belonging to the CC 
family (Locati et al, 2005). It lacks the ability to trigger downstream signalling due to an 
alteration in the DRYLAIV motif to DRYLEIV (Graham et al, 2012, Nibbs et al, 2003).  
 
The D6 receptor is continuously internalised via clathrin coated pits and recycled regardless 
of whether or not chemokine is bound. When chemokine is bound to D6 and subsequently 
internalised, the chemokine rapidly dissociates from the receptor due to the low pH inside the 
endosome. The chemokine is then targeted for degradation by the lysosomes, whilst the D6 
receptor is free to recycle back to the plasma membrane (Comerford and Nibbs, 2005).  
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1.10.5 The CCX-CKR receptor 
Although first referred to as CCR11 and thought to mediate signalling, CCX-CKR, or 
Chemocentryx chemokine receptor, is now described to function as a chemokine scavenging 
receptor as the DRYLAIV motif on the second intracellular loop required for downstream 
signalling is altered to DRYVAVT (Graham et al, 2012, Nibbs et al, 2003). CCX-CKR is 
expressed in the lung, heart and gut (Graham et al, 2012). CCX-CKR selectively binds the 
homeostatic CC chemokines CCL19, CCL21 and CCL25 and therefore may play an 
important role in the regulation of lymphoid trafficking and the triggering of the immune 
response (Comerford et al, 2006, Nibbs et al, 2003). It is also reported to bind the homeostatic 
CXC chemokine, CXCL13, but with low affinity (Comerford and Nibbs, 2005).  
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1.11 Chemokines in rheumatoid arthritis 
Chemokines play a major role in the pathogenesis of RA. Through the recruitment, activation 
and accumulation of various immune cells, chemokines have been shown to contribute 
towards the huge inflammatory infiltrate observed in the synovium. A large number of animal 
studies, as well as human trials have attempted to target chemokines therapeutically in order 
to treat RA.  
Chemokine 
Ligand 
 Chemokine 
Receptor 
CXCL1 Growth Related Oncogene α (GROα) 
 
CXCR1, CXCR2 
 
CXCL2 Growth Related Oncogene β (GROβ) 
 
CXCR2 
 
CXCL3 Growth Related Oncogene γ (GROγ) 
 
CXCR2 
CXCL4 Platelet Factor 4 (PF4) 
 
CXCR3B 
 
CXCL5 Epithelial Neutrophil Activating Peptide 78 (ENA-
78) 
 
CXCR2 
 
CXCL6 
 
Granulocyte Chemotactic Protein-2 (GCP-2) 
 
CXCR1, CXCR2 
 
CXCL7 Neutrophil Activating Peptide-2 (NAP-2) 
 
CXCR1, CXCR2 
 
CXCL8 Interleukin-8 (IL-8) 
 
CXCR1, CXCR2 
 
CXCL9 Monokine Induced by IFNγ (MIG) 
 
CXCR3 
 
CXCL10 IFNγ Inducible Protein-10 (IP-10) 
 
CXCR3 
 
CXCL11 Human interferon-inducible T-cell α chemoattractant 
(I-TAC) 
 
CXCR7 
 
CXCL12 Stromal Derived factor-1 (SDF-1α/β) 
 
CXCR4, CXCR7 
 
CXCL13 B cell Chemoattractant-1 (BCA-1) 
 
CXCR5 
 
CXCL16 SCYB16, SR-PSOX CXCR6 
 
Table 1.4 The CXC chemokines and their receptors in rheumatoid arthritis. Table 
derived from Iwamoto et al, 2008, Szekanecz et al, 2003, and Szekanecz et al, 2009. 
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Chemokine 
Ligand 
 Chemokine 
Receptor 
CCL1 T-cell activation gene-3 (TCA-3) 
 
CCR8 
 
CCL2 Monocyte Chemotactic Protein-1 (MCP-1) 
 
CCR2 
 
CCL3 Macrophage Inflammatory Protein -1α (MIP-1α) 
 
CCR1, CCR5 
 
CCL4 Macrophage Inflammatory Protein-1β (MIP-1β) 
 
CCR5 
 
CCL5 Regulated upon Activation, Normal T-cell 
Expressed, and Secreted (RANTES) 
 
CCR1, CCR3, CCR5 
 
CCL7 Monocyte Chemotactic Protein-3 (MCP-3) 
 
CCR1, CCR3, CCR5 
 
CCL8 Monocyte Chemotactic Protein-2 (MCP-2) 
 
CCR3, CCR5 
 
CCL13 Monocyte Chemotactic Protein-4 (MCP-4) 
 
CCR1, CCR2, CCR3 
 
CCL14 Hemofiltrate C-C chemokine-1 (HCC-1) 
 
CCR5 
 
CCL15 Hemofiltrate C-C chemokine-2 (HCC-2) 
 
CCR3 
 
CCL16 Hemofiltrate C-C chemokine-4 (HCC-4) 
 
CCR2 
 
CCL17 Thymus and activation regulated chemokine (TARC) 
 
CCR4 
 
CCL18 Pulmonary and Activation-Regulated Chemokine 
(PARC) 
 
unknown 
 
CCL19 Macrophage Inflammatory Protein- 3β (MIP-3β) 
 
CCR7 
 
CCL20 Macrophage Inflammatory Protein- 3α (MIP-3α) 
 
CCR6 
 
CCL21 Secondary lymphoid tissue chemokine (SLC) CCR7 
 
Table 1.5 The CC chemokines and their receptors in rheumatoid arthritis. Table derived 
from Iwamoto et al, 2008, Szekanecz et al, 2003, and Szekanecz et al, 2009. 
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Chemokine 
Ligand 
 Chemokine 
Receptor 
XCL1 Lymphotactin XCR1 
CX3CL1 Fractalkine CX3CR1 
 
Table 1.6 The C and CX3C chemokines and their receptors in rheumatoid arthritis. 
Table derived from Szekanecz et al, 2003.  
 
1.11.1 CXC chemokines in rheumatoid arthritis 
A large number of CXC chemokines have been reported in biological samples from patients 
with RA (Table 1.4). Increased levels of both ELR+ and ELR- chemokines have been detected 
in synovial fluid, tissue and sera (Szekanecz and Koch, 2001). CXCL8/IL-8 plays an 
important role in the pathogenesis of RA with synovial macrophages being the major source 
of this chemokine. It recruits neutrophils into the synovium, thus furthering the inflammatory 
process. CXCL8 also promotes angiogenesis and upregulation of cell adhesion molecules in 
the RA joint (Iwamoto et al, 2008, Raman et al, 2011, Vergunst et al, 2005). CXCL12 plays 
an important role in the RA joint through the recruitment of CD4+ T cells into the synovium. 
It prevents activation induced apoptosis of these cells leading to an accumulation within the 
joint (Iwamoto et al, 2008). CXCL12 and its receptor, CXCR4, have been linked to the 
increased survival of B cells in the synovium. Synovial fibroblasts also migrate and 
proliferate in response to CXCL12 (Godessart and Kunkel, 200, Gorman and Cope, 2008).  
 
Like CX3CL/Fractalkine (described in section 1.10.4), CXCL16 can exist as either a 
transmembrane bound chemokine or a soluble chemokine. The transmembrane bound form of 
CXCL16 can act as an adhesion molecule or a scavenger receptor. Upon cleavage from the 
membrane by a disintegrin and metalloproteinase-10 (ADAM-10), CXCL16 can circulate as 
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the soluble form. CXCL16 is expressed by macrophages, T cells, B cells and DCs. CXCL16 
which binds through the receptor CXCR6 is a chemoattractant for NK T cells, NK cells, 
activated T cells, and B cells (Nanki et al, 2005). CXCL16 and CXCR6 have both been 
reported in RA. Nanki et al (2005) observed an increase in CXCL16 in the RA synovium 
compared to the OA synovium. CXCL16 positivity was observed in both the lining and 
sublining layer of the RA synovium. CXCR6 was observed on CD4+ and CD8+ T cells in the 
synovium. The presence of CXCL16 was found to be associated with an accumulation of T 
cells within the synovium. Furthermore, in a CIA mouse model, the blockade of CXCL16 by 
a monoclonal antibody was shown to reduce synovial inflammation (Nanki et al, 2005). 
 
CXC chemokines can aid in the recruitment of B cells to the inflamed synovium. B cell 
chemoattractant-1, CXCL13, is expressed by follicular DCs, fibroblasts and endothelial cells 
within the synovium of RA patients. CXCL13 has been found in germinal centre like 
structures within the synovial tissue (Godessart and Kunkel, 2001, Raman et al, 2011).  
 
Chemokines that prevent angiogenesis have also been reported in the synovium of patients 
with RA, including CXCL9, CXCL10 and CXCL4. It has been suggested that these 
chemokines may play a role in the suppression of inflammation, although little evidence is 
available to support this suggestion.  
 
Recently, CXCL9 and CXCL10 have been identified as potential biomarkers of disease 
activity in RA patients (Kuan et al, 2010). Here, the serum levels of CCL2, CCL5, CXCL8, 
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CXCL9 and CXCL10 were quantified in RA patients at baseline and after 12 weeks of 
treatment with DMARDS or biological agents. All chemokines measured, apart from CCL2, 
were significantly increased in patients with RA compared to healthy controls at baseline. A 
significant reduction in serum CXCL9 and CXCL10 was observed in patients with improved 
clinical activity.  
 
1.11.2 CXCL4, CXCL4L1, and CXCL7 
1.11.2.1 CXCL4 
CXCL4 or Platelet Factor 4 (PF4) is predominantly a platelet derived chemokine. It is 
synthesised in megakaryocytes and subsequently stored in α-granules of platelets (Nurden, 
2011) whereby it is accountable for 2-3% of the total protein in mature platelets. In serum, 
CXCL4 levels range from 0.4-1.9 μM, whereas in plasma, CXCL4 levels are 1000-fold lower 
(Schenk et al, 2002). When platelets become activated, CXCL4 is released alongside two 
chondroitin sulphate proteoglycan molecules as a tetramer complex. CXCL4 binds to 
CXCR3B or membrane chondroitin-sulphate, and has a multitude of different effects on 
various cell types (Pease and Williams, 2006). It has been shown to trigger the release of 
histamine from basophils and CXCL8/IL-8 from NK cells, suppress tumour growth and 
angiogenesis, and lead to neutrophil adhesion to the endothelium and secondary granule 
exocytosis (Kasper and Petersen, 2011, Petersen et al, 1999). Research has reported 
upregulation of CXCL4 in mDCs and pDCs following trauma (Maier et al, 2009). Furuya et 
al (2012) reported that in endometriosis, CXCL4 was strongly expressed on CD68+ 
macrophages. Furthermore, CXCL4 has been shown to inhibit HIV-1 viral attachment and 
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entry into CD4+ T cells and macrophages (Auerbach et al, 2012). McMorren et al (2012) also 
identified an anti-malarial role for CXCL4 via Duffy antigen receptor interactions.  
 
In T cells, CXCL4 can suppress proliferation. Fleischer et al (2002) stimulated mononuclear 
cells with recall Ag tuberculin. The cells were then subsequently treated with varying doses of 
CXCL4. Here, it was observed that CXCL4 concentrations of over 0.5μM triggered a dose-
dependent decrease in cell proliferation. However, in Treg cells, CXCL4 has been shown to 
increase cell proliferation (Liu et al, 2005). This study also reported a decrease in IL-2 mRNA 
expression as well as inhibition of IL-2 and IFNγ release from T cells treated with CXCL4. 
CXCL4 also plays a role in Th1/Th2 polarisation via the regulation of the transcription factors 
GATA3 and T-bet (Kasper and Petersen, 2011).   
 
A number of different effects of CXCL4 on monocytes have been reported. Firstly, it has been 
shown that CXCL4 prevents monocytes from undergoing spontaneous apoptosis via a GM-
CSF and TNF-α independent manner. Cultured monocytes treated over a 72 hour period with 
CXCL4 were also shown to differentiate into a distinct macrophage lineage. The 
differentiated cells were larger in size, adherent to plastic and had a macrophage-like 
morphology. Phenotypic changes were also observed in the differentiated in that CD14 
expression was preserved, CD86 expression was increased, and HLA-DR was decreased 
(Scheuerer et al, 2000).  It has been suggested that these CXCL4 differentiated cells should be 
classed as M4 macrophages (Gleissner et al, 2010). Secondly, CXCL4 has been shown to play 
a role in phagocytosis and ROS production in monocytes (Pervushina et al, 2004).   
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CXCL4 has been identified as a potential biomarker for inflammatory bowel disease (IBD). 
Meuwis et al (2007) identified CXCL4 alongside three other markers; myeloid-related protein 
(MRP8), αfibrinogen (FIBA) and haptoglobulin α2 (Hpα2), as potential discriminators of 
active IBD from other inflammatory diseases. Additionally, CXCL4 has been studied in 
patients with pancreatic adenocarcinoma. In a study by Poruk et al (2011), serum CXCL4 
levels were analysed from patients with either pancreatic adenocarcinoma or chronic 
pancreatitis. Although serum CXCL4 levels were not shown to be significantly different 
between healthy individuals and patients with pancreatic adenocarcinoma, increased serum 
CXCL4 in the pancreatic adenocarcinoma patients was associated with a poor prognosis and 
shorter survival time. Interestingly, CXCL4 levels distinguished between healthy individuals 
and patients with chronic pancreatitis. High CXCL4 was also associated with an increased 
risk of venous thromboembolism in patients with pancreatic adenocarcinoma.  
 
In RA, CXCL4 has been detected in the synovial fluid. Erdem et al (2007) compared synovial 
fluid levels of CXCL4 by ELISA from patients with RA, Behçet’s disease (BD), 
Osteoarthritis (OA) and Spondyloarthritis (SpA). CXCL4 was increased in the synovial fluid 
from patients with RA compared to the other disease groups. CXCL4 has been identified as a 
potential biomarker for the prediction of response to infliximab therapy. In a study by Trocmé 
et al (2009), plasma samples collected from responders and non-responders to infliximab 
treatment were analysed. Patients who responded well to infliximab had increased plasma 
concentrations of apolipoprotein A-1. However, those patients who failed to respond had 
increased levels of CXCL4.  This may suggest a role for CXCL4 in the exacerbation of 
inflammation in RA and aid in the identification of patients who will fail to respond to certain 
biologics so that the correct therapy may be targeted to the individual.  
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1.11.2.2 CXCL4L1   
CXCL4L1 or Platelet Factor 4 variant (PF4V1) is a non-allelic variant of CXCL4 expressed 
in humans, rhesus monkeys and chimpanzees. There is no CXCL4L1 gene expressed in the 
mouse. CXCL4L1 differs from CXCL4 in a three amino acid substitution in the C-terminus; 
Pro58>Leu, Lys66>Glu, and Leu67>His (Figure 1.5). This region is critical for heparin 
interaction (Green et al, 1989). Both CXCL4 and CXCL4L1 are located on the same 
chromosome (chromosome 4) but are separated by the gene for CXCL1. Like CXCL4, 
CXCL4L1 is released from platelets but at a much lower concentration. However, unlike 
CXCL4, other sources of CXCL4L1 include smooth muscle cells and tumour cells. Lasagni et 
al (2007) reported an increase in expression of CXCL4L1 in primary cultures of human aortic 
smooth muscle cells (HASMCs) and human coronary smooth muscle cells (HCoSMCs) when 
compared to CXCL4. This study also identified the expression of both CXCL4L1 and CXCL4 
in platelets, monocytes and T cells. In these cell types CXCL4 expression was greater than 
CXCL4L1 expression. CXCL4L1 plays an important role in the chemoattraction of activated 
T cells, NK cells and DCs.   
 
In RA, CXCL4L1 gene expression was identified in vitro in fibroblast-like synoviocytes.  
However, the level of expression was much lower than observed in fibroblast-like 
synoviocytes cultured from osteoarthritis patients (Cagnard et al, 2005).  
 
1.11.2.3 CXCL7 
CXCL7 or neutrophil activating peptide-2 (NAP-2) is a member of a platelet derived group of 
proteins collectively referred to as the β-thromboglobulins (β-TG Ag) that differ in their 
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number of amino acids following proteolytic truncation at the N-terminus (Figure 1.5). As 
well as including β-TG (81 amino acids), which was the first member of this group to be 
described, and CXCL7/NAP-2 (70 amino acids), other members include the much larger pro-
platelet basic protein (PPBP) (128 amino acids), platelet basic protein (PBP) (94 amino 
acids), and connective tissue activating peptide-III (CTAP-III) (85 amino acids). The family 
of β-TG Ag proteins are secreted as biologically inactive chemokines and therefore require 
proteolytic truncation to become active (Brandt et al, 1991, Brandt et al, 2000). Connective 
tissue activating peptide-III (CTAP-III) is the predominant inactive precursor released from 
activated platelets and requires cleavage by cathepsin-G like enzymes expressed by 
neutrophils. This occurs within 5-10 mins of release. Neutrophils can also cleave β-TG to 
active CXCL7/NAP-2. In serum, CXCL7 levels range from 1.6-4.8μM and within plasma 
levels are approximately 1000-fold lower. The receptors for CXCL7 are CXCR1 and CXCR2, 
both of which are expressed on neutrophils. CXCL7 is mainly responsible for 
chemoattraction, adhesion and transendothelial migration of neutrophils as well as their 
activation leading to the degranulation of lysosomal enzymes and formation of oxygen 
radicals (Blair and Flaumenhaft, 2009, Schenk et al, 2002). Moreover, CXCL7 has been 
reported to be expressed by T cells and monocytes. However, platelets are still considered the 
predominant source. Pillai et al (2006) reported that monocytes expressed CXCL7 when co-
cultured with stromal cells. In this study CD14+ monocytes were co-cultured with the human 
marrow stromal cell line HS27a. Co-culture led to an increase in the expression of CXCL7 
when compared to stromal cells alone.  
 
CXCL7 has been identified as a potential biomarker for chronic obstructive pulmonary 
disease (COPD) (Cazzola and Novelli, 2010, Di Stefano et al, 2009). CXCL7 was evident in 
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sections immunostained from the bronchial submucosa. Fibroblasts, endothelial cells and 
leukocytes stained positive for CXCL7. In the study by Di Stefano et al (2009), CXCL7 was 
significantly higher in patients with severe COPD compared to healthy controls. However, in 
contrast to this, a study by Dickens et al (2011) did not observe a significant difference in 
CXCL7 in COPD patients compared to smoker and non-smoker controls.  
 
In lung cancer, CXCL7/CTAP-III has been identified as a potential biomarker for the 
prediction of early disease. A study by Yee et al (2009) identified increased CXCL7/CTAP-
III in blood taken from the tumour drainage site compared to blood taken from the systemic 
circulation. CXCL7 decreased in the plasma following surgery to remove the tumour. 
However, in those patients whose cancer returned, CXCL7 did not decrease significantly. It 
was also shown that smokers who went on to develop lung cancer had increased levels of 
CXCL7 a number of years prior to clinical diagnosis. Moreover, an increase in CXCL7 has 
been identified in epithelial cells isolated from patients with active ulcerative colitis 
(Kruidenier et al, 2006). Like CXCL4, CXCL7 has also been identified as a potential 
biomarker for the diagnosis of early pancreatic adenocarcinoma. Matsubara et al (2011) 
carried out proteome screening of plasma samples collected from 24 patients with pancreatic 
cancer and 21 healthy controls. A significant decrease in plasma CXCL7 was identified in 
those patients with pancreatic cancer compared to healthy controls. By combining CXCL7 
and a current biomarker used for screening pancreatic cancer, CA19-9, patients with 
pancreatic cancer could be distinguished from healthy controls.  Additionally, Matsubata et al 
(2011) went on to suggest that the decrease in CXCL7 may precede the onset of pancreatic 
cancer and therefore serve as an early biomarker for the detection of early disease. Elsewhere, 
an increase in CXCL7 expression has been reported in an invasive/malignant breast cancer 
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cell line, MCF10CA1a.c11, compared to a pre-malignant breast cancer cell line, MCF10AT. 
Tang et al (2008) demonstrated that transfection of pre-malignant MCF10AT cells with 
CXCL7 led to a highly invasive phenotype, and treatment with an anti-CXCL7 reduced this 
invasiveness. Therefore it was suggested that CXCL7 expression may play an important role 
in breast cancer metastasis. 
 
In RA, CXCL7 is detectable in the synovial fluid, tissue and sera. It has been reported to play 
a role in the proliferation of fibroblasts within the joint and to have angiogenic properties 
(Szekanecz et al, 2003). The uncleaved CXCL7 precursor, β-TG, has been reported at 
increased levels in female patients with RA compared to healthy controls (Karatoprak et al, 
2012). CXCL7 expression has also been reported in PBMCs from patients with primary and 
secondary Sjögren’s syndrome (Egerer et al, 2006). 
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Figure 1.5 The β-Thromboglobulin family, CXCL4/PF4 and CXCL4L1/PF4V1 amino acid sequences. The numbering of the amino 
acid sequence commences at the N-terminus of CXCL7/NAP-2, CXCL4/PF4 and CXCL4L1/PF4V1. The red arrows indicate the 
proteolytic cleavage sites that give rise to CTAP-III (85 amino acids), β-thromboglobulin (81 amino acids) and the active chemokine 
CXCL7/NAP-2 (70 amino acids). CXCL7/NAP-2 is an ELR+ chemokine (motif highlighted in green) whereas both CXCL4/PF4 and 
CXCL4L1/PF4L1 lack the ELR motif. The amino acids highlighted in blue in PF4 indicate sequence homologies with CXCL7/NAP-2.  
The amino acid sequence of CXCL4L1/PF4V1 differs from the sequence of CXCL4/PF4 in three amino acids at the C-terminus: Pro 
58>Leu, Lys 66>Glu, and Leu 67>His (highlighted in red).  Image adapted from Brandt et al, 2000.
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1.11.3 CC chemokines in rheumatoid arthritis 
Of all the CC chemokines found in the synovium, CCL2, CCL3, CCL4 and CCL5 are the 
most commonly described (Godessart and Kunkel, 2001 (Table 1.5). CCL2, produced by 
macrophages and fibroblast-like synoviocytes in the rheumatoid joint, can chemoattract a 
number of immune cells including DCs, NK cells, monocytes and T cells thus exacerbating 
the inflammatory process (Iwamoto et al, 2008, Vergunst et al, 2005). Increased levels have 
been detected in both synovial fluid and tissue of patients with RA (Pease and Williams, 
2006). In a study carried out by Kokkonen et al (2010), CCL2 and CCL3 along with a number 
of other cytokines, were evident at increased levels in the peripheral blood in either anti-CCP 
positive or IgM-RF positive patients who went on to develop RA a number of years later. 
This study demonstrated the potential of pro-inflammatory cytokines and chemokines as 
predictive markers for RA onset. It also suggests that the immune system is activated a 
number of years prior to symptom onset.  
 
In the synovial fluid, neutrophils express high levels of CCL3 which has been shown to 
correlate with disease severity. CCL3 is also produced by T cells, fibroblasts and monocytes 
and can lead to recruitment of T cells, B cells, monocytes and NK cells into the joint 
(Iwamoto et al, 2008). CCL5 can chemoattract a large number of different immune cells into 
the synovium including NK cells, monocytes and T cells (Vergunst et al, 2005). Both CCL2 
and CCL5 have been linked to cartilage degradation by triggering chondrocytes to release 
matrix metalloproteinase-3 (MMP-3) (Iwamoto et al, 2008).  
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An increase in CCL20 has been reported in the synovial fluid and synovial tissue of RA 
patients. CCL20 recruits a number of different cell types to the synovial joint including naïve 
B cells, memory T cells and immature DCs. In a study by Matsui et al (2001), CCL20 
expression was significantly higher in the synovium of RA patients compared to OA patients. 
CCL20 was evident on both synovial lining and sublining cells. The receptor for CCL20, 
CCR6, was also identified in the RA synovium but not OA synovium. Furthermore, in vitro 
cultured synovial fibroblasts were able to produce CCL20 in response to stimulation with IL-
1β and TNFα. This would suggest that the cytokine milieu within the synovium may trigger 
the release of CCL20 from fibroblasts and recruit inflammatory cells to the synovial joint thus 
further exacerbating inflammation. 
 
1.11.4 C chemokines in rheumatoid arthritis 
Lymphotactin (XCL1) is located on chromosome 1 and is expressed by a number of cells 
including NK cells, CD8+ and CD4+ T cells. It signals through the XCR1 receptor located on 
the CD141+ (BDCA3+) subset of DCs (Lei and Takahama, 2011). Lymphotactin has been 
found to play a role in RA (Table 1.6). Research has reported an increase in the concentration 
of XCL1 in the synovial fluid compared to peripheral blood in RA patients (Raman et al, 
2011). Lymphotactin is responsible for the chemoattraction of CD45RO+/CD45RB- T cells 
into the inflamed joint (Borthwick et al, 1997).  
 
1.11.5 CX3C chemokine, Fractalkine, in rheumatoid arthritis 
Fractalkine has been reported in the synovial fluid, tissue and sera of patients with RA 
(Raman et al, 2011) (Table 1.6). A number of cells express this chemokine including DCs, 
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fibroblasts-like synoviocytes and interstitial macrophages (Nanki et al, 2004), whilst the 
receptor CX3CL1 is found on CD4+ and CD8+ T cells, monocytes and NK cells.  Fractalkine 
is also expressed on endothelial cells within the RA synovium. It has been suggested to play 
an important role in the chemoattraction of monocytes, DCs and lymphocytes into the 
synovium (Iwamoto et al, 2008).  
 
In a study carried out by Nanki et al (2004), the effect of inhibiting Fractalkine was studied 
using the murine collagen-induced arthritis (CIA) model.  The mice were injected in the 
peritoneal cavity with a 500 µg/ml dose of hamster anti-mouse Fractalkine monoclonal 
antibody (FKN mAB) three times per week for two weeks. Treatment with FKN mAB 
significantly reduced the clinical arthritis score when compared to control mice injected with 
hamster IgG.  Pannus formation, bone erosion and synovial hyperplasia were, also, markedly 
reduced in ankle joints harvested from the treatment group. This study demonstrated the 
potential of Fractalkine as a therapeutic target for the treatment of RA.  
 
1.12 Targeting chemokines and their receptors for therapeutic benefit in patients 
with rheumatoid arthritis 
The potential of targeting chemokines and their receptors for the treatment of RA has not been 
without its pitfalls. Multiple clinical trials have been carried out, most of which with limited 
success. A number of small molecular weight antagonists and anti-human monoclonal 
antibodies designed to block chemokine receptors have been tested in the past 10 years for the 
treatment of RA. Two CCR5 antagonists, AZD5672 (Gerlag et al, 2010) and SCH351125, 
have been trialled in a randomised, placebo controlled phase IIb trial and a randomised, 
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double blind, placebo controlled phase Ib clinical trial for the treatment of RA, respectively. 
Although both were well tolerated in the patients, they did not show any clinical 
improvement. In the case of SCH351125, there was an improvement in DAS28 in both the 
placebo and treatment groups (Van Kuijk et al, 2010). There was also no significant reduction 
in CCR5+ cells in the treatment group. Similar observations were made in a double blind, 
placebo controlled trial of an anti-human IgG1 CCR2 monoclonal antibody (MLN1202). 
MLN1202 was generally well tolerated, however similar responses were seen in both the 
placebo and treated groups. No clinical benefit was observed (Gerlag and Tak, 2008, 
Vergunst el al, 2008). Moreover, a randomised, placebo controlled, proof of concept trial of a 
human monoclonal antibody against CCL2 led to an increase in C-Reactive Protein (CRP) 
and the number of macrophages in the patients given a high dose (Haringman et al, 2006).  
Nevertheless, the blockade of CCR1 is demonstrating far more potential (Lebre et al, 2011).  
Clinical benefit has been observed using a CCR1 antagonist, CP-481,715 for the treatment of 
RA. The number of macrophages and CCR1+ cells in the synovial tissue were reduced 
(Gerlag and Tak, 2008). 
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1.13 Study background 
Previous work by a member of our research group (Yeo et al, 2011) studied the expression of 
117 different cytokines and chemokines from synovial tissue biopsies using TaqMan low-
density real-time PCR arrays. Synovial tissue biopsies were collected by ultrasound guided 
biopsy from patients with synovitis of at least one joint and symptom duration of ≤ 3 months. 
Upon follow up, 18 months later, patient disease outcomes were determined. Patients were 
either grouped into those that had developed RA in accordance with the 1987 ARA 
classification criteria (early RA group) or those whose early synovitis had spontaneously 
resolved (resolving synovitis group). Synovial biopsies collected from patients with RA (1987 
ARA criteria) of >3 months duration (<3 years duration) (established RA group) were also 
recruited as controls. All the above biopsies were collected from DMARD and glucocorticoid 
naiive patients enrolled in the Birmingham early inflammatory arthritis cohort (BEACON). 
Patients with unexplained joint pain assessed by arthroscopy in a local orthopaedic clinic 
without any clinically apparent or macroscopic synovial inflammation (uninflamed control 
group) were also included as study controls.  
 
In order to analyse cytokine expression in the different outcome groups, a number of 
statistical tests and a mathematical computer model (generalized matrix relevance learning 
vector quantization (GMLVQ)) were applied to the real-time PCR array data. The GMLVQ 
model set out to categorise patients into particular outcome groups based on their cytokine 
data. An interesting finding from this analysis was that when the early RA outcome group was 
compared to the early resolving synovitis outcome group, the two cytokines shown to 
distinguish between the patient groups were the platelet derived chemokines, CXCL4 and 
CXCL7.  
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1.14 Hypothesis and objectives 
 
As a result of the previous observations described in section 1.13 the principal aim of this 
thesis was to investigate the hypothesis that the expression of platelet derived chemokines, 
CXCL4 and CXCL7, in the synovium and peripheral blood could predict disease progression 
in patients presenting with early synovitis.  
 
In order to study this, the primary objective was to stain synovial biopsies taken from patients 
enrolled in the Birmingham Early Inflammatory Arthritis (BEACON) cohort with antibodies 
specific for CXCL4 and CXCL7 and compare the expression data to clinical outcome. 
 
The second objective was to address the potential of both chemokines in plasma as predictive 
biomarkers of disease progression in patients presenting with early synovitis. CXCL4, 
CXCL7 and the platelet activation marker sGPVI was assessed in plasma samples collected 
from patients enrolled in the BEACON cohort. 
 
Although I initially hypothesised that an increase in CXCL4 and CXCL7 expression would be 
due to an increased numbers of platelets within the synovium, the current literature suggested 
that cells outside the megakaryocyte lineage including monocytes, macrophages, and 
dendritic cells express CXCL4 and CXCL7. Therefore the tertiary objective was to identify 
cell populations expressing both chemokines within inflamed synovial tissue. The cellular 
expression of CXCL4 and CXCL7 in monocytes and in vitro differentiated macrophages 
obtained from healthy controls was assessed by qPCR. 
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2 METHODS 
 
2.1 Patient cohort: The Birmingham Early Inflammatory Arthritis Cohort 
(BEACON) 
 
Patients with early synovitis were recruited via new patient clinics for early arthritis at 
Sandwell and West Birmingham Hospitals NHS trust, Birmingham, UK and University 
Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. All patients gave written, 
informed consent. The study was approved by the Birmingham and the Black Country 
Research Ethics Committee (West Midlands Black Country REC 07/H1203/57). Patients 
were assessed by consultant rheumatologists, Dr Andrew Filer or Dr Karim Raza, and were 
deemed to have early synovitis based on the presence of at least one clinically swollen joint, 
inflammatory joint pain and/or early morning stiffness, and/or joint related soft tissue 
swelling for ≤3 months duration. Patients recruited to the Birmingham early inflammatory 
arthritis cohort (BEACON) were DMARD and glucocorticoid naïve at the time of synovial 
biopsy. 
 
Synovial biopsies were obtained by ultrasound guided biopsy. Joints were first assessed using 
a Siemens Acuson Antares scanner (Siemens, Bracknell, UK) and multi-frequency (5-13 
MHz) linear array transducers. Synovial tissue with evidence of grey scale synovitis, was 
collected from multiple regions within the knee, ankle or metacarpophalangeal (MCP) joints. 
Tissue from the knee and ankle was obtained via a single portal using custom manufactured 
2.2 mm cutting edged forceps, whereas tissue from the MCP joints was obtained using a 16- 
gauge core biopsy needle. All biopsies were anonymised at the time of collection and were 
issued with a BX (biopsy) number. Blood and urine samples were also obtained from patients 
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enrolled in the BEACON cohort. Plasma and serum was stored at -80°C for downstream 
analyses. Additionally, age, sex, disease duration, CCP and RF status, ESR, CRP, global 
assessment of disease activity, swollen joint count, tender joint count and DAS28 status of 
each patient were collected upon initial assessment.  
 
During 18 months of follow-up, patients were grouped into those that met the 1987 ARA 
criteria (Arnett et al, 1988), or had gone on to fulfil those criteria, those that had developed a 
non RA- persistent inflammatory arthritis, and those that had gone on to have a resolving 
synovitis. In this thesis, patients who went on to develop RA will be referred to as the ‘Early 
RA’ group, and those that went on to have a resolving synovitis will be referred to as the 
‘Resolving’ group. Patients who went on to develop a non RA-persistent inflammatory 
arthritis were not studied in this context as they represent a very heterogeneous group.  
 
In addition, synovial biopsies were obtained from patients with RA (1987 ARA criteria) of > 
3 months duration (<3 years duration). Patients were DMARD and glucocorticoid naïve at the 
time of biopsy.   In this thesis this group will be referred to as the ‘Established RA’ group. 
Synovial biopsies were also obtained from an uninflamed cohort of patients under 
investigation for mechanical symptoms with normal MRI appearances. This cohort was 
managed by Mr. Martyn Snow. Patients recruited to this group demonstrated an absence of 
joint inflammation clinically, with macroscopically normal synovium at the time of 
arthroscopy under direct vision. Synovial samples demonstrating histological evidence of 
inflammatory arthritis were excluded from the final cohort.  
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2.2 Joint replacement synovial biopsies 
 
Synovial biopsies collected from patients with longstanding RA who had fulfilled the 1987 
ARA classification criteria were used in chapters 3 and 5. Synovial biopsies were collected 
intra-operatively from patients undergoing joint replacement at the Royal Orthopaedic 
Hospital NHS trust. This cohort was kindly managed by Mr. Andrew Thomas. Patient 
information can be found in appendix table 8.1.  
 
2.3 Processing of synovial biopsies 
 
Biopsies were fixed overnight in formaldehyde and placed in pre-labelled cassettes prior to 
being processed using the automated Leica ASP300 tissue processor (Table 2.1). Sections 
were dehydrated in industrial methylated spirits (IMS) 99% alcohol, cleared in xylene and 
embedded in paraffin wax. This process was carried out by the Royal Orthopaedic Hospital, 
Birmingham, UK.  
Step Reagent Time (mins) Temperature (°C) 
1 IMS 99% alcohol 0.45 37 
2 IMS 99% alcohol 0.50 37 
3 IMS 99% alcohol 0.55 37 
4 IMS 99% alcohol 1.30 37 
5 IMS 99% alcohol 1.30 37 
6 IMS 99% alcohol 2.00 37 
7 Xylene 1.00 37 
8 Xylene 1.00 37 
9 Xylene 2.00 37 
10 Paraffin wax 1.00 63 
11 Paraffin wax 2.00 63 
12 Paraffin wax 2.00 63 
 
Table 2.1 Preparation of formalin fixed paraffin embedded tissue sections using the 
Leica ASP300 tissue processor. Synovial biopsies, once collected, were fixed in 
formaldehyde before being sent to the Royal Orthopaedic Hospital (ROH) for processing and 
sectioning.  
  
62 
 
Following embedding in paraffin wax, 3 µm sections were cut. Sections were then air-dried in 
a slide drying cabinet at 65°C for a minimum of 1 hour (not overnight). One section from 
each block was then stained with Haematoxylin and Eosin. 
 
2.4 Synovial fibroblasts 
 
For the work shown in chapter 5, in vitro cultured fibroblasts were used in a number of 
experiments. Synovial fibroblasts were cultured from biopsy sections taken from patients 
enrolled in the BEACON cohort as well as from synovial tissue collected from patients 
undergoing routine joint replacement surgery at the Royal Orthopaedic Hospital.  Patients 
recruited at the Royal Orthopaedic Hospital gave written, informed consent. The study was 
approved by the Birmingham and the Black Country Research Ethics Committee. For our 
experiments, fibroblasts from patients with early RA, established RA, resolving synovitis, 
joint replacement RA, or joint replacement osteoarthritis (OA) were used. Patient information 
can be found in appendix tables 8.4 and 8.5. 
 
2.4.1 Fibroblast chamber slides 
Fibroblast chamber slides were prepared by our lead technician, Miss Holly Adams. In brief, 
fibroblasts were cultured until confluent. Fibroblasts were used at passage 3, passage 4, or 
passage 5 depending on availability. Fibroblasts were trypsinised, counted and suspended in a 
volume of 0.06 x 106 cells/ml of complete fibroblast medium (RPMI-1640 + 10% Foetal Calf 
Serum (FCS) + 1% MEM Non-essential amino acids (Sigma M7145) + 1% Sodium 
Orthopyruvate (Sigma S8636) + 1% L-glutamine-penicillin-streptomycin (GPS)). They were 
then seeded in culture chamber slides (Falcon®, USA) at a density of 0.03 x 106 cells/well in 
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500 μl fibroblast medium. Slides were then cultured in an incubator set at 37°C and 5% CO2 
for 48 hrs. Following incubation, media was discarded from the chamber slides and the 
chamber was removed from the slide. Slides were then washed in PBS for 5 mins before 
being left to dry for 1 hr. Next, slides were fixed in acetone for 20 mins at 4°C and then 
subsequently left to dry for 5-10 mins. Slides were then stored at -80°C for downstream 
immunofluorescence experiments.  
 
2.5 Immunofluorescence 
 
Frozen synovial biopsies previously sectioned (6µm thickness), mounted, and fixed with 
acetone were rehydrated in PBS for 2 x 5 mins. The slides were removed from PBS and 
placed in a wet box and 50 µl of blocking solution (10% FCS/PBS) were added to each 
individual tissue section. The slides were incubated at room temperature for 30 mins. The 
blocking solution was then removed from the sections by gently tapping the slides and 50 µl 
of primary antibody was added for 60 mins. Following incubation with the primary antibodies 
(Table 2.2, 2.3 and 2.6), the slides were washed in PBS for 2 x 5 mins. Biotin antibody (50µl) 
was then added to the sections for 30 mins followed by a further wash in PBS for 2 x 5 mins. 
Finally the secondary antibodies (Table 2.5) were added to the sections (50 µl) and incubated 
for 30 mins followed by a final wash step in PBS for 2 x 5 mins. Sections were then 
counterstained in 10 μg/ml Hoechst 33258 pentahydrate (bis-benzimide) for 90 seconds, 
washed for 5 mins in PBS and mounted in 2.4% w/v 1,4- diazabicyclo [2,2,2] octane 
(DABCO) (Aldrich, Gillingham, England) dissolved in 90% v/v glycerol in PBS, pH 8.6 
(Fisher Scientific, Loughborough, UK). Slides were visualised using the Zeiss LSM 780 Zen 
Confocal microscope (Zeiss, Germany), unless stated elsewhere. Analysis was carried out 
using Zen imaging software and Microsoft Excel.  
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Antibody Isotype Stock 
Concentration 
(if available) 
Dilution Supplier 
Von Willebrand Factor 
(vWF) 
Rabbit NA 1 in 500 Dako  
CD41 Mouse IgG1 100 μg/ml 1 in 500 
1 in 370 
Dako  
CXCL4 Mouse IgG2b 1 mg/ml 1 in 100 Abcam 
CXCL7 Mouse IgG2b 0.5 mg/ml 1 in 50 Novus Biologicals 
CD68 Mouse IgG2a 30 μg/ml 1 in 25 Thermo Scientific: Pierce  
 
Table 2.2 Primary antibodies used for the CXCL4 and CXCL7 5-colour staining panel. 
Antibodies were used in chapter 3. 
 
Antibody Isotype Stock 
Concentration 
(if available) 
Dilution Supplier 
Platelet Factor 4 variant 
1 
Rabbit 1 mg/ml 1 in 1200 Thermo Scientific: Pierce 
hCD90/Thy1 (Clone 
Thy/IAI) 
Mouse IgG2a 0.5 mg/ml 1 in 200 Abcam 
VCAM-1 (Clone P8B1) Mouse IgG2b 1 mg/ml 1 in 100 Millipore 
Podoplanin Mouse IgG1 NA 1 in 100 AbD Serotec 
Protein Disulphide 
Isomerase (PDI) (RL77) 
Mouse IgG2b 2.3 mg/ml 1 in 250 Abcam 
 
Table 2.3 Primary antibodies used for the characterisation of CXCL4L1 in RA. 
Antibodies were used in chapter 5. 
 
Antibody Isotype Stock 
Concentration 
(if available) 
Dilution Supplier 
Mouse IgG1-UNLB 
(clone 15H6) 
Mouse IgG1 1 mg/ml * Southern Biotechnology 
Mouse IgG2a-UNLB 
(clone HOPC-1) 
Mouse IgG2a 1 mg/ml * Southern Biotechnology 
Mouse IgG2b-UNLB 
(Clone A-1) 
Mouse IgG2b 1 mg/ml * Southern Biotechnology 
Rabbit Serum Rabbit NA * Dako 
 
Table 2.4 Isotype-matched controls used for immunofluorescence staining. The same 
concentration was used for the both isotype-matched controls and the primary antibodies, 
denoted by asterisks.   
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Antibody Isotype Stock 
Concentration 
(if available) 
Dilution Supplier 
Chromeo™ 494 Goat pAb 2 mg/ml 1 in 100 Abcam 
Cy™3-conjugated 
Streptavidin 
NA 1.8 mg/ml 1 in 100 Jackson Immunoresearch 
Goat anti mouse Alexa 
Fluor® 488 
Mouse IgG1 1.7 mg/ml 1 in 300 Jackson Immunoresearch 
Goat anti mouse Cy5 Mouse 
IgG2a 
1 mg/ml 1 in 50 Southern Biotechnology 
 
Table 2.5 Secondary antibodies used for immunofluorescence staining.  
 
Antibody Isotype Stock 
Concentration 
(if available) 
Dilution Supplier 
CD303 (BDCA-2) FITC Mouse IgG1 82.5 μg/ml 1 in 100 Miltenyi Biotec 
Goat anti-mouse- BIOT Mouse IgG2b 0.5 mg/ml 1 in 50 Southern Biotechnology 
Alexa Fluor® 647 Mouse Rabbit 1.4 mg/ml 1 in 800 Jackson Immunoresearch 
Goat anti- mouse BIOT Mouse IgG2a 0.5 mg/ml 1 in 50 Southern Biotechnology 
Goat anti- mouse 
TRITC 
Mouse IgG2b 1 mg/ml 1 in 100 Southern Biotechnology 
Cy™5-conjugated 
Streptavidin 
NA 1.8 mg/ml 1 in 100 Jackson Immunoresearch 
 
Table 2.6 Additional antibodies used for immunofluorescence staining. 
 
2.6 CXCL4 and CXCL7 measurement in plasma by ELISA 
 
Quantitative measurement of plasma CXCL4 was assessed using a Quantikine® ELISA kit 
(R&D Systems, UK). Plasma CXCL7 was analysed using the ab100617- CXCL7 ELISA kit 
(Abcam, UK). Upon receipt, the CXCL4 ELISA was stored at 4°C and the CXCL7 ELISA 
was stored at -20°C.  
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2.6.1 CXCL4 Quantikine® ELISA 
All reagents and samples were brought up to room temperature (18-25°C) before use. In order 
to prepare the standard curve for the assay, the recombinant human PF4 standard was first 
reconstituted in 900 µl dH2O to prepare a 500 ng/ml stock solution and left to sit for 30 mins 
prior to use.  A 50 ng/ml top standard was prepared from the stock solution by the addition of 
50 µl of the stock solution to 450 µl of calibrator diluent RD6-13. The standard curve was 
then prepared (Table 2.7). Calibrator diluent RD6-13 was used alone as a zero (0 ng/ml) 
standard. 
Standard 
(ng/ml) 
Volume of 
standard solution 
(µl) 
Volume of 
calibrator diluent: 
RD6-13                
diluent (µl) 
Concentration           
(ng/ml) 
Standard 
500 50 450 50 1 
50 200 200 25 2 
25 200 200  12.5 3 
12.5 200 200  6.25 4 
6.25 200 200  3.13 5 
3.13 200 200 1.56 6 
1.56 200 200  0.781 7 
-  -  200 0 Blank 
 
Table 2.7 Preparation of the CXCL4 Quantikine® ELISA standard curve. 
 
Samples for the ELISA were diluted 1 in 100 or 1 in 200 in calibrator diluent RD6-13. The 
pre-coated ELISA plate was then prepared by adding 100 µl assay diluent RD1-15 to each 
well, followed by 50 µl of the standards and the diluted samples. Standards and samples were 
run in duplicate. After addition to the plate, the plate was incubated for 2 hrs at RT on a 
Denley Well Mixx 3 shaker. Following incubation, the assay plates were washed 4 times 
using a multi-channel pipette (400 µl each well) with 1X wash solution. Wash solution was 
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provided as a 25X concentrated solution in the kit. The solution was diluted with dH2O to a 
1X prior to use. After the final wash step, the plate was tapped on absorbent paper to remove 
any excess wash solution. Next, 200 µl anti-human PF4 conjugate was added to each well. 
The PF4 conjugate consisted of a polyclonal antibody specific for CXCL4 conjugated to 
HRP. The plate was then incubated for a further 2 hrs at RT with gentle shaking before being 
washed 4 times as previously described. Substrate solution (200 µl) was then added to each 
well and the plate was protected from light by covering with foil and left to incubate for 30 
mins at RT without shaking. Prior to addition to the plate, the substrate solution was prepared 
by adding equal volumes of hydrogen peroxide (colour reagent A) and tetramethylbenzidine 
(colour reagent B). Finally, 50 µl 2 N sulphuric acid (stop solution) was added to each well. 
The plate was read immediately using the BioTek EL808 plate reader at 450 nm with a 
wavelength correction of 540 nm. 
 
2.6.2 CXCL7 ELISA 
All reagents and samples were brought up to room temperature (18-25°C) before use. In order 
to prepare a 50 ng/ml standard for the preparation of the standard curve, recombinant CXCL7 
was reconstituted in 400 µl of assay diluent. For the preparation of the standard curve, 20 µl 
of the 50 ng/ml standard was diluted in 980 µl assay diluent to prepare a 1,000 pg/ml standard 
solution. The standard curve was then prepared (Table 2.8). Assay diluent, alone, was used as 
a zero (0 pg/ml) standard.  
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Standard 
(pg/ml) 
Volume of 
standard solution 
(µl) 
Volume of assay                
diluent (µl) 
Concentration           
(pg/ml) 
Standard 
50,000 20 980 1,000 1 
1,000 200 300  400 2 
400 200 300  160 3 
160 200 300  64 4 
64 200 300  25.6 5 
25.6 200 300  10.24 6 
10.24 200 300  4.10 7 
-  -  200 0 Blank 
 
Table 2.8 Preparation of the ab100613- CXCL7 standard curve. 
 
 
Plasma samples were diluted 1 in 5000 or 1 in 10,000 in assay diluent before addition to the 
assay plate. 100 µl of each standard and sample was pipetted into the appropriate wells of the 
pre-coated assay plate. Plates arrived pre-coated with anti-human CXCL7. The standards and 
samples were run in duplicate. The plate was then incubated for 2.5 hrs at room temperature 
with gentle shaking. Following incubation, the plate was washed 4 times with a multi-channel 
pipette with 1X wash solution. Wash solution was provided as a 20X concentrated solution in 
the assay kit. It was therefore diluted with dH2O to a 1X wash solution prior to use. After 
washing, the plate was tapped against absorbent paper to remove any excess wash solution. 
Next, 100 µl of 1X biotinylated antibody (biotinylated anti-human CXCL7) was added to 
each well and incubated for 1 hour at room temperature with gentle shaking. Biotinylated 
antibody was provided as a lyophilized vial. To reconstitute, 100 µl of assay diluent was 
added to the vial. The vial was then gently mixed. Prior to use, the Biotinylated antibody was 
diluted 80-fold with assay diluent. The plate was washed as previously described. HRP- 
conjugated streptavidin solution (100 µl) was then added to the plate and incubated for 45 
mins at room temperature with gentle shaking. Before use, the HRP-conjugated streptavidin 
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solution was diluted 200-fold. The plate was then washed. Next 100 µl of 3,3’,5,5’- 
tetramethylbenzidine (TMB) One-Step Substrate Reagent was added to each well. The plate 
was incubated in the dark with gentle shaking for 30 mins. Finally, 50 µl of 0.2 M H2SO4 
(stop solution) was added to each well. The plate was immediately read at 450 nm and 540nm 
using the BioTek EL808 plate reader.  
 
2.6.3 ELISA Data analysis 
The mean absorbance for each duplicate standard was calculated. The mean zero standard 
optical density (O.D) was subtracted from the standards and samples. A standard curve of the 
standard concentration against the absorbance was plotted using Prism 5 software. A line of 
best-fit was added and unknown serum and plasma concentrations were read from the curve.  
 
2.7 Soluble platelet glycoprotein VI (sGPVI) measurement in human plasma by 
ELISA 
 
Each well of a F96 MaxiSorp Nunc-Immuno plate (Thermo Scientific, Nunc 442404) was 
coated with 100 µl of 1 µg/ml (stock conc. 958 µg/ml) rabbit polyclonal anti-human GPVI 
extracellular domain antibody prepared in coating buffer. The coating buffer was prepared by 
dissolving 1 carbonate-bicarbonate buffer capsule (Sigma, C3041-100CAP) in 100 ml of 
ddH2O. The plate was then covered with an adherent strip and incubated overnight at 4°C. 
The plate was then subsequently washed 6 times in 0.2% Tween-20 in PBS (8.18 g NaCl, 0.2 
g KCl, 1.42 g Na2HPO4, and 0.244 g KH2PO4 in ~900 ml ddH2O, pH 7.4, then volume 
adjusted to 1 L) before being blocked with 200 µl per well of 1% BSA in PBS for 1 hour at 
RT. During the blocking step, N-ethylmaleimide (NEM)-treated platelet poor plasma (PPP), 
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internal control and patient samples were diluted 1/20 in PBS. 5% GPVI-depleted PPP in PBS 
was also prepared. After blocking, the plate was washed as described previously. Next 100 µl 
5% GPVI-depleted PPP was added to wells A1-A10 and B1-B10. This was followed by 100 
µl NEM-PPP (1/20) (320 ng/ml) into wells A1 and B1 to prepare a 160 ng/ml standard. Wells 
A1 and B1 were mixed thoroughly by pipetting up and down 6 times. 100 µl from A1 and B1 
was then transferred to wells A2 and B2 (80 ng/ml standard) using a multi-channel pipette. 
This process was repeated until wells A10 and B10. 100 µl was discarded from wells A10 and 
B10. 100 µl of each sample and control was added to duplicate wells of the plate. The plate 
was then incubated for 1 hour at RT before being washed 6 times with 0.2% Tween-20/PBS. 
Next 100 µl 1 µg/ml (stock conc. 1.17 mg/ml) monoclonal mouse anti-human GPVI antibody 
(1A12) prepared in PBS was added to each well of the plate. The plate was then incubated for 
1 hour at RT before being washed 6 times with 0.2% Tween-20/PBS. 100 µl of 2.6 µg/ml 
(stock conc. 1.3 g/L) polyclonal rabbit anti-mouse Immunoglobulins/HRP (Dako, UK) was 
added to each well. The plate was then incubated for a further 1 hour at RT before being 
washed for the final time as described previously. Finally, 100 µl of Super Signal ELISA 
PICO chemiluminescent substrate (1:1 Luminol/Enhancer solution and Stable Peroxide 
Solution) (Thermo Scientific, PIE 37069) was added to each well of the plate. The plate was 
incubated for 1 min at RT before being read at 425 nm using the Wallac VICTOR2 1420 multi 
label counter (PerkinElmer Life Sciences). 
 
2.8 Peripheral blood mononuclear cell isolation 
 
Peripheral blood was collected from healthy donors into ethylenediaminetetraacetic acid 
(EDTA)-containing tubes (3μl EDTA per 1ml blood) and subsequently diluted at a 1:1 ratio 
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with RPMI-1640 supplemented with 1% GPS. The diluted blood was then layered on to 
Ficoll-Paque at a 1:3 blood to Ficoll ratio (GE Healthcare, UK). Tubes were centrifuged for 
30 mins at 290 x g (acceleration: 0, brake: 0). Following centrifugation, peripheral blood 
mononuclear cells (PBMCs) were carefully removed at the Ficoll-Paque interface with a 
sterile pasteur pipette. The PBMCs were then washed twice in RPMI-1640 + 1% GPS by 
centrifugation for 6 mins at 300 x g (acceleration: 9, brake: 9). Supernatant was removed 
between washes and fresh medium was added. The cells were then counted using a 
haemocytometer and used in downstream experiments.  
 
2.9 CD14+ cell isolation 
 
2.9.1 Magnetic labelling 
Isolated PBMCs were first centrifuged at 290 g for 10 mins and the supernatant was removed. 
The cell pellet was resuspended in 80µl MACs buffer per 107 cells. To this, 20µl of CD14 
magnetic beads were added (Miltenyi Biotec, UK). The cells were incubated for 15 mins at 
4°C. Following this, the cells were washed in 1-2ml of MACs buffer per 107 at 290 g x 10 
mins. The cell pellet was then resuspended in 500µl per 108 cells.  
 
2.9.2 Magnetic separation 
An LS column (Miltenyi Biotec, UK) was placed in the magnetic field of the MACs 
separator. The column was prepared by rinsing through with 3ml of MACs buffer. The cell 
suspension was then added to the column and the flow-through was collected as waste. The 
column was then washed with 3 x 3ml MACs buffer. The column was then removed from the 
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magnetic separator and placed over a collection tube. 5ml of MACs buffer was then added to 
the column and the flow through was collected. The flow through contains the CD14+ cell 
fraction. The cells were subsequently counted and purity checked using the Cyan Flow 
Cytometer (Beckman Coulter, UK).  
 
2.10 Cell sorting of monocyte and platelet complexes 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors by Ficoll-
Paque. Cells were sorted into three populations; CD14+ CD41-, CD14+ CD41+ intermediate, 
and CD14+ CD41+ using the MoFlo™ cell sorter (Beckman Coulter). The cell sorter was 
kindly operated by Mr Roger Bird, a cell sorting and analysis expert, based at The University 
of Birmingham. 
 
 
 
Dilution Antibody Clone Supplier 
Surface antibodies    
Monoclonal mouse anti-human 
CD41, platelet glycoprotein IIb/FITC 
1 in 50 5B12 Dako 
Anti-human CD14 PE-CY7 1 in 100 61D3 ebioscience 
Isotype-matched control antibodies    
Mouse IgG1κ Iso control FITC 1 in 250 P3.6.2.8.1 ebioscience 
Mouse IgG1κ Iso control PE-CY7 1 in 100 P3.6.2.8.1 ebioscience 
Compensation antibodies    
Anti-human CD14 PE-CY7 1 in 50 61D3 ebioscience 
Anti-human CD14 FITC 1 in 50 61D3 ebioscience 
 
Table 2.9 Surface antibodies, isotype-matched control antibodies and compensation 
antibodies used during the cell sort. 
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To prepare the isolated PBMCs for the cell sort, the wells of a round-bottomed 96-well plate 
were coated with 180 µl FCS. The plate was incubated on the bench for 10 mins at RT before 
the FCS was removed by gently tapping the plate on absorbent paper. The isolated PBMCs 
were resuspended in FCS and added to the plate. For the cell sort, the number of cells added 
to each well was dependent on the number of PBMCs isolated from each donor. The plate was 
then centrifuged at 290 g (acceleration: 9, brake: 9) for 4 mins at 4°C in order to pellet the 
cells. The supernatant was then removed and 100 µl of the prepared surface antibodies and 
isotype-matched control antibodies (Table 2.9) diluted in MACs buffer (phosphate buffered 
saline (PBS) supplemented with 0.5% bovine serum albumin (BSA) and 2 mM EDTA) were 
added to the appropriate wells. For compensation, cells were stained with either anti-human 
CD14 FITC or anti-human CD14 PE-CY7 (Table 2.9). The cells were then incubated for 30 
mins at 4°C. Cells were then washed by adding 50 µl of MACs buffer to each well, followed 
by centrifugation at 290 g for 4 mins at 4°C. Supernatant was removed, and the cells were 
resuspended in 150 µl MACs buffer before being transferred to FACs tubes containing 400 µl 
MACs buffer. The stained cells were then stored protected from light at 4°C for 
approximately 30 mins prior to the cell sort. Following the cell sort, cells were stored briefly 
on ice. For qPCR experiments, the sorted cells from the CD14+ CD41-, CD14+ CD41+ 
intermediate, and CD14+ CD41+ populations were centrifuged for 4 mins at 894 g. The 
supernatant was then removed and the cells were resuspended in 350 µl RLT buffer. Lysed 
cells were then stored at -80°C ready for RNA isolation. For downstream cell culture 
experiments, CD14+ CD41- cells were centrifuged for 4 mins at 894 g, the supernatant was 
removed, and the cells were resuspended in 1 ml RPMI-1640 + 10% heat inactivated FCS (Hi 
FCS) + 1% GPS. 
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2.10.1 In vitro monocyte differentiation 
Following the cell sort, the CD14+ CD41- cell population was seeded in a 96 well-plate at 
3.37 x 104 cells/well in RPMI-1640 + 10% Hi FCS + 1% GPS in a volume of 200 µl/well. 
Cells were differentiated to macrophages under M1, M2 or Mo-DC culture conditions (Table 
2.11). Cells were cultured in an incubator set at 37°C and 5% CO2 for 6 days. After 6 days, 
the differentiated cells were treated with 10 ng/ml LPS for 6 hrs or 24 hrs or left unstimulated. 
Isolated CD14+ monocytes used in work shown figure 4.1 were seeded in a 6 well-plate at 1 x 
106 cells/well in RPMI-1640 + 10% Hi FCS + 1% GPS in a volume of 1000 µl/well. They 
were then subsequently differentiated under M1, M2 or Mo-DC culture conditions as 
described (Table 2.10).  
 
 Media Cytokine 
(Peprotech, UK) 
Cytokine 
concentration 
(ng/ml) 
M1 RPMI + 10% Hi FCS +1% GPS GM-CSF 10  
M2 RPMI + 10% Hi FCS +1% GPS M-CSF 10 
Mo-DC RPMI + 10% Hi FCS +1% GPS GM-CSF 
IL-4 
25 
25 
 
Table 2.10 Culture of CD14+ CD41- cells under M1, M2 and Mo-DC culture conditions. 
GM-CSF, M-CSF and IL-4 (stock conc. 100 μg/ml) were supplemented into 10 ml RPMI + 
10% Hi FCS + 1% GPS. For cells cultured under M1 conditions, GM-CSF was added to the 
media, for M2 conditions M-CSF was added, and for Mo-DC, both GM-CSF and IL-4 were 
added.  
 
Supernatants were collected from cells cultured under M1, M2 or Mo-DC conditions and 
TNFα levels were analysed using a TNFα sandwich ELISA MAX™ Deluxe set (Biolegend, 
UK). Upon analysis of the results there was no significant difference in TNFα between the 
cultured subsets. Therefore I was reluctant to refer to the M1, M2 and Mo-DC cultured cells 
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as terminally differentiated populations. Furthermore, due to time restraints I was unable to 
carry out additional phenotyping experiments of these cell populations. 
 
2.11 RNA extraction 
 
RNA was extracted from monocytes and in vitro differentiated macrophages using the Qiagen 
RNeasy Mini Kit. A DNAse step was also included in the protocol in order to remove 
contaminating genomic DNA. To begin, cells that had been lysed in RLT buffer and 
subsequently stored at -80°C were thawed and homogenized by vortexing for 1 min. To the 
lysate, an equal volume of 70% ethanol was added to each sample and mixed well. The 
sample (up to 700µl) was then transferred to an RNeasy spin column, placed in a 2ml 
collection tube and centrifuged for 15 secs at 6708 g. The flow through was discarded and the 
collection tube was reused.  If the sample exceeded 700µl, then the previous step was 
repeated until all the sample had been passed through the column.  
 
In order to carry out the DNAse step, 350µl Buffer RW1 was added to the column, 
centrifuged for 15 secs at 6708 g and the flow through was discarded. Meanwhile, 10µl 
DNase I stock solution was added to 70µl Buffer RDD (80µl per sample required). The 
DNase I/Buffer RDD mix was then added to the membrane of the column and incubated for 
15 mins at room temperature. After 15 mins, 350µl Buffer RW1 was added to the column, 
centrifuged for 15 secs and the flow through was discarded.  
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500µl of Buffer RPE was added to the column, centrifuged for 15 secs, and the flow through 
was discarded. This step was then repeated, but centrifuged for 2 mins. The RNeasy spin 
column was then placed in a 1.5ml collection tube. 30µl of water was added to the column 
membrane and centrifuged for 1 min to elute the RNA. 
 
2.12 Reverse Transcription 
 
In order to carry out reverse transcription from RNA to cDNA, the Superscript® VILO™ 
cDNA synthesis kit from Invitrogen was used. 5X VILO™ reaction mix (containing random 
primers, dNTPs and MgCl2), 10X Superscript® Enzyme mix and RNA (up to 2.5µg) were 
combined in order to create a total reaction volume of 20µl. The reaction was performed on a 
Thermocycler for 10 mins at 25°C, 2 hours at 42°C and 5 mins at 85°C. Following this, the 
cDNA was stored at -20°C. 
 
2.13 PCR (cDNA) clean-up 
 
PCR (cDNA) clean-up was carried out using the NucleoSpin Extract II kit (Macherey-Nagal, 
UK) in order to remove contaminating buffers and enzymes used during the reverse 
transcription protocol. The first step was to combine 1 volume of cDNA sample with 2 
volumes of buffer NT. This was then loaded on to a NucleoSpin extract II column placed over 
a collection tube. The column was centrifuged for 1 min at 11,000 g. The flow through was 
discarded and 600µl of buffer NT3 was added to the column. The column was then 
centrifuged again at 11,000 g for 1 min. The flow through was discarded and the column was 
centrifuged at 11,000 g for 2 mins to remove any excess buffer. The column was then placed 
into a clean 1.5 ml eppendorf and 15-50 µl of Elution buffer NE was added. The elution 
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buffer was incubated on the column for 1 min. The column along with the collection tube was 
centrifuged for 1 min at 11,000 g to collect the cDNA.  
 
2.14 Quantitative PCR 
 
In order to carry out quantitative PCR (qPCR), a total reaction volume of 20µl was prepared 
per sample. 10 µl SensiFAST™ Lo-ROX kit (2X PCR mastermix) (Bioline, UK), 1 µl forward 
primer, reverse primer and probe (Life Technologies, UK) (Table 2.11), 4 µl RNase free 
water and 5 µl cDNA. In chapter 5, qPCR was carried out in a 384 well plate, rather than a 96 
well plate. As a result, the master mix was adjusted; 5 μl 2X TaqMan® PCR master mix 
(Applied Biosystems, UK), 0.5 µl forward primer, reverse primer and probe (Life 
Technologies, UK) (Table 1.3), 3.5 µl RNase free water and 1 µl cDNA. 
 
Gene Assay ID Assay Supplier 
ACTB Hs99999903_m1 TaqMan® Gene Expression assay Life Technologies 
ITGA2B Hs01116228_m1 TaqMan® Gene Expression assay Life Technologies 
PF4 Hs00427220_g1 TaqMan® Gene Expression assay Life Technologies 
PF4V1 Hs01891271_s1 TaqMan® Gene Expression assay Life Technologies 
PPBP Hs00234077_m1 TaqMan® Gene Expression assay Life Technologies 
 
Table 2.11 TaqMan® Gene Expression assays used in this study. 
 
RT PCR was carried out using the Stratagene MX3000P qPCR machine. Reactions were 
incubated at 50°C for 2 mins, 95°C for 10 mins, 95°C for 15 secs (45 cycles) and 60°C for 1 
min. The genes of interest were quantified relative to the housekeeping gene, β-actin, by fold 
change in the gene expression. The formula, power (2,-ΔCt) was used. In chapter 5, an 
alternative qPCR machine was used, the Applied Biosystems 7900 qPCR machine.  
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2.15 In Situ Hybridization 
 
In Situ Hybridization was carried out using the QuantiGene® ViewRNA ISH Tissue 1-Plex 
Assay kit (Panomics, Italy). The kit was comprised of three units; the QuantiGene ViewRNA 
ISH Tissue 1-Plex Assay Kit (QVT0050), the QuantiGene View RNA Chromogenic Signal 
Amplification Kit (QVT0200), and the QuantiGene View RNA Type 1 Probe Set. Each kit 
was designed to be sufficient for 24 assays. However, reagent volumes were adjusted to 
achieve a greater number of assays.  
Three different QuantiGene View RNA Type 1 Probe Sets were used for the experiments:  
 Positive control probe: GAPDH 
 Negative control probe: BACILLUS SUBTILIS, dapB 
 Target probe: Pro-platelet basic protein (PPBP)/ Chemokine (C-X-C motif) ligand 7 
 
The assay was split into two parts, spread over the course of two days. The first part involved 
the sample preparation and hybridization of the target probe (day 1), and the second part 
involved signal amplification and detection (day 2). 
 
2.15.1 Part 1: Sample preparation and hybridization of the target probe  
Prior to commencing the assay, the hybridization system/tissue culture incubator was set at 40 
± 1°C with 0% CO2, and the dry incubator was set at 60 ± 1°C. Slides were labelled and 
placed in a slide rack. The rack of slides was then transferred to the dry incubator and baked 
for 60 mins. During this time, the following reagents were prepared; 
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 2L 1X Phosphate Buffered Saline (PBS) 1 tablet/100ml ddH2O (Oxoid/Thermo 
Scientific, UK) 
 100ml 100% ethanol, 100ml 95% ethanol, and 100ml 70% ethanol (VWR chemicals, 
UK) 
 2L wash buffer: 1.5L ddH2O, 18ml wash component 1, and 5ml wash component 2. 
Adjust to final volume of 2L with ddH2O 
 500ml 1X pretreatment Solution: 5 ml 100X pretreatment solution and 495ml ddH2O 
 100ml storage buffer: 30ml wash component 2 and 70ml ddH2O 
1X PBS, ethanol, pretreatment solution and storage buffer were prepared using HyPure™ 
Molecular Biology Grade Water (HyClone®) (Thermo Scientific, UK). 
 
During the baking step, the probes were thawed, mixed and briefly centrifuged and placed on 
ice. 10ml 1X PBS and the probe set diluent QF were pre-warmed to 40°C. Following the 
baking the step, the sections were de-waxed in 100ml xylene (VWR chemicals, UK) for 5 
mins x 3, and then subsequently rehydrated in 100ml 100% ethanol for 5 mins, 95% ethanol 
for 5 mins, and 70% ethanol for 5 mins. Slides were then removed from the rack, and air dried 
for 5 mins. A hydrophobic barrier was drawn around the tissue sections to prevent the spread 
of reagents across the slide (Vector Laboratories, UK). When dry, the slides were loaded into 
a slide rack and placed in the pre-warmed 1X pretreatment solution (85-90°C). Slides were 
incubated for the desired time, 10 mins, as determined by the optimisation experiments (Table 
2.12). Following pretreatment, the slides were removed from the solution and submerged in 
100ml ddH2O. Slides were washed for 1 min with frequent agitation and then transferred to 
1X PBS.  
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Tonsil Slide  Heat pre-
treatment 
Protease 
digestion 
Quantigene ViewRNA 
probe set 
S077007 1 5 10 GAPDH 
S077008 2 10 10 GAPDH 
S077009 3 10 20 GAPDH 
S077010 4 5 10 PPBP 
S077011 5 10 10 PPBP 
S077012 6 10 20 PPBP 
S077013 7 5 10 Bacillus subtillis dapB 
S077014 8 10 10 Bacillus subtillis dapB 
S077015 9 10 20 Bacillus subtillis dapB 
 
Table 2.12 Optimisation protocol for determining appropriate heat pre-treatment and 
protease digestion times for the Quantigene ViewRNA ISH Tissue 1-Plex Assays. 
Optimisation of the In Situ Hybridization experiments was carried out using 4µm cut sections 
from formalin-fixed, paraffin-embedded (FFPE) tonsil biopsies. Sections were obtained from 
the Human Biomaterials Resource Centre (HBRC): Biobank (University of Birmingham, 
UK). Each probe; GAPDH, PPBP, and Bacillus subtillis dapB, was tested using three 
different heat pre-treatment and protease digestion combinations. Slides 1, 4 and 7, had 5 
mins heat pre-treatment and 10 mins protease digestion. Slides 2, 5, and 8, had 10 mins heat 
pre-treatment and 10 mins protease digestion. Slides 3, 6, and 9, had 10 mins heat pre-
treatment and 20 mins protease digestion.  Following the optimisation experiments a heat pre-
treatment time of 10 mins and a protease digestion time of 10 mins was used for all 
experiments. 
 
Next, the protease solution was prepared by diluting the protease solution ‘Protease QF’ 1:100 
in pre-warmed 1X PBS (Table 2.13). The solution was scaled according to the number of 
slides run per experiment. The protease solution was briefly vortexed.  
 
Working Protease Solution 
Reagent Volume 
Protease QF 2µl 
1X PBS (pre-warmed to 40°C) 198µl 
Total volume 200µl 
 
Table 2.13 Preparation of the working protease solution for the protease digestion step 
of the In Situ Hybridization. Volumes were scaled up depending on the number of slides run 
during each experiment. 
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The 1X PBS was removed from the slides by gently tapping onto laboratory tissue. The slides 
were then placed in a wet box and 200µl of protease solution was added to each section. The 
sections were then covered with a square of parafilm to enable the protease solution to spread 
across the entire section and to prevent drying. The slides were then transferred to the 
hybridization system and incubated at 40 ± 1°C for the desired time, 10 mins, as determined 
during the optimisation experiments (Table 2.12). Following the protease digestion step, the 
parafilm was removed from the section and the working protease solution was tapped off the 
slide onto laboratory tissue. The slides were washed in 100ml 1X PBS for 1min x 2 and then 
fixed in 100ml 4% formaldehyde/Formalin solution (Sigma Aldrich, UK) for 4 mins at RT . 
The slides were then washed, once more, with 100ml 1X PBS for 1 min with frequent 
agitation.  
 
Meanwhile, the probes for the In Situ Hybridization were prepared (Table 2.14). Probes were 
diluted 1:50 in pre-warmed probe set diluent QF. The solution was scaled according to the 
number of slides run per experiment. The probes were briefly vortexed.   
 
Working Probe Set Solution 
Reagent Volume 
Probe Set Diluent QF (pre-warmed to 40°C) 196µl 
Quantigene ViewRNA TYPE 1 probe set 4µl 
Total Volume 200µl 
 
Table 2.14 Preparation of the working probe set solution for In Situ Hybridization. 
Volumes were scaled up depending on the number of slides run during each experiment. 
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The 1X PBS was removed from the slides by gently tapping onto laboratory tissue. The slides 
were then placed in a wet box and 200µl working probe set solution was added to each 
section. Each section was covered with a square of parafilm. The slides were then transferred 
to the hybridization system and incubated at 40 ± 1°C for 3 hrs. Following incubation, the 
working probe set solution was tapped off the slide, excess solution was removed with PBS 
and the slides were washed in 100ml wash buffer for 2 mins x3. Slides were then transferred 
into 100ml storage buffer. Slides were stored overnight at RT.  
 
2.15.2 Part 2: Signal amplification, detection and visualisation 
The hybridization system/tissue culture incubator was set at 40 ± 1°C with 0% CO2. Prior to 
commencing part 2, both the Amplifier Diluent QF and Label Probe Diluent QF were pre-
warmed to 40°C. The PreAmp1 QF and Amp1 QF were thawed and placed on ice until use. 
The Label Probe-AP was placed on ice, and the Fast Red tablets, Naphol buffer and AP 
enhancer solution was brought to RT.  
 
Slides were removed from the storage buffer and washed in 200ml wash buffer for 2 mins x 2 
with frequent agitation. Meanwhile, the PreAmp1 solution was prepared (Table 2.15). The 
PreAmpl 1 QF solution was diluted 1:100 in pre-warmed Amplifier Diluent QF. The solution 
was scaled according to the number of slides run per experiment. The probes were mixed by 
gentle inversion. 
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Working PreAmp1 Solution 
Reagent Volume 
Amplifier Diluent QF (pre-warmed to 40°C) 198µl 
PreAmp1 QF 2µl 
Total Volume 200µl 
 
Table 2.15 Preparation of the working PreAmp1 solution for In Situ Hybridization. 
Volumes were scaled up depending on the number of slides run during each experiment. 
 
Following the wash step, the slides were removed from the wash buffer and tapped on 
laboratory tissue. 200µl working Pre Amp 1 solution was added to each tissue section. Slides 
were then transferred to the hybridization system and incubated at 40 ± 1°C for 35 mins. 
Slides were tapped on laboratory tissue and washed in 100ml wash buffer for 3 mins x 3 with 
constant agitation. Next, the working Amp1 solution was prepared by diluting the Amp1 QF 
1:100 in pre-warmed Amplifier Diluent QF (Table 2.16). The solution was scaled according 
to the number of slides run per experiment. The probes were mixed by gentle inversion. 
 
Working Amp1 Solution  
Reagent Volume 
Amplifier Diluent QF (pre-warmed to 40°C) 198µl 
Amp1 QF 2µl 
Total Volume 200µl 
 
Table 2.16 Preparation of the working Amp1 solution for In Situ Hybridization. 
Volumes were scaled up depending on the number of slides run during each experiment. 
 
Slides were removed from the wash buffer, tapped on laboratory tissue and transferred to a 
wet box. 200µL working Amp1 solution was added to each section. The slides were then 
transferred to the hybridization system and incubated at 40 ± 1°C for 22 mins. Following 
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incubation, the working Amp1 solution was tapped off the slides and the slides were washed 
in 100ml wash buffer for 3 mins x 3 with constant agitation. During the wash steps the Label 
Probe-AP solution was prepared by diluting the Label Probe AP 1:1000 in pre-warmed Label 
Probe Diluent QF (Table 2.17). The solution was mixed by gentle inversion. 
 
Working Label Probe-AP Solution 
Reagent Volume 
Label Probe Diluent QF (pre-warmed to 40°C) 999µl 
Label Probe-AP 1µl 
Total Volume 1000µl 
 
Table 2.17 Preparation of the working Label Probe-AP solution for In Situ 
Hybridization. 
 
The slides were removed from the wash buffer, tapped on laboratory tissue and transferred to 
a wet box. 200µl working Label Probe-AP was added to each section. The slides were then 
transferred to the hybridization system and incubated at 40 ± 1°C for 22 mins. Following 
incubation, the Label Probe-AP solution was tapped off the slides and the slides were washed 
in 100ml wash buffer for 2 mins x 4 with constant agitation. Slides were removed from the 
wash buffer, and placed face up on laboratory tissue. Immediately 200µl AP-Enhancer 
solution was added to each tissue section and incubated for 5 mins at RT. During this 
incubation the Fast Red substrate was prepared. To a 1.5ml tube, 1.25ml Naphol buffer and ¼ 
Fast Red tablet was added. The solution was then vortexed at high speed to dissolve the tablet. 
After 5 mins, the AP-Enhancer solution was removed from the sections. The slides were 
transferred to a wet box and 200µl Fast Red substrate was immediately added to each tissue 
section. The slides were then transferred to the hybridization system and incubated at 40± 1°C 
for 30 mins. The Fast Red substrate was removed from each section by washing in 100ml 1X 
  
85 
 
PBS for 1 min. The sections were then counterstained using 3µg/ml DAPI prepared in PBS. 
200µl DAPI was added to each section for approximately 1 min. Excess DAPI was removed 
from each section and the slides were washed in 100ml ddH2O. The sections were then 
removed from the ddH2O and left to air dry for 20-30 mins. Sections were subsequently 
mounted in 1 drop of Vectamount™ AQ aqueous mounting medium (Vector Laboratories 
Ltd, UK). Coverslips (22mm x 40 mm rectangular) were placed on top of the mountant and 
the slides were left to dry at RT until visualisation.  
 
2.15.3 In Situ Hybridization visualisation 
Sections stained during the optimisation experiments were first visualised using the Zeiss 
LSM 780 Zen Confocal microscope at x40 and later x63 objective magnification/total 
magnification x400 and x630. Gain and threshold settings were adjusted so that the 
background staining on the negative probe, Bacillus subtillis dapB, was minimal. A 
background of <1 dot/10 cells was deemed acceptable by Affymetrix/Panomics. Images were 
subsequently taken of the GAPDH sections and finally the target probe, PPBP sections.  
   
Coverslips were then removed from the slides by soaking in 1X PBS for 3-5 hours. The 
sections were counterstained using Haematoxylin for 30 seconds before being washed gently 
in tap water to ‘blue’ the Haematoxylin. Sections were then re-mounted in Vectamount™ as 
described previously. Images were taken using the Nikon Eclipse E400 microscope.  
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2.15.4 Immunofluorescence following In Situ Hybridization 
Coverslips were removed from the sections by soaking in 1X PBS for 3-5 hours. The slides 
were then washed 3 x 5 mins in PBS with gentle shaking. Sections were blocked in 2% 
BSA/0.1% Triton-X/PBS for 1 hour at RT. Following this, the blocking solution was removed 
from the sections by gently tapping on laboratory tissue. Immediately 100µl primary antibody 
prepared in the blocking solution was added. The slides were then incubated overnight at 4°C 
in a wet box. The following day, slides were transferred to PBS and washed 3 x 5 mins with 
gentle shaking. 100µl of secondary antibody prepared in the blocking solution was then added 
to each section and incubated for 2 hours at RT in a wet box. The slides were then washed as 
described previously and subsequently counterstained with 3µg/ml DAPI for 1 min. Finally, 
slides were washed for 1 min in dH2O and re-mounted in Vectamount™. Images were taken 
using the Zeiss LSM 780 Zen Confocal microscope at x400 total magnification. 
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3 CXCL4 AND CXCL7: POTENTIAL PREDICTORS OF 
DIAGNOSTIC OUTCOME IN EARLY INFLAMMATORY 
ARTHRITIS? 
 
 
3.1 INTRODUCTION 
 
The National Institutes of Health Biomarkers Definitions Working Group defines a biomarker 
as ‘a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention’. Biomarkers are extremely powerful tools that can be utilised in a number of 
clinical applications including the prediction of both diagnosis and prognosis of disease 
(Mayeux, 2004, Perlis, 2011, Tesch et al, 2010).  Biomarkers are predominantly measured in 
tissue and biological fluids including serum, plasma, urine, bronchoalveolar lavage, sputum 
and cerebrospinal fluid (Schrohl et al, 2008). In RA, biomarkers include autoantibodies (e.g. 
RF and anti-CCP), various cytokines and chemokines, proteases, collagen degradation 
products, markers of inflammation (e.g. ESR and CRP) and genetic polymorphisms (e.g. 
shared epitope and PTPN22) (Tesch et al, 2010). Clinical assessment by X-ray, ultrasound, 
and Magnetic Resonance Imaging (MRI) are examples of imaging biomarkers that are 
commonly used in the diagnosis and monitoring of disease progression in RA (Tesch et al, 
2010). Assays that measure more than one biomarker at a time are also becoming increasingly 
attractive (O’Hurley et al, 2014, Rifai et al, 2006). The opportunity to offer personalised 
medicine and improve patient care may also be made a possibility with the use of biomarkers. 
They may be used to assess patients who are most likely to respond to certain therapeutics, to 
establish safety and dosing regimens, and to identify any patients likely to suffer from adverse 
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events. Moreover, biomarkers may be used within clinical trials as determinants of clinical 
and surrogate endpoints (Tesch et al, 2010).  
 
In this chapter I sought to determine CXCL4 and CXCL7 protein expression within the 
rheumatoid synovium. This body of work was influenced by previous findings within our 
research group suggesting that CXCL4 and CXCL7 mRNA expression in synovial tissue 
biopsies could distinguish patients with early RA from those with resolving synovitis. I 
systematically addressed the suitability of both chemokines as predictive markers of outcome 
in patients presenting with early synovitis at our early arthritis clinics.  Using synovial 
biopsies collected by ultrasound guided biopsy, I stained sections with antibodies specific for 
CXCL4, CXCL7, vWF, CD41 and CD68 by immunofluorescence. I also explored the 
potential of both chemokines as predictive biomarkers in plasma samples collected from 
patients enrolled in the BEACON cohort.  
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3.2 RESULTS 
 
3.2.1 CXCL4 and CXCL7 expression at the protein level in the rheumatoid synovium 
I first set out to stain rheumatoid synovial tissue sections taken from patients who had 
undergone joint replacement with CXCL4 and CXCL7 alongside CD41 (GPIIb) and von 
Willebrand Factor (vWF). Here I observed CXCL4 (Figure 3.1 A) and CXCL7 (Figure 3.1B) 
expression at the protein level in the tissue. CXCL4 and CXCL7 expression was observed 
outside the vasculature. Platelets stained with the surface marker CD41 were also detectable 
in the tissue. Although platelets were mainly detectable in the blood vessels, there were also a 
number found outside the vessels. Co-localisation of both CXCL4 and CXCL7 with CD41 
was limited in the rheumatoid synovium. It was predominantly observed in thrombi.  
 
The specificity of the CXCL7 antibody was confirmed by a blocking with the CXCL7 
peptide. In brief the antibody was incubated overnight with increasing concentrations of 
CXCL7 peptide. The CXCL7-peptide complex was then used to stain a section of rheumatoid 
synovium from a patient who had undergone joint replacement. The anti-CXCL7 staining was 
successfully inhibited when incubated with the CXCL7 peptide (see appendix, Figure 8.1). 
 
 
 
 
 
  
90 
 
 
  
   
 
  
   
Figure 3.1 Staining of the rheumatoid synovium with antibodies specific for 
CXCL4/CXCL7, CD41 and vWF. Sections of rheumatoid synovium taken from patients 
who had undergone joint replacement were stained with antibodies specific for A) CXCL4 
(red) or B) CXCL7 (red) alongside CD41 (green), and vWF (blue). Nuclei were 
counterstained with Hoechst 33258 (grey). Images were taken at x400 total magnification 
using the Zeiss LSM 510-UV confocal. Tissue sections were stained alongside isotype 
matched controls which were negative. CXCL4 (n=7), CXCL7 (n=6). Scale bar: 20µm. 
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3.2.2 CXCL4 and CXCL7 staining on CD68 positive macrophages and plasmacytoid 
dendritic cells 
Synovial biopsies taken from patients who had undergone joint replacement due to 
longstanding RA and subsequently stained with the macrophage specific marker CD68, 
clearly identified macrophages as an abundant cell population within the rheumatoid 
synovium (Figure 3.2). As the CXCL4 and CXCL7 staining described in the previous section 
was largely observed outside the vasculature and was not predominantly localised to platelets, 
I decided to stain rheumatoid synovium with antibodies specific to CXCL4 and CXCL7 
alongside CD68. I observed co-localisation of both CXCL4 (Figure 3.3A) and CXCL7 
(Figure 3.3B) with CD68 (pink/purple staining). Moreover, not all CD68+ stained cells were 
CXCL4+ or CXCL7+, and vice versa.  
 
Figure 3.2 Staining of the rheumatoid synovium with an antibody specific for CD68. A 
section of synovium taken from a patient with long standing rheumatoid arthritis who had 
undergone joint replacement was stained with antibodies specific for CD68 (blue) and as a 
contrast CD248 (green). Sections were stained and images were taken at x400 total 
magnification using the Zeiss LSM 780 confocal by Dr. Jennifer Marshall.  
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During the course of these experiments, it was reported that increased CXCL4 expression in 
the plasma of patients with systemic sclerosis and scleroderma was attributed to expression by 
plasmacytoid DCs (Van Bon et al, 2014). In response to these observations, I stained 
rheumatoid synovial tissue taken from patients undergoing joint replacement with BDCA-2, 
an antibody specific for pDCs, alongside CXCL4 and CXCL7. I observed co-localisation of 
CXCL4 with BDCA-2 in the rheumatoid synovium (Figure 3.4). However, not all cells 
positive for CXCL4 were also positive for BDCA-2. Co-localisation of CXCL7 with BDCA-2 
was not observed in the majority of rheumatoid synovium analysed. Moreover, CXCL4 and 
CXCL7 was not found to co-localise with CD1c, BDCA-2 and CD123 in tonsils (data not 
shown). As a result macrophages, rather than pDCs, may be the predominant source of both 
chemokines in rheumatoid arthritis. 
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Figure 3.3 Staining of the rheumatoid synovium with antibodies specific for 
CXCL4/CXCL7 and CD68. Sections of rheumatoid synovium taken from patients who had 
undergone joint replacement were stained with antibodies specific for A) CXCL4 (red) or B) 
CXCL7 (red) alongside CD68 (blue). Nuclei were counterstained with Hoechst 33258 (grey). 
Images were taken at x400 total magnification using the Zeiss LSM 510-UV confocal. Tissue 
sections were stained alongside isotype matched controls which were negative (n=5). CXCL4 
(n=5), CXCL7 (n=5) Scale bar: 20µm. 
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Figure 3.4 Staining of plasmacytoid dendritic cells in the rheumatoid synovium with 
antibodies specific for CXCL4 and BDCA-2. Sections of synovium from RA patients who 
had undergone joint replacement were stained with antibodies specific for BDCA-2 (green) 
and CXCL4 (red) (n=6). Nuclei were counterstained using Hoechst 33258 (grey). Sections 
were stained alongside isotype matched controls which were negative. Images were taken at 
x400 total magnification using the Zeiss LSM 780 Zen confocal. Scale bar: 50µm. 
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3.2.3 Expression of CXCL4 and CXCL7 within the synovium of patients enrolled in 
the BEACON cohort 
I sought to determine the expression of CXCL4 and CXCL7 at the protein level within 
synovial biopsies taken from four different patient groups; established RA patients (symptom 
duration >12 weeks, <3 years), early RA patients (symptom duration <12 weeks), resolving 
synovitis patients, and uninflamed controls (Table 3.1, Appendix Table 8.2). All biopsies 
were taken from individuals naive for DMARDs and glucocorticoids. Each synovial biopsy 
was stained with antibodies specific for CXCL4 (Figure 3.5 A) or CXCL7 (Figure 3.5 B), 
CD68, CD41 and vWF. Co-staining of CXCL4 or CXCL7 with CD68 and CD41 enabled us 
to identify CXCL4 or CXCL7 staining on macrophages and platelets, respectively. Co-
staining sections with vWF and both chemokines enabled us to distinguish positive staining 
inside and outside the synovial vasculature. A section from each patient was also stained for 
CXCL4 alongside BDCA-2. All sections were stained alongside isotype matched negative 
controls. 
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Figure 3.5 Synovial tissue section from an early RA patient stained with antibodies 
specific for CXCL4 or CXCL7, CD68, CD41 and vWF. Tissue sections were stained with 
antibodies specific for A) CXCL4 (red) or B) CXCL7 (red), CD68 (blue), CD41 (green) and 
vWF (orange). Nuclei were counterstained using Hoechst 33258 (grey). Sections were stained 
alongside isotype matched controls which were negative. 2 x 2 tile scans were taken at x400 
total magnification using the Zeiss LSM 780 Zen confocal. Co-staining of CXCL4 or CXCL7 
with CD68 and CD41 identified CXCL4 or CXCL7 expression on macrophages and platelets, 
respectively. Co-staining with vWF distinguished between CXCL4 or CXCL7 expression 
inside and outside the vasculature. Scale bar: 100µm. 
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CXCL4 and CXCL7 were expressed in the synovium of all patient groups analysed. CD41+ 
platelets were predominantly evident inside the vasculature as opposed to outside. Co-
localisation of CXCL4 and CXCL7 with CD68+ macrophages was observed in the synovium. 
However, not all CXCL4 and CXCL7 positive cells were also CD68+ and vice-versa. Co-
localisation of CD41+ platelets with CXCL4 and CXCL7 was also observed, however this 
was largely evident in thrombi within blood vessels. No co-localisation of CXCL4 and 
CXCL7 with CD41+ platelets was observed outside the vasculature. BDCA-2+ cells were not 
observed in the sections. 
 
3.2.4 Quantification of CXCL4 and CXCL7 in tissue sections from established RA 
patients, early RA patients, resolving synovitis patients and uninflamed controls 
(BEACON cohort) 
CXCL4 and CXCL7, CD68, CD41, and vWF immunofluorescence was quantified in synovial 
biopsies from established RA patients (n=11), early RA patients (n=10), resolving synovitis 
patients (n=9) and uninflamed controls (n=9) using the Zeiss LSM 780 Zen confocal and the  
Zen 2010 software. There was no statistically significant difference in the acute phase 
markers; CRP (Kruskall-Wallis p=0.2059) and ESR (Kruskall-Wallis p=0.1370) between the 
patient groups. Although a small number of patients who went on to develop a non RA-
persistent inflammatory arthritis were stained with the antibody panel, they were not included 
in the quantification analysis as they represented a very heterogeneous group (psoriatic 
arthritis n=2, sarcoidosis n=1, ankylosing spondylitis n=1, unclassified n=1). Please refer to 
table 3.1 and appendix table 8.2 for further patient demographics and clinical characteristics. 
For each biopsy an 8 x 8 overview scan (0.7 zoom) was first taken at x400 total 
magnification. Using the position tool on the Zen 2010 software, 5 or 6 regions were then 
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selected from the overview scan to 2 x 2 tile scan (5% overlap, 0.0080 rotation) at x400 total 
magnification. To avoid experimental bias when selecting regions from the large overview to 
tile scan, the CXCL4/CXCL7 channel (ChS2-T3) was turned off.  Prior to analysis, each 2 x 2 
tile scan was stitched together using the processing function within the software. This resulted 
in each tile scan being recognised as a single image. 
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 Uninflamed Resolving arthritis Early RA Established 
RA 
Early non-RA 
Number 9 9 10 11 5 
Symptom duration (weeks); median (IQR) na 6 (3-7) 7 (4.8-9.3) 45 (16-53) 7 (2-8.5) 
Female; n (%) 4 (44) 3 (33) 5 (50) 6 (55) 2 (40) 
Age, years; median (IQR) 41 (31-43) 37 (33-65) 58 (50-65) 62 (57-65) 41 (37-56) 
RF and/or anti-CCP positive; n (%) na 0 (0) 4 (40) 6 (55) 1 (20) 
Global disease-related variables      
CRP; median (IQR) na 8 (13-13.5) 26 (7.5-58) 10 (0-79) 25 (18.5-54) 
ESR; median (IQR) na 18 (5.5-51) 19 (4.75-39.25) 50 (34-70) 44 (24-73.5) 
DAS28; median (IQR) na 4.1 (3.4-5.7) 4.7 (3.8-5.8) 5.2 (4.6-7.5) 4.8 (4.1-6.4) 
Biopsied joint-related variables      
Joint biopsied      
Ankle; n (%) 0 (0) 2 (22) 2 (20) 3 (27) 2 (40) 
Knee; n (%) 9 (100) 7 (78) 7 (70) 8 (73) 3 (60) 
MCP joint; n (%) 0 (0) 0 1 (10) 0 (0) 0 (0) 
 
Early non-RA group; psoriatic arthritis n=2, sarcoidosis n=1, ankylosing spondylitis n=1, unclassified n=1.  
CCP, cyclic citrullinated peptide; RF, rheumatoid factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DAS28, Disease Activity Score 
in 28 joints; MCP, metacarpophalangeal; na, not available. 
Table 3.1 Demographic and clinical characteristics of study participants used for the detection of CXCL4 and CXCL7 by 
immunofluorescence. 
 
  
101 
 
To quantify the immunofluorescence signal for CXCL4 and CXCL7, CD68, CD41 and vWF, 
areas of tissue were selected using the overlay function within the Zen 2010 software (Figure 
3.6A). Any areas of tissue that were folded or damaged were excluded from the analysis. 
Pixel counts were then obtained using the histogram function within the software for each 
individual channel; CXCL4 and CXCL7 (ChS2-T3), CD68 (Ch2-T1), CD41 (ChS1-T2) and 
vWF (Ch2-T4). The pixel counts for the nuclei channel (Ch1-T1) were not included in the 
analysis (Figure 3.6B).  The pixel counts were then exported into Microsoft Excel. Here, the 
total number of pixels for each channel from intensity 30 to 255 was calculated. This value 
was then divided by the area [µm x µm] to give the number of pixels per µm2 area. The mean 
values for the number of pixels per µm2 area were calculated from the 5-6 2 x 2 tile scans and 
subsequently plotted on graphs (Figure 3.7).    
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Figure 3.6 Quantification of CXCL4 and CXCL7 protein expression within synovial 
tissue biopsies using the Zen 2010 software. A) Synovial tissue section taken from an early 
RA patient. The tissue section was stained with antibodies specific for CXCL4 (red), CD68 
(blue), CD41 (green), and vWF (orange). Nuclei were counterstained using Hoechst 33258 
(grey). Sections were stained alongside isotype matched controls which were negative. 2 x 2 
tile scans were taken at x400 total magnification using the Zeiss LSM 780 Zen confocal. To 
carry out the analysis, tissue sections were drawn around using the overlay function within the 
Zen 2010 software. Any areas of tissue that were badly damaged or folded were excluded 
from the analysis. B) A screen shot taken from the Carl Zeiss Zen 2010 software. By using 
the histogram function within the software, pixel counts for each channel were obtained: 
CD68 (Ch2-T1), CD41 (ChS1-T2), CXCL4/CXCL7 (ChS2-T3) and vWF (Ch2-T4). Pixel 
counts from the nuclei channel (Ch1-T1) were not included in the analysis. Results from both 
tables shown in B) were exported into Microsoft Excel. The total number of pixels within 
each channel from intensity 30 to 255 was calculated. This number was then divided by the 
area [µm x µm] to give the number of pixels per µm2 area. 
 
 
 
B 
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CXCL4 expression within synovial biopsies was significantly higher in patients with early 
RA as compared to established RA patients (Mann Whitney p=0.001) and resolving synovitis 
patients (Mann Whitney p=0.043) (Figure 3.7A). Likewise, for CXCL7, expression was 
significantly higher in the early RA patient group as compared to established RA (Mann 
Whitney p=0.004) and resolving synovitis patients (Mann Whitney p=0.010) (Figure 3.7B). 
No significant differences in the expression of CXCL4 and CXCL7 were observed in biopsies 
taken from different synovial joints (Figure 3.9). CXCL4 expression within the synovial 
biopsies correlated with CXCL7 expression (Spearman r=0.7557, p<0.0001) (Figure 3.7). No 
correlation was observed for CXCL4 and CXCL7 with erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP), Disease Activity Score 28 (DAS28), swollen joint count 28 
(SWJ28) and tender joint count 28 (TJC28). No significant difference in CXCL4 and CXCL7 
expression was observed when data was split based on the patients RF status (positive or 
negative) (CXCL4 Mann Whitney p=0.6669, CXCL7 Mann Whitney p=0.5468) or anti-CCP 
status (positive or negative) (CXCL4 Mann Whitney p=0.3910, CXCL7 Mann Whitney 
p=0.5235). Furthermore, no significance was observed when CXCL4 and CXCL7 expression 
from the early RA group (CXCL4 Mann Whitney p=0.1714, CXCL7 Mann Whitney 
p=0.1714) and established RA group (CXCL4 Mann Whitney p=0.9307, CXCL7 Mann 
Whitney p=0.6623) were split based on anti-CCP status (Figure 3.10). However, it is 
important to note that upon splitting patients based on anti-CCP status, this resulted in 
reduced patient numbers in each group. Therefore, in the future, increasing patient numbers 
may allow this question to be addressed with appropriate power. 
 
CXCL4 expression within the synovial biopsies correlated with CD68 expression (Spearman 
r=0.4741, p=0.0023) (Figure 3.11A). However, CXCL7 expression within the synovial 
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biopsies did not show a correlation with CD68 (Spearman r=0.2006, p=0.2208) (Figure 
3.11B). CXCL4 and CXCL7 expression did not correlate with CD41 expression in the 
synovial biopsies (CXCL4: Spearman r= 0.07975, p= 0.6293, CXCL7: Spearman r= -0.0431, 
p=0.7944) (Figure 3.11C and Figure 3.11D). 
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Figure 3.7 CXCL4 and CXCL7 protein quantification within synovial biopsies taken 
from uninflamed controls and patients enrolled in the BEACON cohort. CXCL4 (A) and 
CXCL7 (B) protein expression was quantified in synovial biopsies taken from uninflamed 
controls (n=9), resolving synovitis patients (n=9), early RA patients (n=10) and established 
RA patients (n=11) by calculating the number of pixels per µm2 from 5-6 2x2 tile scans taken 
at x400 total magnification. Significance was calculated using a Mann-Whitney test. The 
median value is indicated by a horizontal bar. 
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Figure 3.8 Correlation of synovial CXCL4 and CXCL7 expression in uninflamed 
controls and patients enrolled in the BEACON cohort. The CXCL4 pixel count per μm2 
was plotted against the corresponding pixel count per μm2 for CXCL7.  Upside down 
triangles indicate uninflamed controls, triangles indicate resolving synovitis patients, squares 
indicate early RA patients, and circles indicate established RA patients. The Spearman’s 
correlation coefficient ‘r’ value and p value are shown.  
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Figure 3.9 CXCL4 and CXCL7 expression in synovium taken from different sites of 
biopsy. For this study, synovial biopsies were either obtained from the knee, ankle or MCP 
joint. To observe any probable influence of the site of biopsy on the expression of CXCL4 
and CXCL7, the pixel count per μm2 for A) CXCL4 and B) CXCL7 were divided based on 
the site of biopsy. The median value is indicated by a horizontal bar. 
 
 
 
r= 0.7557, p<0.0001 
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Figure 3.10 CXCL4 and CXCL7 protein quantification from patients with anti-CCP 
positive/negative early RA or established RA. The anti-CCP status was obtained for each 
patient included in this study. The CXCL4 and CXCL7 quantification results for early RA 
patients and established RA patients were split into either CCP negative or CCP positive 
groups. Figures A) and B) show the quantification of CXCL4 and CXCL7, respectively, in 
anti-CCP negative and positive early RA patients.  The median value is indicated by a 
horizontal bar. 
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Figure 3.11 Correlation of synovial CXCL4 and CXCL7 with CD68 and CD41 
expression in uninflamed controls and in patients enrolled in the BEACON cohort. The 
CD68 and CD41 pixel counts per μm2 were plotted against the corresponding pixel counts per 
μm2 for CXCL4 and CXCL7. A and C display CD68 and CD41 plotted against CXCL4, 
respectively. B and D display CD68 and CD41 plotted against CXCL7, respectively. Upside 
down triangles indicate uninflamed controls, triangles indicate resolving synovitis patients, 
squares indicate early RA patients, and circles indicate established RA patients. The 
Spearman’s correlation coefficient ‘r’ value and p value are shown.  
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3.2.5 Quantification of CXCL4, CXCL7 and CD41 inside and outside the synovial 
vasculature 
As I observed a large proportion of CXCL4 and CXCL7 outside as opposed to inside the 
vasculature, I set out to quantify this. In addition I also quantified the CD41+ platelet staining 
inside and outside the vasculature. Similar to the quantification technique described 
previously, I used the overlay function within the Zen Software, but this time I identified each 
blood vessel as a region of interest (Figure 3.12). The pixel counts from within these regions 
were then exported and subsequently subtracted from the total tissue quantification result.  
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Figure 3.12 Quantification of CXCL4 and CXCL7 protein expression inside and outside 
the vasculature within synovial tissue biopsies using the Zen 2010 software. Resolving 
synovitis tissue section stained with antibodies specific for CXCL7 (red), CD68 (blue), CD41 
(green) and vWF (orange). Nuclei were counterstained with Hoechst 33258 (grey). Sections 
were stained alongside isotype matched controls which were negative. 2 x 2 tile scans were 
taken at x400 total magnification using the Zeiss LSM 780 Zen confocal. Quantification of 
CXCL4 and CXCL7 inside and outside the vasculature was calculated using the Carl Zeiss 
Zen 2010 software. For each image, the channels for CXCL4/CXCL7 (ChS2-T3), CD68 
(Ch2-T1), CD41 (ChS1-T2) and nuclei (Ch1-T1) were turned off. Using the vWF (Ch2-T4) 
channel only, each vessel was drawn around using the overlay function (yellow ‘closed poly-
lines’). Pixel counts for each channel were then exported to Microsoft Excel.  The total 
number of pixels within each channel from intensity 30 to 255 was calculated. This number 
was then divided by the area [µm x µm] to give the number of pixels per µm2 area inside the 
vasculature. To calculate staining outside the vasculature, quantification within the vessels 
was subtracted from the total quantification.  
CD68 CD41 
CXCL7 vWF Merge 
Negative 
Nuclei 
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Figure 3.13 CXCL4, CXCL7 and CD41 quantification inside and outside the 
vasculature. The numbers of CXCL4 (A), CXCL7 (B), and CD41 (C and D) pixels per µm2 
area were calculated inside (blue dots) and outside (red dots) the vasculature for uninflamed 
controls, resolving synovitis patients, early RA patients and established RA patients. A 
Kruskall Wallis (****p=0.0001) test followed by a Dunn’s post-test for multiple comparisons 
was carried out (**p=0.01, *p=0.05). The median value is indicated by a horizontal bar. 
 
 
 
A B 
C D 
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There was an increase in CXCL4 outside the vasculature as opposed to inside the vasculature 
in the early RA patients, established RA patients, resolving synovitis and uninflamed controls 
(Kruskall-Wallis p<0.0001) (Figure 3.13A). CXCL7 was increased outside the vasculature in 
the early RA patients and the uninflamed controls but not the resolving synovitis or 
established RA patients (Figure 3.13B). A Kruskall-Wallis test (p<0.0001) followed by a 
Dunn’s post-test for multiple comparisons identified a significant increase in CXCL7 outside 
the vasculature as opposed to inside in the uninflamed (p=0.01) and established RA groups 
(p=0.05) (Figure 3.13B).  
 
In contrast to the chemokine staining which was predominantly found outside the vasculature, 
quantification of CD41+ staining resulted in a clear trend with the majority of platelets found 
inside the vasculature as opposed to outside in the synovium (Kruskall Wallis p<0.0001) 
(Figure 3.13C and Figure 3.13D). Differences between the quantification of CD41 on the 
CXCL4 stained sections and the CXCL7 stained sections may indicate differences in the 
scanning positions.  
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3.2.6 Investigation of plasma CXCL4, CXCL7 and sGPVI in the BEACON cohort 
 
In order to investigate the potential of peripheral blood levels of CXCL4 and CXCL7 as 
predictors of disease outcome in patients presenting with synovitis (<12 week symptom 
duration and >12 week symptom duration), the concentrations of CXCL4 and CXCL7 in 
plasma samples were quantified by ELISA. Plasma sGPVI was also assessed as a marker of 
platelet activation. Samples were obtained from patients attending the early arthritis clinics at 
the Sandwell and West Birmingham Hospital. Patients were assessed by the consultant 
rheumatologist Dr Karim Raza and samples were collected by Mr Biruk Asfaw. Upon 
collection, samples were transferred to and processed by The University of Birmingham staff 
members, Miss Holly Adams and Mr Philip Jones at the Queen Elizabeth Hospital, 
Birmingham. Plasma samples were stored at -80°C prior to ELISA analysis. Please refer to 
table 3.2 and appendix table 8.3 for patient clinical characteristics. 
 
Furthermore, I carried out sample analysis for CXCL4 and CXCL7 in serum samples 
collected from patients in the BEACON cohort. The concentration of both chemokines ranged 
from 4-20 μg/ml in the serum.  A number of sample results exceeded the assay cut off of 20 
μg/ml. Interestingly, patients with psoriatic arthritis had significantly increased CXCL7 
concentrations compared to early resolving synovitis patients (Dunn’s post-test *p≤0.05). 
CXCL7 in early RA patients was comparable to that observed in established RA and 
resolving synovitis patients (data not shown)
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 RA Unclassified Inflammatory arthritis Psoriatic arthritis Inflammatory 
arthralgia 
Number 12 15 8 19 
Symptom duration (weeks); median (IQR) 39 (11-170) 22 (17-104) 19 (8-46) 18 (13-43) 
RF positive and/or CCP positive; n (%) 7 (58) 3 (20) 2 (25) 5 (26) 
Global disease-related variables     
CRP; median (IQR) 7 (0-20.5) 6 (0-30) 5 (0-13.75) 6 (2-12) 
ESR; median (IQR) 30 (7.25-31) 13 (2-32.5) 10.5 (2.75-36.5) 5 (2-20) 
TJC 28; median (IQR) 5 (3-8) 3 (1-7) 5.5 (3-16) 1 (1-5) 
SJC 28; median (IQR) 2 (1-5) 2 (1-4) 3 (0-14) 0 (0-0) 
 
Inflammatory arthralgia group; Inflammatory arthralgia n=17 and palindromic rheumatism n=2.  
CCP, cyclic citrullinated peptide; RF, rheumatoid factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TJC 28, Tender Joint Count of 
28 joints; SJC 28, Swollen Joint Count of 28 joints. 
Table 3.2 Clinical characteristics of study participants used for the detection of CXCL4 and CXCL7 in plasma by ELISA. 
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3.2.6.1 CXCL4 in the plasma 
 
The concentration of CXCL4 in the plasma was quantified in 53 patients enrolled in the 
BEACON cohort. Two patients had a CXCL4 result outside the assay range and were 
therefore excluded from the analysis; of those patients excluded from the analysis, one had 
persistent arthritis, and the other inflammatory arthralgia with an unknown outcome. Samples 
from these patients will be run at a higher dilution in future experiments. CXCL4 was also 
assessed in 10 healthy controls. 
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Figure 3.14 CXCL4 in plasma samples from BEACON cohort patients and healthy 
controls.  A) CXCL4 was quantified in plasma samples collected from patients enrolled in 
the BEACON cohort (n=53) and healthy controls (n=10) using a Quantikine® ELISA (R&D 
systems, UK). Patient results were divided into B) anti-CCP negative (n=40) and anti-CCP 
positive groups (n=9), and C) RF negative (n=35) and RF positive groups (n=17). Patients 
whose anti-CCP and RF status was unknown were excluded. In D the CXCL4 plasma 
concentrations were split in accordance with disease diagnosis. Patients were split into those 
with a diagnosis of RA (n=11), unclassified inflammatory arthritis (n=15), or psoriatic 
arthritis (n=8). In E the CXCL4 plasma concentrations were split into those patients with a 
disease diagnosis of arthritis (n=35) vs those with inflammatory arthralgia or palindromic 
rheumatism (n=18). In F, CXCL4 plasma concentrations were divided based on patient 
outcome. Patients were split into those with persistent disease (n=20), resolving disease (n=5) 
or an unknown outcome (n=27). In G, CXCL4 plasma concentrations in patients with either 
persistent disease, resolving disease or an unknown outcome were split according to disease 
duration at the time of sample collection. Patients were split into <12 weeks symptomduration 
and >12 weeks symptom duration. In H the CRP result for each patient was plotted against 
the corresponding CXCL4 plasma concentration. Here, upside down triangles indicate 
patients with inflammatory arthralgia, triangles indicate patients with unclassified 
inflammatory arthritis, squares indicate patients with RA, circles indicate those with psoriatic 
arthritis, and diamonds indicate patients with palindromic rheumatism. The Spearman’s 
correlation coefficient ‘r’ value and p value are shown. Significance was calculated using a 
Mann-Whitney test for A, B, C, and E. A Kruskall-Wallis test followed by a Dunn’s post-test 
for multiple comparisons was used to calculate significance in D, F and G. The Kruskall-
Wallis p value is shown. The median value is indicated by a horizontal bar. 
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CXCL4 was expressed in the plasma of both patients and healthy controls. CXCL4 was 
significantly increased in patient samples compared to healthy controls (Mann-Whitney 
p=0.0343) (Figure 3.14A) and correlated weakly with CRP (Spearman r=0.2994, p=0.0347, 
Figure 3.14H) but not ESR (data not shown). Next, plasma CXCL4 results were split into 
those with anti-CCP negative or positive disease, and those with RF negative or positive 
disease (Figure 3.14B and 3.14C). An anti-CCP result of >7 and a RF result of >20 was 
classified as positive. No statistically significant differences between the anti-CCP negative 
and anti-CCP positive patients (Mann-Whitney p=0.2506), and the RF negative and RF 
positive patients was observed (Mann-Whitney p=0.1097).  
 
No significant difference in CXCL4 was observed when patients with RA were compared to 
those with a different diagnosis (unclassified inflammatory arthritis, inflammatory arthralgia, 
palindromic rheumatism, or psoriatic arthritis) and the healthy controls (Figure 3.14D). 
Moreover, no statistical significance was observed when the results were split into patients 
diagnosed with arthritis versus inflammatory arthralgia and palindromic rheumatism (Figure 
3.14E). Due to the low number of patients with palindromic rheumatism (n=2) they were 
grouped with the patients with inflammatory arthralgia. Division of CXCL4 results based on 
patient outcome (persistent and resolving synovitis) was not significant (Figure 3.14F), 
however there was a trend towards an increase in CXCL4 in patients presenting with <12 
weeks symptom duration who went on to a persistent outcome (Figure 3.14G). 52% of patient 
outcomes were unknown at the point of analysis, therefore this result may change as new 
patient information becomes available.   
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3.2.6.2 CXCL7 in the plasma 
 
The concentration of CXCL7 in the plasma was quantified in 49 patients enrolled in the 
BEACON cohort. Six patients had a CXCL7 result outside the assay range and were therefore 
excluded from the analysis; of those patients excluded from the analysis, three patients were 
diagnosed with inflammatory arthralgia with an unknown outcome, one patient was diagnosed 
as having persistent RA, one patient with persistent psoriatic arthritis, and the other patient 
with unclassified inflammatory arthritis. Samples from these patients will be run at a higher 
dilution in future experiments. CXCL7 was also assessed in 9 healthy controls. One healthy 
control had a CXCL7 result outside the assay range and was therefore excluded from the 
analysis.  
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Figure 3.15 CXCL7 in plasma samples from BEACON cohort patients and healthy 
controls. A) CXCL7 was quantified in plasma samples collected from patients enrolled in the 
BEACON cohort (n=49) and healthy controls (n=9) by ELISA (Abcam, UK). Patient results 
were divided into B) anti-CCP negative (n=37) and anti-CCP positive groups (n=8), and C) 
RF negative (n=32) and RF positive groups (n=16). Patients whose anti-CCP and RF status 
were unknown were excluded. In D the CXCL7 plasma concentrations were split in 
accordance with disease diagnosis. Patients were split into those with RA (n=10) versus those 
with unclassified inflammatory arthritis (n=14) or psoriatic arthritis (n=7). In E the CXCL7 
plasma concentrations were split into those patients with a disease diagnosis of arthritis 
(n=33) vs those with inflammatory arthralgia or palindromic rheumatism (n=16). In F, 
CXCL7 plasma concentrations were divided based on patient outcome. Patients were split 
into those with persistent disease (n=19), resolving disease (n=5) or an unknown outcome 
(n=24). In G, CXCL7 plasma concentrations in patients with either persistent disease, 
resolving disease or an unknown outcome were split according to symptom duration at the 
time of sample collection. Patients were split into <12 weeks symptom duration and >12 
weeks symptom duration. In H the CRP result for each patient was plotted against the 
corresponding CXCL7 plasma concentration. Here, upside down triangles indicate patients 
with inflammatory arthralgia, triangles indicate patients with unclassified inflammatory 
arthritis, squares indicate patients with RA, circles indicate those with psoriatic arthritis, and 
diamonds indicate patients with palindromic rheumatism. The Spearman’s correlation 
coefficient ‘r’ value and p value are shown. Significance was calculated using a Mann-
Whitney test for A, B, C, and E. A Kruskall-Wallis test followed by a Dunn’s post-test for 
multiple comparisons was used to calculate significance in D, F and G. The Kruskall-Wallis p 
value is shown. The median value is indicated by a horizontal bar.  
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CXCL7 was expressed in both patients and healthy control plasma, however no significant 
difference was observed (Mann-Whitney p=0.3786) (Figure 3.15A). Like the results obtained 
in the CXCL4 ELISA, no significant difference between the anti-CCP negative and anti-CCP 
positive patients (Mann-Whitney p=0.2786), and the RF negative and RF positive patients 
was observed (Mann-Whitney p=0.1786) (Figure 3.15B and 3.15C). Grouping of CXCL7 
results based on disease diagnosis and outcome was not statistically significant, however there 
was a trend towards an increase in CXCL7 in patients with a symptom duration of <12 weeks 
who went on to a persistent outcome (Figure 3.15D, E, F and G). Moreover CXCL7 weakly 
correlated with CRP (Spearman r=0.2914, p=0.0469, Figure 3.15H), but not ESR (data not 
shown).  
 
When comparisons were made between plasma CXCL4 and CXCL7, a significant strong 
positive correlation (Spearman r= 0.8931, p<0.0001) was observed (Figure 3.16).   
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Figure 3.16 Correlation of plasma CXCL4 and CXCL7 in patients enrolled in the 
BEACON cohort. The plasma CXCL4 results were plotted against the CXCL7 plasma 
results. The Spearman’s correlation coefficient ‘r’ value and p value are shown.  
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3.2.6.3 sGPVI in the plasma 
 
The concentration of sGPVI in the plasma was quantified in 53 patients enrolled in the 
BEACON cohort. Two patients had a sGPVI result outside the assay range and were therefore 
excluded from the analysis; of those patients excluded from the analysis, one patient was 
diagnosed with persistent unclassified inflammatory arthritis, and the other was diagnosed 
with inflammatory arthralgia. sGPVI was also quantified in 6 healthy controls. 
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Figure 3.17 sGPVI in plasma samples from BEACON cohort patients and healthy 
controls. A) sGPVI was quantified by ELISA in plasma samples collected from patients 
enrolled in the BEACON cohort (n=53) and healthy controls (n=6). The ELISA method was 
published by Al-Tamimi et al, 2009. Patient results were divided into B) anti-CCP negative 
(n=41) and anti-CCP positive groups (n=8), and C) RF negative (n=36) and RF positive 
groups (n=16). Patients whose anti-CCP and RF status were unknown were excluded. In D 
the sGPVI plasma concentrations were split in accordance with disease diagnosis. Patients 
were split into those with RA (n=12), unclassified inflammatory arthritis (n=14) or psoriatic 
arthritis (n=8).  In E the sGPVI plasma concentrations were split into those patients with a 
disease diagnosis of arthritis (n=35) vs those with inflammatory arthralgia or palindromic 
rheumatism (n=18). In F, sGPVI plasma concentrations were divided based on patient 
outcome. Patients were split into those with persistent disease (n=20), resolving disease (n=5) 
or an unknown outcome (n=27). In G, sGPVI plasma concentrations in patients with either 
persistent disease, resolving disease or an unknown outcome were split according to symptom 
duration at the time of sample collection. Patients were split into <12 weeks symptom 
duration and >12 weeks symptom duration. In H the CRP result for each patient was plotted 
against the corresponding sGPVI plasma concentration. Here, upside down triangles indicate 
patients with inflammatory arthralgia, triangles indicate patients with unclassified 
inflammatory arthritis, squares indicate patients with RA, circles indicate those with psoriatic 
arthritis, and diamonds indicate patients with palindromic rheumatism. The Spearman’s 
correlation coefficient ‘r’ value and p value are shown. Significance was calculated using a 
Mann-Whitney test for A, B, C, and E. A Kruskall-Wallis test followed by a Dunn’s post-test 
for multiple comparisons was used to calculate significance in D, F and G. The Kruskall-
Wallis p value is shown. The median value is indicated by a horizontal bar. 
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No significant difference in the concentration of sGPVI in the patients and the healthy 
controls was observed (Mann-Whitney, p=0.5063) (Figure 3.17A). There was a trend towards 
an increase in sGPVI in anti-CCP positive patients compared to anti-CCP negative patients, 
although this was not significant (Mann-Whitney p=0.01199) (Figure 3.17B). There was no 
significant difference in the concentration of sGPVI in the RF negative and RF positive 
patients (Mann-Whitney p=0.51931) (Figure 3.17C). Like, the CXCL4 and CXCL7 results, 
grouping of sGPVI results based on disease diagnosis and outcome was not statistically 
significant, however there was a trend towards an increase in sGPVI in patients with <12 
weeks symptom duration who went on to develop a persistent outcome (Figure 3.17 D, E, F 
and G). Yet again sGPVI correlated weakly with CRP (Spearman r=0.3002, p=0.0342, Figure 
3.17H) but not ESR (data not shown). Furthermore, a significant positive correlation was 
observed for sGPVI and both CXCL4 (Spearman r=0.4910, p=0.0002) (Figure 3.18A) and 
CXCL7 (Spearman r=0.4588, p=0.0011) (Figure 3.18B). 
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Figure 3.18 Correlation of plasma sGPVI with CXCL4 and CXCL7 in patients enrolled 
in the BEACON cohort. Correlation of plasma A) sGPVI and CXCL4, and B) sGPVI and 
CXCL7 are shown. The Spearman’s correlation coefficient ‘r’ value and p value are shown 
for both plots.  
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3.3 DISCUSSION 
 
Biomarkers for early diagnosis and progression, disease severity, and response to therapy are 
pivotal in RA. In this chapter I have identified two chemokines, CXCL4 and CXCL7, which 
were transiently increased in the synovium of patients with early RA. As a result, both 
CXCL4 and CXCL7 may be considered as interesting potential biomarker candidates in 
biopsy sections for the prediction of RA in patients presenting with early synovitis. 
Chemokines are an attractive choice for potential biomarkers with a number of studies 
presenting evidence for their use in prostate cancer (Blum et al, 2008), cancer metastasis 
(Kakinuma and Hwang, 2006) and SLE (Rovin et al, 2005). Recent studies have also reported 
on the use of CXCL4 and CXCL7 as potential biomarkers for IBD and COPD, respectively 
(Cazzola and Novelli, 2010, Di Stefano et al, 2009, Meuwis et al, 2007).  
 
Although biomarkers are becoming increasingly attractive, they are not without their 
disadvantages. Firstly, the development of biomarkers is extremely costly and time-
consuming. Before a biomarker can be used within the clinic, they require thorough analytical 
and clinical validation. This is not only difficult due to the large number of samples required, 
but also validation requires collaboration between scientists, clinicians, pharmaceutical 
companies and regulatory bodies. Strict guidelines must be in place for sample collection, 
transportation and storage (Mayeux, 2004, Schrohl et al, 2008). Secondly, if the biomarker is 
to be detected within tissue, for example by immunohistochemistry, the method for sample 
handling, fixation and processing, choice of antigen retrieval, antibody selection and detection 
method, and interpretation of results must be standardized so that it can be carried out 
efficiently across multiple locations. If this is done early in the development process, then the 
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biomarkers have an increased chance of gaining approval (O’Hurley et al, 2014). Moreover, 
the collection of biopsy samples may be difficult and not as easily accessible as blood or 
urine.  
 
It was the work carried out by Yeo et al (2011) in our research team that initially drew our 
attention to CXCL4 and CXCL7 in the context of RA. Within this study, expression of 
CXCL4 and CXCL7 at the mRNA level was increased in patients with early RA compared to 
those with established RA, resolving synovitis and uninflamed controls. Further analysis of 
the cytokine mRNA expression data by a mathematical based computer model; ‘generalized 
matrix relevance learning vector quantization (GMLVQ)’ enabled the division of patient 
cytokine profiles into categories based on the contribution of individual mRNA results. 
GMLVQ is an extremely useful model as it can use large data sets to predict diagnosis and 
identify novel biomarker targets (Biehl et al, 2013). When comparisons between the early RA 
and the resolving synovitis category were made, the two cytokine mRNA results shown to 
contribute most to the categorisation were CXCL4 and CXCL7. This highlighted the 
importance of CXCL4 and CXCL7 in the classification of disease.  
 
As a result of the previous mRNA findings, I analysed the expression of CXCL4 and CXCL7 
at the protein level in synovial biopsies taken from patients enrolled in the BEACON cohort.  
Within this chapter I observed expression of CXCL4 and CXCL7 in synovial biopsies taken 
from patients with early RA, established RA, and resolving synovitis. Furthermore, I also 
observed expression of both chemokines in uninflamed controls. Upon quantification of 
CXCL4 and CXCL7 in the synovial biopsies, I observed significantly higher expression of 
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both CXCL4 and CXCL7 in patients with early RA compared to those with a resolving 
synovitis. This increase reflected a transient phase in early RA, as results observed in the 
established RA patients were significantly lower. Furthermore the increased expression of 
both CXCL4 and CXCL7 in the early RA patients was not influenced by anti-CCP status. As 
a result, CXCL4 and CXCL7 may play an important role during the earliest stage of 
inflammation in RA and may enable us to distinguish those patients who are likely to develop 
RA from those whose synovitis is likely to resolve. Studies have suggested a pro-
inflammatory and angiogenic role for CTAP-III, the pre-cursor molecule to CXCL7, in RA, 
with levels of the chemokine evident in the sera, synovial fluid and tissue (Szekanecz and 
Koch, 2001). CXCL7 is known to chemoattract neutrophils and activate their granule release. 
Therefore, an increase in CXCL7 in early RA may drive increased neutrophil recruitment to 
the synovium, thus driving early pathogenesis. I can hypothesise that the increase in the 
angiostatic chemokine, CXCL4, in early disease may be a means of trying to prevent or 
minimise the first signs of inflammation and angiogenesis, but as inflammation spreads 
throughout the joint, the effect of CXCL4 is outweighed by other mediators within the joint. 
A study by Wooley et al (1997) reported an anti-inflammatory role for CXCL4 in models of 
experimental arthritis. Here, a CXCL4 peptide sequence (CT-112) was delivered to a type II 
collagen induced arthritis model either as a prophylactic or a therapeutic. When the peptide 
was given as a prophylactic, the development of type II collagen induced arthritis was 
prevented and when given as a therapeutic the progression of disease was reduced.   
 
Both CXCL4 and CXCL7 are still considered to be, predominantly, platelet derived 
chemokines. Therefore I initially hypothesised that CXCL4 and CXCL7 in the synovium 
would be due to the presence of platelets. An increased number of platelets were observed 
  
132 
 
inside the vasculature as opposed to outside the vasculature in the synovium. However, apart 
from the co-localisation of platelets with both chemokines in thrombi within blood vessels, I 
did not observe co-localisation of CXCL4 and CXCL7 with platelets outside the blood vessels 
and furthermore CXCL4 and CXCL7 was not found to correlate with CD41 expression. In 
addition to this, the expression of CXCL4 and CXCL7 was increased outside the vasculature 
as opposed to inside. Moreover, I observed co-localisation of CXCL4 and CXCL7 with 
CD68+ macrophages in the synovium. I observed weak positive correlation of CXCL4 with 
CD68, however I did not observe the same for CXCL7 with CD68. Increasing the sample 
number, eliminating any outliers, or increasing the number of images taken from each section 
may rectify this in the future. From this I may hypothesise that both chemokines are not solely 
platelet derived. In agreement, Schaffner et al (2005) reported that both CXCL4 and CXCL7 
were not restricted to the megakaryocyte lineage and that in fact monocytes expressed both 
chemokines. In this study they detected CXCL4 expression in monocytes by Western blot, 
qPCR, immunofluorescence and ELISA. Using a Pf4-Cre mouse model, Calaminus et al 
(2012) also reported that CXCL4 was no longer restricted to the megakaryocyte lineage but 
that both myeloid and lymphoid lineages were a source. The expression of CXCL4 and 
CXCL7 in monocytes and macrophages will be further explored in the next chapter.  
 
Our interest in pDCs and CXCL4 expression arose from the patent filed by Radstake in 2010 
and the more recent publication by van Bon et al (2014). Van Bon et al (2014) reported an 
increased plasma level of CXCL4 in patients with systemic sclerosis compared to patients 
with SLE, hepatic fibrosis, ankylosing spondylitis and healthy controls. An increase in 
CXCL4 mRNA expression was reported in pDCs isolated from patients with systemic 
sclerosis compared to controls. Moreover, CXCL4 protein was expressed in pDCs within the 
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circulation and the skin. Furthermore, studies have reported the expression of both CXCL4 
and CXCL7 in pDCs and mDCs. Maier et al (2009) reported the expression of CXCL4 in 
both DC subsets and observed a correlation with injury severity score in patients with trauma. 
Piqueras et al (2006) also reported the expression of both CXCL4 and CXCL7 in pDCs and 
mDCs. In this study, the host response to influenza virus infection was reported. Interestingly, 
CXCL4 expression was downregulated in pDCs and mDCs following viral exposure, whereas 
CXCL7 was released following infection resulting in neutrophil recruitment. Furthermore, 
CXCL4 released from pDCs has identified as a potential biomarker for systemic sclerosis 
(van Bon et al, 2014). 
 
In this chapter, I identified co-localisation of CXCL4 with the pDC marker BDCA-2 in 
rheumatoid synovium taken from patients who had undergone joint replacement (Figure 3.3). 
Staining for CXCL7 alongside BDCA-2 was less convincing. Upon staining of synovial 
biopsy sections taken from patients enrolled in the BEACON cohort, I did not observe any co-
localisation of CXCL4 with BDCA-2. Moreover, it was often extremely difficult to locate 
BDCA-2 positive cells within the sections. In our work I used antibodies specific for the pDC 
marker, BDCA-2. However in hindsight this may not have been the best marker to use in 
labelling rheumatoid synovium. Immature pDCs express BDCA-2 and BDCA-4 and a number 
of studies have suggested that both markers are downregulated upon entry into tissue. The 
marker CD123 is predominantly used as a marker for both immature and mature pDCs. 
However, other than being found on pDCs it is also expressed on mast cells, macrophages, 
and basophils amongst many others.  
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When visualising some of the patient’s synovial biopsy sections, I did observe CD41+ staining 
on the membrane of particular cells. Occasionally I observed this staining on CD68+ cells, 
thus suggesting that platelets could possibly attach to the macrophage membrane. I, also, 
observed CD41 positive staining on the membrane of other cells. It is possible that these cells 
could be mast cells as a study carried out by Berlanga et al (2005) reported that mast cells 
express the CD41 integrin. Mast cells have been reported in the synovial fluid and tissue of 
patients with RA and they are often found at sites of cartilage degradation. Therefore it is 
quite possible that the CD41 positive staining I observed on the membrane of unidentified 
cells could be mast cells. One way to test this would be to stain for mast cell markers such as 
CD203c and FcεRIα. It is also possible that CXCL4 and CXCL7 observed on the 
macrophages may be a result of their interactions with platelet microparticles. Platelet 
microparticles are known to contain an abundance of inflammatory mediators, and have been 
shown to contribute to the exacerbation of inflammation in RA (Boilard et al, 2010). 
 
In this chapter I identified a significant increase in the plasma concentration of CXCL4 in 
patients from the BEACON cohort compared to healthy controls. However, the CXCL4, 
CXCL7 and sGPVI plasma results must be given careful consideration before any firm 
conclusions are drawn. I analysed sGPVI as a marker of platelet activation in our samples. Al-
Tamimi et al (2009) published the method for the measurement of sGPVI in human plasma. 
In this published method, the measurement of sGPVI in plasma was not affected by the use of 
different anti-coagulants used during blood collected such as acid-citrate-dextrose, trisodium 
citrate or EDTA. However, the method used to obtain the plasma samples differed greatly 
from what was done in this chapter. Al-Tamimi et al (2009) used twice spun platelet poor 
plasma (blood centrifuged at 100g for 20 mins, followed by centrifugation of platelet rich 
  
135 
 
plasma at 300g for 15 mins. In this method, plasma was also further centrifuged to remove 
platelet microparticle contamination (platelet poor plasma centrifuged at 8000 g for 2 mins, 
then ultracentrifuged at 10,000g for 1 hr). Plasma samples used in my study were processed 
from blood collected from patients enrolled in the BEACON cohort. All samples were 
processed by a laboratory technician using standard operating procedures routinely carried out 
by our laboratory. Blood was centrifuged once at 3000rpm for 10 mins, before being stored 
first at -20°C, and then at -80°C. As plasma samples were obtained from the BEACON cohort 
a number of years prior to the onset of this study, unfortunately due to time constraints I was 
unable to collect new samples from the cohort and process them as described in the published 
method. Al-Tamimi et al (2009) established a normal range of sGPVI in healthy control 
plasma; 18.9 ± 4.1 ng/ml (mean ± stdev), range 11-24 ng/ml, however in my study the range 
of sGPVI in healthy control plasma was 62.4 ± 15.4 ng/ml (mean ± stdev), range 37.4-84.0 
ng/ml. Hence, it is possible that the results obtained in this study may be attributed to platelet 
or platelet microparticle contamination, and therefore I must consider this when evaluating 
my results. Furthermore, as sGPVI is an indicator of platelet activation, the positive 
correlation observed between sGPVI, CXCL4 and CXCL7 may be explained by increased 
platelet activation in these samples (Figure 3.17). Moreover, I must also consider the duration 
of time from blood collection to sample processing as this can have a detrimental effect on the 
results obtained. Jackman et al (2011) reported that levels of certain plasma cytokines 
increased or decreased depending on whether the sample was processed immediately, after 24 
hours, 48 hours and 72 hours. For example, the concentration of IL-8/CXCL8, TNFα and IL-
1β were all found to increase as the time to processing increased in trauma patients, whereas 
the concentrations of CXCL10, IL-12 (p40), and CX3CL1 were found to decrease. Now, 
although, all of the samples used within my study were processed within 24 hours, there was 
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often a delay of ~1-4 hours between sample collection and processing. This may have resulted 
in differences in the concentrations of CXCL4, CXCL7 and sGPVI. Similarly, agitation of 
samples during the shipping process may have led to platelet activation and a subsequent 
increase in both chemokines and sGPVI concentrations.  
 
A final analysis of the use of plasma levels of CXCL4 and CXCL7 is not yet possible, as I am 
still awaiting disease outcomes from a proportion of patients. However, the data so far suggest 
that neither of these cytokines allows prediction of patient outcome if measured in plasma. 
This may be due to a larger contribution of platelet derived chemokines in the plasma, 
compared to the macrophage linked expression in the tissue. I did however, observe a positive 
correlation of both CXCL4 and CXCL7 with the acute phase protein CRP, suggesting that 
plasma CXCL4 and CXCL7 expression may be a marker for early inflammatory disease, but 
not prediction of patient outcome. 
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4 CXCL4 AND CXCL7 EXPRESSION WITHIN THE 
MONOCYTE LINEAGE  
 
4.1 INTRODUCTION 
 
Macrophages play a pivotal role in driving the pathogenesis of RA through their release of a 
large array of both pro- and anti-inflammatory mediators.  Moreover increased numbers of 
macrophages in the synovium are associated with severe disease, whilst a reduction in 
macrophages in response to therapy has been shown to predict a positive outcome.  
 
Although I initially thought that platelets were the sole producers of CXCL4 and CXCL7, I 
was surprised when I observed co-localisation of CXCL4 and CXCL7 with what appeared to 
be CD68+ macrophages in the rheumatoid synovium. As a result, I sought to explore this 
further. Firstly, I investigated the expression of CXCL4 and CXCL7 at the mRNA level in 
monocytes and in vitro differentiated macrophages cultured under M1 and M2 conditions. I 
also studied the expression of both chemokines in cells cultured under monocyte-derived DC 
conditions. In order to eliminate the risk of contaminating platelets during our mRNA 
analysis, I devised a cell sorting strategy to obtain CD14+ CD41- cells from healthy donors. 
These cells were then used for downstream differentiation protocols.  
 
In this chapter, I also sought to validate an in situ hybridization method for use by us and a 
number of other groups within our rheumatology department. For our work, I sought to 
validate the method for the detection of CXCL7/PPBP single RNA molecules with the overall 
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aim of detecting CXCL4 in a similar way once I had the method up and running. Upon trying 
to validate the method, I ran into a number of problems which required troubleshooting. 
Although in the end I was not entirely satisfied with the method for the detection of our target 
of interest in the rheumatoid synovium, I obtained more promising results in tonsil tissue.   
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4.2 RESULTS 
 
4.2.1 CXCL4 and CXCL7 mRNA expression in monocytes and in vitro differentiated 
macrophages 
Within chapter 3 I described co-localisation of CXCL4 and CXCL7 with the marker for 
macrophages, CD68, at the protein level within the rheumatoid synovium. Following on from  
these observations I sought to determine the expression of CXCL4 and CXCL7 at the mRNA 
level in healthy donor CD14+ monocytes, and monocytes differentiated to macrophages and 
monocyte derived dendritic cells (Mo-DCs) under M1, M2 and Mo-DC culture conditions 
established in Birmingham by Prof. Andrew Clark’s team.  
 
mRNA coding for CXCL4 and CXCL7 was expressed in all four cell populations. Both 
CXCL4 and CXCL7 mRNA expression was significantly higher in CD14+ monocytes 
compared to the cells cultured under M1, M2 and Mo-DC conditions. There was no 
statistically significant difference in CXCL4 and CXCL7 mRNA expression between the cells 
cultured under M1, M2 and Mo-DC conditions as assessed by the Dunn’s multiple 
comparison test (Figure 4.1). 
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Figure 4.1 CXCL4 and CXCL7 mRNA expression in CD14+ monocytes differentiated to 
macrophages and monocyte-derived dendritic cells (Mo-DC) under M1, M2 and Mo-DC 
culture conditions. PBMCs were isolated from peripheral blood taken from healthy donors 
using Ficoll-Paque. CD14+ monocytes were isolated via positive selection using CD14+ 
conjugated magnetic beads (Miltenyi Biotec, UK). Monocytes were seeded in a 6 well-plate at 
1 x 106 cells/well in RPMI-1640 + 10% Hi FCS + 1% GPS in a volume of 1000 µl/well. Cells 
were differentiated to macrophages and Mo-DCs under M1 (10 ng/ml GM-CSF), M2 (10 
ng/ml M-CSF), and Mo-DC (25 ng/ml GM-CSF and 25 ng/ml IL-4) culture conditions for 6 
days. Monocytes were also immediately lysed in RLT lysis buffer following the isolation to 
act as a control. CXCL4 and CXCL7 mRNA expression in monocytes (black bar) and cells 
cultured under M1 (dark grey bar), M2 (medium grey bar) and Mo-DCs (light grey bar) 
conditions was assessed using the Stratagene MX3000p qPCR machine. Gene expression was 
normalised to the housekeeping gene, beta actin. The results show median + interquartile 
range (IQR) of 5 independent experiments. Statistical significance was calculated using the 
Kruskall-Wallis test followed by the Dunn’s multiple comparison test; **p≤0.01, ***p≤0.001.  
 
 
As I observed increased expression of both CXCL4 and CXCL7 mRNA in CD14+ monocytes, 
I was concerned that the expression could be largely due to platelet contamination following 
the cell isolation, as monocytes can bind platelets on their surface. Therefore I established a 
cell sorting method to isolate CD14+ monocytes with or without CD41+ platelets (Figure 4.2). 
CXCL4, CXCL7 and CD41 mRNA was expressed in the CD14+ CD41-, CD14+ CD41+ 
  
141 
 
intermediate, and CD14+ CD41+ cell sorted populations. CXCL4 mRNA expression was 
significantly increased in the CD14+ CD41+ population compared to the CD14+ CD41- 
population (Kruskall Wallis followed by Dunn’s multiple comparison test p≤0.001) (Figure 
4.2D). Likewise, CXCL7 mRNA expression was also significantly increased in the CD14+ 
CD41+ population compared to the CD14+ CD41- population (Dunn’s multiple comparison 
test p≤0.001). CXCL7 was also significantly increased in the CD14+ CD41+ intermediate 
population compared to the CD14+ CD41- population (Dunn’s multiple comparison test 
p≤0.01) (Figure 4.2E). CD41 mRNA was also expressed in all three sorted populations. CD41 
mRNA was significantly increased in the CD14+ CD41+ population compared to the CD14+ 
CD41- (Dunn’s multiple comparison test p≤0.001) and CD14+ CD41+ intermediate 
populations (Dunn’s multiple comparison test p≤0.05) (Figure 4.2F). 
 
 
 
 
 
 
 
  
142 
 
                      
       
C
D
1
4
+
 C
D
4
1
-
C
D
1
4
+
 C
D
4
1
+
 i
n
te
rm
ed
ia
te
C
D
1
4
+
 C
D
4
1
+
0 .0 0 0
0 .0 0 2
0 .0 0 4
0 .0 0 6
0 .0 0 8
0 .0 1 0
0 .0 4
0 .0 8
C X C L 4
* * *
R
Q
 C
X
C
L
4
 n
o
r
m
a
li
s
e
d
 t
o
 h
o
u
s
e
k
e
e
p
in
g
 g
e
n
e
 b
e
t
a
 a
c
t
in
         
C
D
1
4
+
 C
D
4
1
-
C
D
1
4
+
 C
D
4
1
+
 i
n
te
rm
ed
ia
te
C
D
1
4
+
 C
D
4
1
+
0 .0 0 0
0 .0 0 5
0 .0 1 0
0 .0 1 5
0 .0 2 0
0 .0 5
0 .1 0
C X C L 7
* *
* * *
R
Q
 C
X
C
L
7
 n
o
r
m
a
li
s
e
d
 t
o
h
o
u
s
e
k
e
e
p
in
g
 g
e
n
e
 b
e
t
a
 a
c
t
in
C
D
1
4
+
 C
D
4
1
-
C
D
1
4
+
 C
D
4
1
+
 i
n
te
rm
ed
ia
te
C
D
1
4
+
 C
D
4
1
+
0 .0 0 0 0
0 .0 0 0 5
0 .0 0 1 0
0 .0 0 1 5
0 .0 0 2 0
0 .0 0 2 5
0 .0 1 0
0 .0 1 5
0 .0 2 0
0 .0 2 5
C D 4 1
*
* * *
R
Q
 C
D
4
1
 n
o
r
m
a
li
s
e
d
 t
o
h
o
u
s
e
k
e
e
p
in
g
 g
e
n
e
 b
e
t
a
 a
c
t
in
 
A B 
C 
D E 
F 
Gated on 
monocytes (R1) 
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Figure 4.2 Cell sorting protocol for CD14+ monocytes with or without CD41+ platelets 
and subsequent analysis of CXCL4, CXCL7 and CD41 mRNA expression. PBMCs were 
isolated from peripheral blood collected from healthy donors using Ficoll-Paque. Cells were 
fluorescently labelled with antibodies specific for CD14 and CD41 and subsequently sorted 
into three different cell populations using the MoFlo™ cell sorter operated by Mr. Roger Bird. 
Cells were gated on the monocyte population as determined by forward scatter versus side 
scatter (A) before being gated by forward scatter versus pulse width to exclude cell doublets 
(B). The cells were then sorted into CD14+ CD41- (R3), CD14+ CD41+ intermediate (R4), and 
CD14+ CD41+ (R5) populations (C). The purity of the sort was routinely above 95%. Dot 
plots were generated using Summit v4.3 software. CXCL4 (D), CXCL7 (E) and CD41 (F) 
mRNA expression was assessed using the Stratagene MX3000p qPCR machine. Gene 
expression was normalised to the housekeeping gene, beta actin. The results show median + 
IQR of 5 independent experiments. Light grey bar; CD41+ CD41- population, dark grey bar; 
CD14+ CD41+ intermediate population, and black bar; CD14+ CD41+ population. Statistical 
significance was calculated using the Kruskall-Wallis test followed by the Dunn’s multiple 
comparison test; *p≤0.05, **p≤0.01, ***p≤0.001.  
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Finally, I studied the effect of 6 hour and 24 hour LPS (10 ng/ml) stimulation on the 
expression of CXCL4, CXCL7 and CD41 on CD14+ CD41- cells differentiated to 
macrophages and Mo-DCs under M1 (GM-CSF), M2 (M-CSF) and Mo-DC (GM-CSF and 
IL-4) culture conditions.  I observed significantly higher CXCL4 mRNA expression in CD14+ 
CD41- monocytes compared to unstimulated cells cultured under M1 conditions (Dunn’s 
multiple comparison test p≤0.01). CXCL4 mRNA expression was higher in the cells cultured 
under M2 conditions compared to those cultured under M1 and Mo-DC conditions. 
Furthermore there was significantly more CXCL4 mRNA expressed in the M2 cultured cells 
following 6 hrs of LPS stimulation compared to the Mo-DCs stimulated with LPS for 6 hrs 
(Dunn’s multiple comparison test p≤0.05). Cells cultured under Mo-DC conditions and left 
unstimulated expressed greater CXCL4 mRNA than those following stimulation with LPS 
(Figure 4.3A).  
 
CXCL7 mRNA was expressed in CD14+ CD41- monocytes and monocytes differentiated to 
macrophages and Mo-DCs under M1, M2 and Mo-DC culture conditions. Cells differentiated 
under M1 conditions had significantly more CXCL7 mRNA expression following 6 hrs LPS 
stimulation than cells differentiated under M2 conditions and stimulated for 6 hours (Dunn’s 
multiple comparison test p≤0.05). Cells differentiated under Mo-DC conditions and 
stimulated for 6 hrs expressed the greatest level of CXCL7 mRNA (Figure 4.3B).  
 
A potential confounder may be that, although I used the CD14+ CD41- sorted cell population 
during these experiments, CD41 mRNA was still detectable in this population as well as in 
cells following differentiation under M1, M2 and Mo-DC conditions. Therefore further 
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experiments must be performed before drawing a firm conclusion. CD41 mRNA expression 
was significantly higher in the unstimulated Mo-DC cultured population compared to the M1 
(Dunn’s multiple comparison test p≤0.01) and M2 cultured populations (Dunn’s multiple 
comparison test p≤0.001). Also, significantly higher CD41 mRNA expression was also 
observed in Mo-DCs stimulated for 6 hrs with LPS compared to M2 cultured cells stimulated 
for 6 hrs (Dunn’s multiple comparison test p≤0.01) (Figure 4.3C). I currently have no method 
to determine whether the CD41 mRNA expression indicates a remainder of platelet derived 
contamination, although in the future I could explore the potential of other platelet or platelet 
microparticle markers. However, residual platelet contamination should be equal in the 
individual samples, unless platelet survival in culture was affected by the Mo-DC culture 
condition. As the expression pattern of CD41 differs from that of CXCL4 and CXCL7, it is 
unlikely that the higher expression of CXCL4 in the M2 stimulated macrophages can be 
explained by residual platelets. 
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Figure 4.3 CXCL4, CXCL7 and CD41 mRNA expression in CD14+ CD41- monocytes 
differentiated under M1, M2 and Mo-DC conditions and subsequently stimulated with 
LPS. CD14+ CD41– sorted cells were seeded in a 96 well-plate at 3.37 x 104 cells/well in 
RPMI-1640 + 10% Hi FCS + 1% GPS in a volume of 200 µl/well. Cells were differentiated to 
macrophages under M1, M2 or Mo-DC culture conditions and subsequently stimulated with 
10 ng/ml LPS for 6 hours (dark grey bar) or 24 hours (black bar). Undifferentiated CD14+ 
CD41- monocytes were also immediately lysed in RLT lysis buffer following the cell sort to 
act as a control. A) CXCL4, B) CXCL7 and C) CD41 mRNA expression was assessed using 
the Stratagene MX3000p qPCR machine. Gene expression was normalised to the 
housekeeping gene, beta actin. The results show median + IQR of 5 independent experiments. 
Statistical significance was calculated using the Kruskall-Wallis test followed by the Dunn’s 
multiple comparison test; *p≤0.05, **p≤0.01, ***p≤0.001.  
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4.2.2 Detection of CXCL7 by In Situ Hybridization 
I set out to validate an In Situ Hybridization method for the detection of PPBP/CXCL7 (target 
probe), GAPDH (positive control), and Bacillus subtilis dapB (negative control) as I sought to 
identify the exact source of the chemokine message within the tissue. Due to a shortage of 
early RA formalin fixed paraffin embedded (FFPE) sections I decided that it was best to set 
up the In Situ Hybridization method using human tonsil tissue FFPE sections. In order to 
carry out the In Situ Hybridization I used the QuantiGene® ViewRNA In Situ Hybridization 
Tissue 1-Plex Assay from Affymetrix/Panomics.  
 
The QuantiGene® View RNA In Situ Hybridization Tissue 1-Plex Assay method was 
optimised using human tonsil FFPE sections cut and mounted by the Human Biomaterials 
Resource Centre (HBRC): Biobank (University of Birmingham, UK). Sections were viewed 
using the Zeiss LSM 780 Zen confocal. Initially I set out to visualise the sections by light 
microscopy, following Haematoxylin and Eosin staining of the sections. However, observing 
any signal was difficult following this method. During the initial experiments, optimisation of 
the heat pre-treatment and protease digestion steps was carried out. Sections were either heat 
pre-treated for 5 mins followed by protease digestion for 10 mins, heat pre-treated for 10 mins 
followed by protease digestion for 10 mins or heat pre-treated for 10 mins followed by 
protease digestion for 20 mins. The sections displayed good tissue morphology following all 
combinations of heat pre-treatment and protease digestion. The GAPDH (positive control) 
probe was evident in the FFPE tonsil sections. The majority of GAPDH signal was observed 
within germinal centres of the tonsil. Sections probed for Bacillus subtilis dapB (negative 
control) were predominantly negative.  The level of background was deemed acceptable if <1 
dot was evident per 10 cells.  PPBP/CXCL7 (target probe) expression was barely evident in 
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the tonsil sections. This was comparable to what was observed in FFPE tonsil sections stained 
by immunofluorescence with an antibody specific to CXCL7.  Following the optimisation I 
decided to go ahead with a heat pre-treatment time of 10 mins and a protease digestion time of 
10 mins (Figure 4.4). 
 
   
                                      
Figure 4.4 In Situ Hybridization of FFPE human tonsil. In Situ Hybridization was carried 
out using the QuantiGene® ViewRNA ISH Tissue 1-Plex Assay (Panomics/Affymetrix) for 
the presence of GAPDH (positive control probe) (Image A), Bacillus subtilis dapB (negative 
control probe) (Image B), and PPBP (target probe) (Image C). Sections underwent heat pre-
treatment for 10 mins and protease digestion for 10 mins. Sections were viewed on the Zeiss 
LSM 780 Zen confocal. Images were taken at x400 total magnification. Probe-red, DAPI 
stained nuclei-blue.  
 
 
Following on from my initial experiments in the tonsil tissue and prior to moving on to the 
early RA sections, I wanted to address whether or not I could carry out immunofluorescence 
staining with an antibody specific to CD68 after the In Situ Hybridization method. 
Establishment of this method would enable me to identify the cellular localisation of the RNA 
signal and thus support my data at the protein and mRNA level. Using a section of tonsil 
tissue previously used for In Situ Hybridization I was able to stain CD68+ macrophages. I did 
not observe any co-localisation of the GAPDH probe with CD68 (Figure 4.5).  
C B A 
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Figure 4.5 Immunofluorescence following the QuantiGene® ViewRNA ISH Tissue 1-Plex 
Assay in FFPE tonsil tissue. Following In Situ Hybridization, Immunofluorescence with an 
antibody specific for CD68 (blue) was carried out in FFPE human tonsil tissue. The image 
above was taken from a section previously probed for GAPDH (positive control probe (red)). 
Sections were viewed on the Zeiss LSM 780 Zen confocal. Images were taken at x400 total 
magnification.  
 
 
Next I carried out In Situ Hybridization method in early RA sections. I decided to use the 
early RA sections as I observed an increase in CXCL7 protein expression by 
immunofluorescence in this patient group. First of all, as the numbers of sections were 
extremely limited I decided to trial the In Situ Hybridization method on three RA FFPE 
sections (positive, negative, and target probe) from one patient. In this experiment I observed 
expression of GAPDH and PPBP/CXCL7. I observed a large proportion of the PPBP/CXCL7 
target probe signal outside the nuclei. However, some positive staining was observed within 
the nuclei. Positive staining was observed on the Bacillus subtilis dapB negative control; 
however I initially deemed the level of staining acceptable. On further inspection of the slides, 
Nuclei CD68 
Merge Probe: GAPDH 
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I identified non-specific binding on the glass slide. This gave rise to an increased background 
signal and therefore I was hesitant regarding the PPBP/CXCL7 result (Figure 4.6).  
 
   
Figure 4.6 In Situ Hybridization of FFPE early RA tissue. In Situ Hybridization was 
carried out using the QuantiGene® ViewRNA ISH Tissue 1-Plex Assay 
(Panomics/Affymetrix) for the presence of GAPDH (positive control probe) (Image A), 
Bacillus subtilis dapB (negative control probe) (Image B), and PPBP (target probe) (Image 
C). Sections underwent heat pre-treatment for 10 mins and protease digestion for 10 mins. 
Sections were viewed on the Zeiss LSM 780 Zen confocal. Images were taken at x400 total 
magnification. Probe-red, DAPI stained nuclei-blue.  
 
In order to try and address this issue, I adjusted the In Situ Hybridization method. I had the 
synovial biopsy sections cut and mounted on the recommended glass slides; Leica non-
clipped X-tra slides by The Royal Orthopaedic Hospital NHS Foundation Trust (Birmingham, 
UK). I increased the number of xylene steps to ensure the full removal of paraffin and 
prolonged the wash times by 1 min following hybridization with the pre-amplifier and 
amplifier solutions.  On first trying the adjusted protocol on tonsil sections (sections from the 
Biobank), the glass background was reduced. I observed expression of GAPDH, again 
predominantly within the germinal centres, and limited expression of Bacillus subtilis dapB in 
the sections as described previously. However, when I repeated the method in the early RA 
sections, the GAPDH and PPBP/CXCL7 signal was absent and I observed an increase in the 
glass background.  
A B C 
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Next, I sought to determine whether or not the duration of tissue fixation in formaldehyde had 
any effect on the absence of the signal observed in the previous experiments in the early RA 
tissue. Some synovial biopsies used in the previous experiments, once collected, were fixed in 
formaldehyde for weeks if not months before being processed into paraffin and sectioned. 
Therefore synovial biopsies were collected and fixed for a maximum of 24 hours before being 
processed into paraffin and sectioned. I observed an increase in the GAPDH signal in the 
section fixed in formaldehyde for a maximum of 24 hours (Figure 4.7). Bacillus subtilis dapB 
signal was low. The section with a prolonged fixation time in formaldehyde had an increased 
Bacillus subtilis dapB signal. I did observe, again, an increase in glass background on the 
section probed with GAPDH. This was not observed on the section probed with Bacillus 
subtilis dapB. Moreover, blocking sections with 1% BSA/PBS did not eliminate the glass 
background issue.  
 
                                       
Figure 4.7 In Situ Hybridization of sections fixed and processed within 24 hours of 
collection (BX149B). Sections were probed for GAPDH (A and B) and Bacillus subtillis 
dapB (C and D). Sections were viewed on the Zeiss LSM 780 Zen confocal. Images were 
taken at x400 total magnification. Probe-red, DAPI stained nuclei-blue. 
 
 
A B 
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In conclusion, I validated the In Situ Hybridization method for the detection of the positive 
control probe, GAPDH, and the negative control probe, Bacillus subtillis dapB, in the tonsil 
sections. I was also able to design and perform an immunofluorescence protocol for the 
detection of CD68 within the tissue following the In Situ Hybridization method. Although I 
took multiple steps to validate the method for use in the RA tissue sections, I failed to 
eliminate non-specific binding of the probe to the glass slide. I was therefore unable to 
quantify and study the localisation of the CXCL7/PPBP target probe in the RA tissue.  
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4.3 DISCUSSION 
 
In this chapter, I investigated the expression of CXCL4 and CXCL7 mRNA outside of the 
megakaryocyte lineage. The data supported my findings at the protein level in chapter 3, 
whereby I observed co-localisation of CXCL4 and CXCL7 with the macrophage marker, 
CD68. Here, I reported CXCL4 and CXCL7 mRNA expression in monocytes isolated from 
healthy controls. Furthermore, upon differentiation under M1, M2 and Mo-DC conditions in 
vitro I observed expression of both CXCL4 and CXCL7 mRNA in these cell populations, 
although relative mRNA quantification was significantly lower than observed in the freshly 
isolated monocytes (Figure 4.1). Within this chapter I was very reluctant to refer to the M1, 
M2 and Mo-DC cultured cells as terminally differentiated populations as the supernatants 
taken from cultured cells did not differ significantly in their TNFα levels. Therefore I referred 
to these populations as being cultured under M1, M2 and Mo-DC conditions.  
 
Although there is no clearly defined marker that distinguishes between the M1 and M2 
macrophage subsets, there have been several studies that outline a panel of markers than may 
be useful. M1 macrophages express high levels of pro-inflammatory mediators including 
TNFα, IL-1, IL-6, and IL-12 whilst M2 macrophages express high levels of anti-inflammatory 
mediators including IL-1RA, IL-10, and TGFβ.  Additionally M2 macrophages can be 
characterised by their expression of the mannose receptor CD206 and the scavenger receptor 
CD163 on their surface, whilst M1 macrophages express increased levels of MHC class II and 
CD80/CD86 (Stöger et al, 2012). Furthermore M1 and M2 macrophages can be distinguished 
from one another by their metabolism of L-arginine. M1 macrophages upregulate nitric oxide 
synthase (iNOS) whilst M2 macrophages upregulate arginase 1 (Hao et al, 2012). Therefore in 
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the future, any cells differentiated in culture would be assessed using a number of these 
different markers to confirm their phenotype either by qPCR or flow cytometry.   
 
My findings are in agreement with a study by Pertuy et al (2015). They studied the 
recombination of platelet factor 4 (Pf4)-cre in the Pf4-cre transgene mouse. Here, the 
expression of PF4/CXCL4 was not only reported in the megakaryocyte lineage but also in a 
small population of circulating leukocytes. Pf4-cre recombined cells were evident in all 
organs examined in the study including the heart, kidney, liver, stomach, brain and lung. 
Interestingly, the Pf4-cre recombined cells were identified as murine macrophages as they 
stained positive with an antibody specific for the surface marker F4/80. In humans, F4/80 is 
expressed by eosinophils, not macrophages (Murray and Wynn, 2011). F4/80 is a pan 
macrophage marker for macrophages in the mouse. Similar to our findings that not all 
CXCL4 positive cells were positive for CD68 and vice versa, Pertuy et al (2015) reported that 
not all F4/80 positive cells demonstrated Pf4-cre recombination. Therefore it was suggested 
that expression of PF4 was in a particular subset of macrophages. In our results I observed 
greater expression of CXCL4 mRNA in the cells differentiated to macrophages under M2 
conditions (Figure 4.3A) compared to M1 and Mo-DC conditions. Therefore, I speculate that 
the F4/80 positive population expressing Pf4-cre observed by Pertuy et al (2015) may belong 
to the M2 macrophage subset. Moreover, the F4/80 negative cells expressing recombined 
PF4-cre are unlikely to be dendritic cells as they were negative for CD11c. However, as 
CD11c is a marker for mDCs as well as monocytes and macrophages (Murray and Wynn, 
2011), it would have been interesting for this report to have stained with a more specific 
marker for pDCs, especially in light of the publication by van Bon et al (2014) which 
identified CXCL4 expression by pDCs in patients with systemic sclerosis. In support of my 
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findings, Schaffner et al (2005) reported the expression of CXCL4 in human monocytes. An 
increase in CXCL4 mRNA expression was observed in monocytes in response to thrombin 
stimulation. Moreover Mo-DCs were also found to express CXCL4 mRNA following 
thrombin stimulation, but not as high as observed in monocytes.  
 
Likewise, the expression of CXCL7 has also been reported outside the megakaryocyte 
lineage. This is not surprising as the gene for CXCL4/PF4 is located only 5.3kb upstream of 
CXCL7/PBP. A recent study by Smith et al (2015) identified elevated levels of pro-platelet 
basic protein (PPBP) in human monocyte derived macrophages in patients with allergic 
bronchopulmonary aspergillosis and chronic cavitary pulmonary aspergillosis. PPBP mRNA 
expression was higher in the disease groups compared to healthy controls. In a study by El-
Gedaily et al (2004) human mononuclear phagocytes were reported to transcribe and translate 
PPBP. Furthermore, PPBP mRNA expression was found to be negatively regulated by IL-4 
and IL-10. Glucocorticoids were also found to have a negative effect on PPBP mRNA 
expression in monocytes and platelets. Interestingly, El-Gedaily et al (2004) reported that LPS 
stimulation of monocytes did not increase PPBP mRNA expression but instead decreased 
expression. This finding may support my results, as I observed a decrease in CXCL7 mRNA 
expression following 6 hours of LPS stimulation in monocytes differentiated to macrophages 
under M2 culture conditions compared to the unstimulated cells. However, CXCL7 mRNA 
expression increased following 24 hours of LPS stimulation in this population. Furthermore, 
El-Gedaily et al (2004) reported that NAP-2 release into the supernatant from stimulated 
monocytes was not substantial, and therefore it was suggested that PPBP and its cleavage 
products may play a role in intracellular functions such as anti-microbial activity. As a result, 
the expression of CXCL4 and CXCL7 by macrophages may result in extra care needing to be 
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taken when studying the function of megakaryocytes in animal models, especially where 
inflammatory cells are present (Pertuy et al, 2015).  
 
It has also been reported in a number of studies that platelets may form complexes/aggregates 
with other immune cells within the circulation and trigger inflammation. Joseph et al (2001) 
carried out a study looking at the formation of platelet-leukocyte complexes in the peripheral 
blood of patients with systemic lupus erythematosus (SLE), primary antiphospholipid 
syndrome (PAP) and RA. Here, it was reported, that within the peripheral blood of patients 
with RA, there was a significant increase in platelet-granulocyte and platelet-monocyte 
complexes compared to healthy controls. They also reported an increase in circulating 
platelet-lymphocyte complexes, although this was not significant compared to controls. 
Pamuk et al (2008) also reported an increase in circulating platelet-monocyte- and platelet-
neutrophil-complexes within the peripheral blood of patients with RA compared to controls. I 
was able to demonstrate that monocytes were capable of forming complexes with platelets 
using flow cytometry. These complexes were observed upon cell sorting from freshly isolated 
PBMCs and also positively selected isolated CD14+ monocytes. A similar method was 
described by Jung et al (2014). I observed expression of CXCL4, CXCL7 and CD41 mRNA 
on CD14+ CD41- monocytes. This suggests that monocytes are a source of both chemokines 
at the mRNA level. Furthermore, when CD41+ platelets were included in the sorted 
populations, the expression of CXCL4, CXCL7, and CD41 mRNA was significantly higher. 
Hence, this would suggest that although monocytes express CXCL4 and CXCL7 in the blood, 
platelets are still the predominant source of both chemokines. Interestingly in the CD14+ 
CD41- sorted population, I did observe a low level of CD41 mRNA expression.  This may 
indicate that my gates were set too large or it is quite possible that platelet microparticles may 
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have been attached to the surface of the monocytes. Although I did not have the opportunity 
to look for monocyte-platelet complexes in the peripheral blood from patients with RA, I did 
observe CD41+ staining on the membrane of certain cells within the synovium. This could 
suggest that the formation of monocyte-platelet complexes in the peripheral blood may also 
be evident in the synovium of RA patients. This may also be a potential mechanism of how 
platelets leave the circulation and enter the synovium. 
 
In Situ Hybridization allows the visualisation of target RNA at the single cell level in frozen 
and paraffin embedded tissue without disruption of the tissue architecture. The technique 
offers higher specificity when compared to qPCR and has an advantage in that it can be 
coupled with immunohistochemistry and immunofluorescence for identification of cell 
populations expressing the target RNA (Reichard et al, 2006). In this chapter, I set out to 
validate a method for In Situ Hybridization for the detection of single CXCL7/PPBP RNA 
molecules within the rheumatoid synovium. As CXCL7/PPBP target probes were 
commercially available from Affymetrix/Panomics, I initially set about validating the method 
using this probe alongside positive and negative controls with the overall aim of designing my 
own CXCL4/PF4 target probe once the method worked. I was also keen on establishing the 
method within our laboratory so that it could be utilised by other members of our research 
group for different targets of interest. Overall, I was generally satisfied with the In Situ 
Hybridization method in tonsil sections and moreover I was able to carry out 
immunofluorescence with an antibody specific for CD68 following In Situ Hybridization 
(Figure 4.5) whilst still retaining good tissue architecture. I observed strong positive control 
GAPDH and minimal negative control Bacillus subtilis dapB RNA signal. Interestingly I 
observed GAPDH signal predominantly targeted to germinal centres within the tonsil tissue. 
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This was not a result I was anticipating as I expected GAPDH to be found across the entire 
tissue (Figure 4.4A). Similar to my observations in tonsil sections by immunofluorescence I 
was not surprised by the low levels of PPBP/CXCL7 in this tissue detected by In Situ 
Hybridization. However, upon moving to rheumatoid synovium sections in which I had 
previously observed high expression of CXCL7 by immunofluorescence, I struggled to 
produce an In Situ Hybridization result that I was satisfied with. The main issue I encountered 
when moving from the tonsil sections to the synovium was the increase in glass slide 
background and although I tried multiple optimisation protocols to try and eliminate this 
issue, I was unable to distinguish a positive result over background. To conclude, although I 
detected a positive signal for GAPDH in the tonsil, further work must be performed to fully 
validate the In Situ Hybridization method for use in the synovial tissue.  
 
 
 
 
 
 
 
  
160 
 
5 CHARACTERISATION OF CXCL4L1 EXPRESSION IN 
THE RHEUMATOID SYNOVIUM 
 
5.1 INTRODUCTION 
 
In the work shown in chapter 3, I observed CXCL4 expression within the synovium of 
patients with early RA, established RA, and early resolving synovitis. Expression was also 
observed in uninflamed controls. During this study I became aware of the variant form of 
CXCL4 which differs in only three amino acids; Proline58>Leucine, Lysine66>Glutamic 
acid, and Leucine67>Histidine, within the C-terminus (Green et al, 1989). The variant is 
referred to as CXCL4L1 or platelet factor 4 variant (PF4V1). CXCL4L1 is expressed 
predominantly by thrombin stimulated platelets, smooth muscle cells and tumour cells (Struyf 
et al, 2004). It functions as a potent inhibitor of endothelial cell migration and angiogenesis 
(Vandercappellen et al, 2011).  
 
Angiogenesis is the development of new blood vessels from pre-existing vessels. It is 
involved in physiological processes such as embryogenesis, wound healing and the female 
reproductive cycle. It is also a key player in tumour growth and metastasis, RA, psoriasis, and 
diabetic retinopathy amongst many others (Friis et al, 2013). Angiogenesis is regulated by a 
balance between both angiogenic and angiostatic factors. Angiogenic factors promote 
angiogenesis and include vascular endothelial growth factor (VEGF), fibroblast growth 
factor-1 (FGF-1), fibroblast growth factor-2 (FGF-2), platelet derived growth factor (PDGF), 
epidermal growth factor (EGF), insulin-like growth factor (IGF), hepatocyte growth factor 
(HGF) and the angiopoietins 1-4 (Ang 1-4). A large number of cytokines and chemokines 
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also drive angiogenesis. These include; TGFβ, TNFα, IL-1, IL-6, IL-13, IL-15, IL-18, and the 
ELR+ CXC chemokines. They are released when tissue becomes injured, diseased or hypoxic. 
CXCL4L1 is an angiostatic factor. 
 
Currently, there is very little known about CXCL4L1 in the context of RA. Thus far a single 
study exists that briefly describes the expression of CXCL4L1 at the mRNA level in vitro 
fibroblast-like synoviocytes from OA and RA patients (Cagnard et al, 2005). However, as of 
yet there is no research regarding the expression of CXCL4L1 at the protein level within the 
RA synovium.  
 
In this chapter, the primary objective was to determine whether or not the antibody used for 
the CXCL4 study was indeed specific for CXCL4 and was not detecting CXCL4L1. 
Interesting preliminary data led me to study the expression of CXCL4L1 at the protein level 
in the rheumatoid synovium alongside markers for synovial fibroblasts. Furthermore, I 
progressed on to study the expression of CXCL4L1 at the protein and mRNA level in in vitro 
cultured fibroblasts. I hypothesised that expression of CXCL4L1 in the synovium and 
cultured fibroblasts would explain the pathology observed in rheumatoid arthritis. 
 
The normal synovium can be subdivided into two regions; the synovial lining layer and the 
synovial sublining layer. The synovial lining is 2-3 cell layers thick and consists of type A 
macrophage-like synoviocytes and type B fibroblast-like synoviocytes. Type B fibroblast-like 
synoviocytes produce hyaluronan, a constituent of synovial fluid, whilst type A macrophage-
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like synoviocytes clear debris from the joint. The sublining is relatively acellular, with a small 
number of scattered blood vessels, fibroblasts, lymphocytes, and macrophages (Smith, 2011). 
Capillaries, venules and arterioles, as well as the lymphatics are positioned within the 
sublining (Smith, 2011).  In RA, it is the synovial fibroblasts that are thought to play a key 
role in driving RA progression and the persistence of inflammation (Filer, 2013). They 
produce a large array of different inflammatory cytokines, chemokines, angiogenesis 
mediators, serine proteases, matrix metalloproteinases and cathepsins, and as a result exhibit 
an aggressive and invasive phenotype (Pap et al, 2000). Rheumatoid synovial fibroblasts (RA-
SFs) produce CCL2, CCL3, CCL5, CCL20, CCL21, CXCL1, CXCL5, CXCL8, CXCL10, 
CXCL12, and CXCL13 which drive leukocyte recruitment to the synovial joint and retention 
of leukocytes within the synovium. They release IL-15 and IL-16. RA-SFs are highly invasive 
and are often characterised by their large pale nuclei, rounded shape, abundant cytoplasm, and 
prominent nucleoli (Pap et al, 2000). On activation they upregulate expression of adhesion 
molecules and as a result are capable of attaching to cartilage. Müller-Ladner et al (1996) 
reported that RA-SFs were capable of invading healthy human cartilage when engrafted into 
the severe combined immunodeficiency (SCID) mouse, whereas fibroblasts taken from OA, 
skin and healthy donors showed very little if any invasive growth. This study also identified 
the expression of cathepsins B, D, and L at the site of invasion, as well as VCAM-1. RA-SFs 
also produce MMP-1 and MMP-3 which drive cartilage degradation. Moreover, Lefevre et al 
(2009) described the potential of RA-SFs to spread disease to unaffected joints using healthy 
cartilage co-implanted subcutaneously into SCID mice alongside RA-SFs and detecting 
migration of RA-SFs into contralaterally implanted cartilage. RA-SFs produce RANKL 
which promotes osteoclast formation and drives bone erosion. They also release DKK-1 
which inhibits osteoblast function, thus preventing the repair of bone erosions. Additionally, 
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synovial fibroblasts have been shown to protect CD4+ T cells from undergoing spontaneous 
apoptosis (Salmon et al, 1997). In the study by Salmon et al (1997), synovial fibroblasts co-
cultured with CD4+ T cells isolated from peripheral blood and synovial fluid were shown to 
inhibit apoptosis via the upregulation of Bcl-xL. Moreover, factors released by synovial 
fibroblasts were also effective.  
 
A number of different markers can be used to define fibroblast subpopulations in the RA 
synovium (Table 5.1). Within this chapter, I used CD90 (Thy-1), protein disulphide isomerase 
(PDI) and vascular cell adhesion molecule (VCAM-1) to aid in the study of the expression of 
CXCL4L1 in the rheumatoid synovium and in vitro cultured fibroblasts.  
 
Name Synonyms Geographical marker Role in disease 
CD55 DAF Lining layer subpopulation Interacts with 
macrophage CD97 
VCAM-1 CD106 Lining layer subpopulation Adhesion via VLA-4 
Cadherin-
11 
 Lining layer Homotypic adhesion 
Gp38 Podoplanin Lining layer and lymphatics Invasiveness in cancer 
FAP Fibroblast 
activation protein 
Lining layer subpopulation in 
RA 
Resistant to cancer 
chemotherapy 
CD90 Thy-1 Sublining layer and 
endothelial cells 
Cell adhesion via 
Mac-1 
CD248 Endosialin Sublining layer and pericytes Invasiveness in 
cancer, angiogenesis 
 
Table 5.1 Markers of fibroblast subpopulations in the RA synovium. Table from Filer, 
2013. 
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CD90 was originally identified on mouse thymocytes and as a result is also referred to as 
thymocyte differentiation antigen-1 (Thy-1). CD90 (Thy-1) is a 25-35 kDa cell surface 
glycoprotein that is anchored to the membrane via glycosylphosphatidylinositol. CD90 (Thy-
1) is expressed by mesenchymal, haematopoietic and keratinocytic stem cells as well as 
fibroblasts, neuronal cells and activated endothelial cells. It functions in inflammation and 
wound healing by playing a role in the synthesis and release of cytokines, growth factors and 
extracellular matrix constituents. It also plays a role in cell-matrix and cell-cell adhesion. 
CD90 (Thy-1) is expressed in the synovium of RA patients (Saalbach et al, 1999). It is used 
as a marker of the synovial sublining and endothelial cells.  
 
Protein disulphide isomerase (PDI) is a 55 kDa member of a large family of thiol-disulphide 
oxidoreductases. It is expressed in the lumen of the endoplasmic reticulum whereby it plays a 
role in the synthesis and folding of proteins. Protein disulphide isomerase is a non-catalytic β-
subunit of prolyl-4-hydroxylase. It is involved in the biosynthesis of collagen triple helix 
formation. It is responsible for the hydroxylation of proline residues within collagen 
(Appenzeller-Herzog and Ellgaard, 2008, Wilkinson and Gilbert, 2004).  Prolyl-4-
hydroxylase also plays a role in the regulation of hypoxia inducible factors (Myllyharju, 
2003). Prolyl-4-hydroxylase and PDI can be used as fibroblast markers (Hirohata et al, 2001). 
 
Vascular cell adhesion molecule-1 (VCAM-1/CD106) is 100-105 kDa member of the 
immunoglobulin family. VCAM-1 is expressed by the endothelium in response to 
inflammatory stimuli such as cytokines. It is involved in leukocyte trafficking via the α4β1 
integrin and retention of said leukocytes at sites of inflammation. VCAM-1 also plays 
  
165 
 
important roles in embryogenesis, angiogenesis, B cell development, and B cell and T cell 
activation (Carter et al, 2002, Reparon-Schuijt et al, 2001). In RA, VCAM-1 is expressed by 
fibroblast-like synoviocytes in the lining layer, chondrocytes and endothelial cells (Carter et 
al, 2002). Tak et al, (1995) also reported the expression of VCAM-1 in lymphocyte 
aggregates and diffuse leukocyte infiltrates in RA patients of <1 year disease duration. 
Sublining fibroblasts do not express VCAM-1. Therefore, VCAM-1 is often used as a marker 
to distinguish between fibroblasts of the synovial lining and sublining.  
 
Other markers used for fibroblast identification within the rheumatoid synovium, although not 
used in this chapter, include CD55, cadherin-11, Fibroblast activation protein (FAP), CD248 
and podoplanin (gp38) (Table 5.1) (Filer, 2013).  Cadherin-11; a molecule involved in cell-
cell adhesion, and development and organisation of the synovium (Lee et al, 2007) CD55; a 
negative regulator of the complement system (Hoek et al, 2010), and FAP; a potential 
promoter of extracellular matrix degradation reported to co-localise with MMP-1 and MMP-
13, are all expressed within the synovial lining layer (Bauer et al, 2006). CD248 is a type I 
transmembrane glycoprotein expressed by pericytes and sublining fibroblasts. CD248 has 
been reported in RA and PsA synovium but not in healthy synovium (Maia et al, 2010). In 
RA, podoplanin (gp38) has been observed early in disease as well as in established destructive 
disease. It is expressed by both lining and sublining fibroblasts within the rheumatoid 
synovium (Del Rey et al, 2014, Ekwall et al, 2011).  
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5.2 RESULTS 
 
CXCL4L1 differs from CXCL4 in a three amino acid substitution in the C-terminus. I was 
therefore concerned that the antibody used for the CXCL4 study may also bind to CXCL4L1. 
Therefore to address these concerns I set out to analyse protein expression of CXCL4L1 in the 
synovial tissue of patients with RA. An antibody specific for CXCL4L1 was titrated for 
immunofluorescence by staining synovial tissue section cut from biopsies taken from patients 
with RA that had undergone joint replacement. My initial observations identified CXCL4L1 
predominantly within the lining layer of the RA synovium (Figure 5.1).  
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Figure 5.1 CXCL4L1 staining of the rheumatoid synovium (H03.12). Sections of 
rheumatoid synovium taken from patients who had undergone joint replacement was stained 
with an antibody specific for CXCL4L1 (blue). Nuclei were counterstained with Hoechst 
33258 (grey). Image A depicts an 8 x 8 (0.7 zoom) overview tile scan taken using the Zeiss 
LSM 780 Zen confocal. Image B represents a selected region from the overview tile scan. 
Images were taken at x400 total magnification. Tissue sections were stained alongside an 
isotype matched control. The isotype matched controls were negative. Scale bar: A 200µm 
and B: 50µm. 
 
Next, I double stained synovial tissue with antibodies specific for CXCL4 and CXCL4L1 to 
test whether there was an overlap in the staining pattern indicating possible cross-reactivity 
(Figure 5.2). Expression of both CXCL4 and CXCL4L1 was observed in the RA synovial 
tissue. CXCL4 and CXCL4L1 co-localisation was extremely limited. Positive staining for 
CXCL4 and CXCL4L1 was largely segregated within the synovial tissue. Likewise, in the 
A 
Negative B 
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tonsil tissue, that I had available, CXCL4L1 and CXCL4 did not co-localise (data not shown). 
Therefore cross-reactivity between the two antibodies was deemed unlikely. 
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Figure 5.2 CXCL4L1 and CXCL4 staining of the rheumatoid synovium (H03.11). 
Sections of rheumatoid synovium taken from patients who had undergone joint replacement 
were stained with antibodies specific for CXCL4L1 (blue) and CXCL4 (red). Nuclei were 
counterstained with Hoechst 33258 (grey). Images were taken at x400 total magnification 
using the Zeiss LSM 780 Zen confocal. Tissue sections were stained alongside isotype 
matched controls which were negative (n=5). Scale bar: 50µm. 
 
Nuclei CXCL4L1 
CXCL4 Merge 
Negative 
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Next, I sought to determine whether or not CXCL4L1 was evident within the lining layer or 
the sublining of the RA synovium. For this purpose I stained RA synovial sections with 
antibodies specific for VCAM-1 and CD90. VCAM-1 and CD90 aid in distinguishing the 
lining layer of the synovium from the sublining layer, respectively. RA synovial tissue 
sections were stained with antibodies specific for CXCL4L1 alongside VCAM-1 and CD68 or 
CXCL4L1 and CD90. No co-localisation of CXCL4L1 with CD68 was observed. CXCL4L1 
was evident in the lining layer of the synovium, as defined by the presence of VCAM-
1(Figure 5.3 and Figure 5.4). CXCL4L1 and CD90 staining was largely distinct.  However, 
co-localisation of CXCL4L1 and CD90 was evident in the areas where the sublining was 
adjacent to the lining layer (Figure 5.5 and Figure 5.6).  
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Figure 5.3 CXCL4L1, VCAM-1 and CD68 overview scan of the rheumatoid synovium 
(H03.12). Sections of rheumatoid synovium taken from patients who had undergone joint 
replacement were stained with antibodies specific for CXCL4L1 (blue), VCAM-1 (green), 
and CD68 (red). Nuclei were counterstained with Hoechst 33258 (grey). An 8 x 8 (0.7 zoom) 
overview tile scan was taken using the Zeiss LSM 780 Zen confocal. An area of interest was 
selected from the overview scan as depicted by the white box. This area was then scanned. It 
is shown in Figure 1.3. Scale bar: 200µm. 
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Figure 5.4 CXCL4L1, VCAM-1, and CD68 staining of the rheumatoid synovium 
(H03.12). Sections of rheumatoid synovium taken from patients who had undergone joint 
replacement were stained with antibodies specific for CXCL4L1 (blue), VCAM-1 (green), 
and CD68 (red). Nuclei were counterstained with Hoechst 33258 (grey). Images were taken at 
x400 total magnification using the Zeiss LSM 780 Zen confocal. Tissue sections were stained 
alongside isotype matched controls which were negative (n=5). Scale bar: 50µm. 
Nuclei CXCL4L1 
VCAM-1 CD68 
Merge Negative 
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Figure 5.5 CXCL4L1 and CD90 overview scan of the rheumatoid synovium (H03.12). 
Sections of rheumatoid synovium taken from patients who had undergone joint replacement 
were stained with antibodies specific for CXCL4L1 (blue) and CD90 (red). Nuclei were 
counterstained with Hoechst 33258 (grey). An 8 x 8 (0.7 zoom) overview tile scan was taken 
using the Zeiss LSM 780 Zen confocal. An area of interest was selected from the overview 
scan as depicted by the white box. This area was then scanned. It is shown in Figure 1.5. 
Scale bar: 200µm. 
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Figure 5.6 CXCL4L1 and CD90 staining of the rheumatoid synovium (H03.12). Sections 
of rheumatoid synovium taken from patients who had undergone joint replacement were 
stained with antibodies specific for CXCL4L1 (blue) and CD90 (red). Nuclei were 
counterstained with Hoechst 33258 (grey). Images were taken at x400 total magnification 
using the Zeiss LSM 780 Zen confocal. Tissue sections were stained alongside isotype 
matched controls which were negative (n=5). Scale bar: 50µm. 
 
 
Nuclei CXCL4L1 
CD90 Merge 
Negative 
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As my results indicated that CXCL4L1 was largely expressed within the lining layer, but not 
associated with CD68+ macrophages, I decided to stain RA sections with a fibroblast marker. 
RA sections were stained with antibodies specific for CXCL4L1 and protein disulphide 
isomerase (PDI). Co-localisation of CXCL4L1 with PDI was observed within the tissue, 
however not all CXCL4L1 positive cells stained for PDI and vice versa (Figure 5.7).  
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Figure 5.7 CXCL4L1 and protein disulphide isomerase (PDI) staining of the rheumatoid 
synovium (H07.6). Sections of rheumatoid synovium taken from patients who had undergone 
joint replacement were stained with antibodies specific for CXCL4L1 (blue) and PDI (red). 
Nuclei were counterstained with Hoechst 33258 (grey). Images were taken at x400 total 
magnification using the Zeiss LSM 780 Zen confocal. Tissue sections were stained alongside 
isotype matched controls which were negative (n=4). Scale bar: 50µm. 
 
Nuclei 
Merge 
CXCL4L1 
PDI 
Negative 
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To follow up on these data and to formally establish expression of CXCL4L1 by synovial 
fibroblasts, I stained in vitro cultured synovial fibroblasts. Chamber slide cultures were 
prepared from in vitro cultured synovial fibroblasts from 5 different patient groups; mainly 
from patients with osteoarthritis (Figure 5.8) and late stage RA from tissue extracted from 
joint replacement surgery. As a pilot experiment I also used a small number of samples from 
treatment naïve patients from the Birmingham Early Arthritis Cohort (BEACON). These were 
grouped into patients with early RA <12 weeks symptom duration, patients with established 
RA (>12 weeks, <3 years symptom duration) and patients with resolving disease. Fibroblasts 
were stained with antibodies specific for CXCL4L1 and PDI (Figure 5.8). The majority of 
cultured fibroblasts from all 5 patient groups expressed CXCL4L1 and PDI. The detection of 
PDI expression in the cultured cells clearly identified the cells as fibroblasts. CXCL4L1 and 
PDI protein expression was quantified using the Zen 2010 software (Figure 5.9). In order to 
do this, 5-7 x400 total magnification images were obtained from each chamber slide. Regions 
were drawn around individual fibroblasts using the overlay function within the Zen 2010 
software. Individual pixel counts were then obtained from the selected regions and exported 
to Microsoft Excel. Here, a mean of the pixel count per µm2 area was calculated. Overall 
these data suggest that in vitro cultured synovial fibroblasts homogeneously express 
CXCL4L1. As these cells are likely to be a mixture of fibroblasts derived from lining and 
sublining, the data would suggest that the restriction of CXCL4L1 expression to the lining 
layer in the intact tissue is lost in culture. There was no clear difference in CXCL4L1 in 
cultured fibroblasts derived from patients with OA or RA or any of the groups of the 
BEACON cohort.  
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Figure 5.8 CXCL4L1 and protein disulphide isomerase (PDI) staining of in vitro 
cultured fibroblasts (ST01SY). A chamber slide of in vitro cultured fibroblasts taken from a 
patient with osteoarthritis was stained with antibodies specific for CXCL4L1 (blue) and PDI 
(red). Nuclei were counterstained with Hoechst 33258 (grey). Images were taken at x400 total 
magnification using the Zeiss LSM 780 Zen confocal. Tissue sections were stained alongside 
isotype matched controls which were negative. Scale bar: 50µm. 
Nuclei CXCL4L1 
PDI 
Negative 
Merge 
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Figure 5.9 Quantification of CXCL4L1 and protein disulphide isomerase expression in 
in vitro cultured fibroblasts. A) CXCL4L1 and B) PDI expression was calculated using the 
Zen 2010 software. Individual fibroblasts were drawn around using the overlay function in the 
Zen 2010 software. Pixel counts were exported and transferred to Microsoft Excel. A formula 
was applied to calculate the number of pixels per µm2 area. Co-localisation of C) CXCL4L1 
and PDI was calculated by applying a formula within the Zen 2010 software that calculated 
the number of pixels in the CXCL4L1 channel overlaid by the number of pixels in the PDI 
channel. Fibroblasts were cultured from osteoarthritis (OA) and long standing RA (J rep Est 
RA) patients who had undergone joint replacement. Moreover fibroblasts were cultured from 
synovial biopsies taken from patients enrolled in the BEACON cohort; early resolving 
synovitis (Early Res), early RA (<12 weeks symptom duration) and established RA (Est RA) 
(>12 weeks, <3 years symptom duration).   
 
A B 
C 
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Finally, I studied the expression of CXCL4L1 at the mRNA level in fibroblasts taken from 
patients with joint replacement RA (n=5) and fibroblasts taken from individuals that had 
undergone synovial biopsy due to unexplained joint pain with no obvious signs of 
inflammation (n=5). The latter were used as controls. Fibroblasts were treated with or without 
TNFα for 72 hours. CXCL4L1 mRNA was expressed by untreated control fibroblasts and 
joint replacement RA fibroblasts (Figure 5.10). CXCL4L1 mRNA expression was 
significantly increased in both control fibroblasts and joint replacement RA fibroblasts 
following treatment with TNFα (Wilcoxon matched pairs signed rank test ***p≤0.001). No 
significant difference in CXCL4L1 mRNA expression was observed between TNFα treated 
control fibroblasts and TNFα treated joint replacement RA fibroblasts (Mann Whitney, non-
significant p=0.4194). Moreover these was no significant difference in fold-induction of 
CXCL4L1 observed between the joint replacement RA fibroblasts and the control fibroblasts 
(Mann Whitney, p=0.222).  
 
I would therefore conclude from this set of experiments that TNFα is a strong inducer of 
CXCL4L1 expression. This response is independent of whether the fibroblasts were derived 
from patients with or without inflammatory joint conditions.  
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Figure 5.10 mRNA expression of CXCL4L1 in in vitro cultured control and RA 
fibroblasts treated with or without TNFα. A) 5 fibroblast cell lines from healthy controls 
(denoted by BX) and 5 fibroblast cell lines from patients with RA (joint replacement- 
established RA) (denoted by RA) were treated with or without 10 ng/ml TNFα for 72 hours. 
Relative quantification (RQ) of mRNA expression for CXCL4L1 was determined by 
normalisation to the housekeeping gene beta actin. In B) results shown in A) were grouped 
into healthy control fibroblasts treated with or without TNFα and RA fibroblasts (joint 
replacement-established RA) treated with or without TNFα. cDNA for this experiment was a 
kind gift from Miss Dominika Nanus. Significance was calculated in B) using a Wilcoxon 
matched pairs signed rank test (*** p ≤0.001). Error bars represent the IQR. 
 
*** 
*** 
B 
A 
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5.3 DISCUSSION 
 
In this chapter, I have identified the expression of CXCL4L1 at the protein level within 
synovial biopsies taken from patients with RA, and as far as I am aware this is the first study 
to do so. Although I have little information regarding the function of CXCL4L1 in RA, I can 
hypothesise based on pre-existing literature that it may play an important role in the 
regulation of both angiogenesis and lymphangiogenesis.  
 
As mentioned previously, angiogenesis plays a pivotal role in the pathogenesis of RA. 
Angiogenesis within the rheumatoid synovium can exacerbate synovitis by promoting the 
ingress of leukocytes into the tissue and by driving pannus growth. The number of blood 
vessels within the rheumatoid synovium has been shown to correlate with the number of 
infiltrating leukocytes, synovial hyperplasia and joint tenderness. As a result, angiogenesis 
has been considered to be an early event that drives RA progression. Within the rheumatoid 
synovium, fibroblasts, lymphocytes, macrophages and mast cells have been shown to produce 
angiogenic factors, thus driving angiogenesis. Most notably are the synovial fibroblasts that 
have been shown to upregulate their expression of VEGF and FGF-1 in response to the 
cytokine milieu during inflammation. The formation of new blood vessels can also deliver 
nutrients and oxygen to the growing synovium. The synovial joint is highly hypoxic and as a 
result, overexpression of the transcription factors hypoxia inducible factors- 1 (HIF-1) and -2 
(HIF-2) have been reported in the rheumatoid synovium. HIFs are known to upregulate VEGF 
release, as well as CXC chemokines, MMPs, and TNFα converting enzyme (TACE). VEGF 
has been reported at increased levels in synovial fluid and synovial tissue. Increased serum 
levels have been shown to correlate with CRP, ESR and swollen joint counts as well as being 
  
183 
 
associated with an increase in joint damage as assessed by radiological progression (Sone et 
al, 2001). An RA disease duration of >12 years was also associated with higher VEGF levels 
than controls. However, levels did not correlate with markers of disease activity.  
 
CXCL4L1 is a potent inhibitor of angiogenesis, tumour growth and metastasis. 
Vandercappellen et al (2010) studied the effect of the COOH-terminal peptide of CXCL4L1 
(CXCL4L1/PF-4var47-70) and CXCL4 (CXCL4/PF-447-70) on monocyte and lymphocyte 
chemotactic activity, endothelial cell motility and proliferation, and anti-tumour and 
angiostatic activity. Both peptides were found to lack monocytic THP-1 cell and activated T 
cell chemotactic activity. A 5-fold lower dose of CXCL4L1/PF-4var47-70 was required to 
inhibit endothelial cell motility and proliferation whilst angiogenesis as assessed by tube 
formation in Matrigel assays was also significantly reduced in CXCL4L1/PF-4var47-70 treated 
assays compared to CXCL4/PF-447-70. Furthermore in this study, the effect of CXCL4L1/PF-
4var47-70 and CXCL4/PF-447-70 on B16 melanoma tumour development, growth and apoptosis 
was assessed. Here, nude mice were injected subcutaneously with B16 melanoma cells and 
subsequently treated three times per week with either 1μg CXCL4L1/PF-4var47-70, 1μg 
CXCL4/PF-447-70, or 1μg of control buffer. In mice treated with CXCL4L1/PF-4var47-70, 
tumour growth was reduced when compared to control treated mice. Upon sacrifice, tumours 
dissected from the CXCL4L1/PF-4var47-70 treated mice were significantly smaller in volume 
and weight compared to control treated mice. A lower number of small and medium sized 
tumour blood vessels was also observed compared to controls. Moreover, tumour cell 
apoptosis was also increased in CXCL4L1/PF-4var47-70 treated tumours.  Mice treated with 
CXCL4/PF-447-70 did not show any significant differences in tumour development, final 
tumour volume and weight, and tumour cell apoptosis when compared to controls. Struyf et al 
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(2011) also reported that human adenocarcinoma cell growth was inhibited in the SCID 
mouse model when treated with 0.1 µg of either native CXCL4 or recombinant CXCL4L1 
over an 8 week period. It was also identified that in CXCR3-/- animals, treatment with 
CXCL4L1 was no longer able to reduce tumour growth or size. More recently, Van 
Raemdonck et al (2014) described the angiostatic, tumour inflammatory and anti-tumour 
effects of CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 in a human epidermal growth factor 
(EGF)-dependent breast cancer model. Interestingly, administration of the CXCL4/PF-447-70 
peptide led to a better reduction in tumour growth than when CXCL4L1/PF-4var47-70 was 
given.   
 
Osteosarcoma cells stimulated with IL-1β, TNFα and IL-17A have been reported to express 
CXCL4L1. Positive staining for CXCL4L1 has also been observed in tissue biopsies taken 
from leiomyosarcoma, liposarcoma and colon adenocarcinoma patients. In the study by 
Verbeke et al (2010), CXCL4L1 was identified in the upper crypts of normal colon and in the 
tumour cells, fibroblasts, endothelial cells and inflammatory cells of colon adenocarcinoma.  
Furthermore, in a study by Vandercappellen et al (2007) CXCL4L1 was produced by 
monocytes in vitro in response to various inflammatory stimuli including LPS, IL-1β, Con A, 
PMA and thrombin. However, upon differentiation to macrophages after 5 days of culture, 
CXCL4L1 was not produced following stimulation. Moreover, CXCL4L1 remained 
undetectable in isolated neutrophils. Conversely, CXCL4 was produced by both monocytes 
and macrophages. Following stimulation, the levels of CXCL4 were much lower in 
macrophages than monocytes. Neutrophils also produced CXCL4, but at extremely low levels 
regardless of stimulation.  In this chapter, I did not observe CXCL4L1 expression in CD68+ 
macrophages in the rheumatoid synovium.  
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In this chapter, I identified the expression of CXCL4L1 predominantly within the synovial 
lining of RA patients with established disease. This area was void of any blood vessels. Given 
the tumour-like characteristics of the rheumatoid synovium as it expands and invades nearby 
cartilage, I can speculate that CXCL4L1 attempts to counteract this tumour-like behaviour by 
inhibiting the growth of new blood vessel formation which provide nutrients and oxygen to 
the expanding synovium. Furthermore the expression of an angiostatic chemokine may be 
produced constitutively within the lining layer may act to prevent bleeding into the synovial 
joint space following mechanical pressure and friction, and maintain its barrier function. 
However, due to the abundance of angiogenic mediators in the synovium during disease, these 
may outweigh the angiostatic effects of CXCL4L1 and shift the balance towards angiogenesis 
which drives the exacerbation of disease. Pablos et al (2003) studied the expression of the 
angiogenic chemokine CXCL12 in the synovium of patients with either rheumatoid arthritis 
or osteoarthritis, and healthy controls. CXCL12 staining was observed in all synovial 
biopsies. Within the healthy synovium, CXCL12 expression was observed in a single cell 
layer in the lining. One the other hand, in the rheumatoid synovium, CXCL12 expression was 
observed in the hyperplastic lining. Positive staining was also observed in the perivascular 
areas of the sublining, as well as in blood vessels. Blood vessels in the healthy synovium did 
not express CXCL12. In a study carried out by Verbeke et al (2010), CXCL4L1 was reported 
to counterbalance CXCL12, as well as CXCL8 expression, in oesophageal and colorectal 
cancers. Moreover in this chapter, I identified synovial fibroblasts as a source of CXCL4L1 at 
the mRNA and protein level. In the in vitro cultured cells, I was unable to distinguish cells 
originating from lining layer from sublining derived synovial fibroblasts. The homogenous 
expression of CXCL4L1 in the in vitro cultured cells could either suggest that the lines were 
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only derived from lining layer fibroblasts, or more plausibly, that the restricted expression I 
have observed in the synovium is deregulated in vitro.  
 
Prats et al (2013) studied the role of CXCL4L1 in angiogenesis, metastasis and 
lymphangiogenesis and identified a synergistic role for CXCL4L1 and fibstatin, an 
endogenous anti-angiogenic molecule derived from fibronectin, in the inhibition of tumour 
lymphangiogenesis and metastasis. Fibstatin, endostatin, and CXCL4L1 were able to inhibit 
angiogenesis and invasion of the inguinal draining lymph nodes, but were unable to prevent 
tumour development at the early stages. Additionally, the administration of the 
CXCL4L1/PF-4var47-70 peptide or CXCL4/PF-447-70 peptide was reported to inhibit lymphatic 
endothelial cell proliferation (Van Raemdonck et al, 2014).   
 
In conclusion, I have identified CXCL4L1, a potent angiostatic chemokine and the variant 
form of CXCL4, in the rheumatoid synovium. CXCL4L1 expression within the synovium was 
distinct from CXCL4. CXCL4L1 was identified in the synovial lining as indicated by its 
distinct localisation alongside VCAM-1 and its expression may explain the absence of blood 
vessels in the lining layer. Furthermore in this chapter, I have demonstrated that in vitro 
cultured synovial fibroblasts express CXCL4L1 mRNA and upregulate this expression upon 
stimulation with TNFα. Future work will be important to study the functional role of 
CXCL4L1 in RA and to address its therapeutic potential. 
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6 DISCUSSION 
 
6.1 Early arthritis and outcome prediction 
 
In this thesis, I took advantage of the well-established Birmingham early inflammatory 
arthritis cohort (BEACON) to test whether the chemokines CXCL4 and CXCL7 could be 
potential biomarkers to allow prediction of progression of early synovitis to RA or 
spontaneously resolving disease. This body of work was novel in that CXCL4 and CXCL7 
had not been previously explored in early synovitis and the prediction of outcome in 
synovitis, largely due to the preconception that both CXCL4 and CXCL7 were considered 
mainly platelet derived chemokines and that platelet involvement in RA had been overlooked 
until fairly recently when Boilard et al (2010) studied the role of platelet microparticles in RA 
pathogenesis. Here, I demonstrated an increase in both CXCL4 and CXCL7 at an early stage 
of disease and moreover this expression was lower in patients with a resolving disease course. 
Furthermore, I was able to demonstrate that both chemokines were not limited to the 
megakaryocyte lineage as previously thought, but instead were largely expressed by 
macrophages. 
 
CD68+ macrophages are key drivers of disease pathogenesis in RA (Kennedy et al, 2011, Li et 
al, 2012). Moreover, they have been identified as a biomarker within the synovium for 
monitoring the early response to therapy (Bresnihan et al, 2007, Haringman et al, 2005, 
Wijbrandts et al, 2007). In this thesis, CXCL4 and CXCL7 expression within the synovium 
was found to co-localise and correlate with CD68+ macrophages. Moreover at the mRNA 
level, isolated monocytes cultured under M1, M2 and Mo-DC culture conditions were found 
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to express CXCL4 and CXCL7. It will be interesting in the future to investigate whether these 
particular macrophages derive from circulating monocytes that leave the blood and 
subsequently enter the synovium, or if they are locally dividing cells that can proliferate 
independently of HSCs (Schulz et al, 2012, Hashimoto et al, 2013). Both CXCL4 and CXCL7 
did not correlate with CD41 expression in the synovium, and furthermore co-localisation of 
CXCL4 and CXCL7 with CD41 was largely confined to thrombi within blood vessels. 
Despite the current literature identifying CXCL4 expression and production by pDCs in early 
scleroderma and systemic sclerosis, I rarely observed such co-localisation in our cohort (van 
Bon et al, 2015). 
 
CXCL4 and CXCL7, both of which are located on chromosome 4, have a diverse array of 
functions. CXCL4 plays an important role in pro- and anti-coagulation, inhibition of 
megakaryopoiesis, inhibition of angiogenesis, tumourigenesis and metastasis, and promotion 
of the inflammatory response (Wang and Huang, 2013). CXCL4 can drive differentiation of 
monocytes towards a distinct population of macrophages, deemed the M4 population. 
Moreover CXCL4 can inhibit monocyte apoptosis, enhance phagocytosis, and increase 
production of ROS (Gleissner et al, 2010, Pervushina et al, 2004, Scheuerer et al, 2000). In T 
cells, CXCL4 drives the proliferation of CD4+ CD25+ T cells whilst inhibiting proliferation of 
CD4+ CD25- T cells. Furthermore, CXCL4 can influence intracellular signalling pathways 
within T cells through the downregulation of the Th1 cytokine IFNγ and the upregulation of 
Th2 cytokines IL-4, IL-5 and IL-13 (Fleischer et al, 2002, Kasper and Petersen, 2011, Liu et 
al, 2005). Additionally, CXCL4 has been shown to trigger the release of histamine from 
basophils, and IL-8 from NK cells (Kasper and Petersen, 2011, Petersen et al, 1999). CXCL7 
can drive neutrophil chemoattraction, adhesion and transendothelial cell migration, and 
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activation (Blair and Flaumenhaft, 2009, Schenk et al, 2002). In this thesis, both CXCL4 and 
CXCL7 were expressed within the synovium at the early stage of disease. This expression 
appeared to be transient, as in established disease, the expression of CXCL4 and CXCL7 was 
lower and was comparable to those patients with a resolving disease course. These findings 
have to be taken in context, as these outcome groups were made up of different individuals; 
no investigators as yet possess the tissue resource to examine progression of disease 
longitudinally within a patient cohort. I can conclude that the presence of both chemokines 
may act to exacerbate and drive early inflammation.  
 
CXCL4, an ELR- chemokine, was the first angiostatic chemokine to be identified. CXCL4 
can inhibit endothelial cell proliferation and migration through interaction with FGF-2 and 
VEGF. In this thesis, I identified CXCL4L1, a potent inhibitor of angiogenesis, in the 
rheumatoid synovial lining layer. The structure of CXCL4L1 differs from CXCL4 in three 
amino acids within the C-terminus (Green et al, 1989). Conversely, CXCL7, an ELR+ 
chemokine, is angiogenic. I may speculate that within the synovium, increased CXCL4 and 
CXCL4L1 production may act to counterbalance the angiogenic effects of CXCL7. 
Furthermore, as CXCL4L1 was largely found in the synovial lining, it may explain the lack of 
blood vessels observed in this region. 
 
The diagnosis of RA regularly involves assessment of patient history, examination of the 
affected joints, routine laboratory tests such as the measurement of RF and ACPA, and the 
analysis of synovial fluid through joint aspiration. The requirement for routine synovial 
biopsy collection by blind needle biopsy, arthroscopy or ultrasound guided biopsy, which are 
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generally safe and well-tolerated procedures, are often not considered a high priority (Gerlag 
and Tak, 2005, Kane et al, 2002, Vordenbäumen et al, 2009). A significant number of 
synovial biopsies are collected within clinical practice by orthopaedic surgeons when 
infection is suspected. When infection is suspected, for example by Neisseria gonorrhoeae or 
Mycobacterium tuberculosis, a synovial biopsy can aid in the differential diagnosis. Often 
aspirated synovial fluid and peripheral blood samples will give rise to a negative culture, 
whereas the tissue itself may stain positive by stains such as Gram and Ziehl Neelsen. 
Alternatively, staining of the biopsy may reveal crystal deposition within the synovium thus 
leading to a diagnosis of gout or pseudogout. The presence of malignant cells within the 
synovium can also be identified and can indicate primary tumour or metastasis (Gerlag and 
Tak, 2005, Vordenbäumen et al, 2009).  
 
In patients who fulfil the 1987 ARA/ACR criteria for RA, synovial biopsies may not be 
required. However, the prediction of disease outcome is growing increasingly important in 
patients presenting with early synovitis or undifferentiated arthritis. The term undifferentiated 
arthritis is given to those patients whose symptoms do not fulfil specific criteria. Not only is it 
important to identify patients who are likely to develop RA and therefore target therapies 
accordingly and at the earliest possible stage to reduce eventual progression to joint 
destruction, it is also important to identify those whose arthritis is likely to resolve as this 
occurs in 30-50% of patients, therefore eliminating the need for treatment with DMARDs 
which may result in more harm than good (Van de Helm-van Mil et al 2007). Therefore, as a 
result, the collection of synovial biopsies may be beneficial in these patients.  
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A large number of early arthritis cohorts have been established worldwide with the aim of 
capturing patients within the first stages of disease onset. Cohorts include the Leiden Early 
Arthritis cohort established in The Netherlands, the French ESPOIR cohort study, and the 
Canadian early arthritis cohort (CATCH). Although it is generally accepted that there is a 
‘window of opportunity’ for the treatment of disease, there is still often a delay between 
patients visiting their general practitioner, being referred to a rheumatologist, and 
subsequently being enrolled into a cohort. Therefore the time course of what is referred to as 
‘early arthritis’ can often differ between the different cohorts. An advantage of enrolling 
patients into early arthritis cohorts is that a large number of samples can be taken and stored 
for further analysis including serum, plasma, urine and whole blood for DNA analysis. These 
samples enable us to develop strategies to predict disease outcome and identify prognostic 
markers in RA. Van de Helm-van Mil et al (2007) utilised the Leiden early arthritis cohort, 
which has enrolled over a thousand patients since 1993, to develop a prediction rule for 
disease outcome in patients with undifferentiated arthritis. In this study a number of clinical 
variables including age, sex, CRP, anti-CCP status, tender joint count and swollen joint count 
were able to predict the development of RA in patients presenting with undifferentiated 
arthritis. The results presented in this thesis have the potential to become useful additions to 
this prediction rule, particularly if combined with other novel discriminating tissue variables. 
However, it may be difficult to implement immunofluorescence staining of synovial biopsies 
for CXCL4 and CXCL7 in clinical practice. Detection of CXCL4 and CXCL7 in the plasma 
would be more acceptable in clinical practice. Unfortunately, the differences identified 
between the patient groups at the biopsy level were not reflected in plasma.  
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In order to eliminate sampling error and experimental bias during the quantification of 
immunofluorescence, it is recommended that at least six synovial biopsies are taken from 
each joint to be assessed. In this thesis, sections were comprised of multiple biopsies taken 
from a single joint during ultrasound guided biopsy (Bresnihan et al, 2005, Gerlag and Tak, 
2005). The site of biopsy did not result in significant differences in CXCL4 and CXCL7 
expression. To quantify CXCL4 and CXCL7 within the joint, I selected areas of tissue at 
random in order to eliminate any experimental bias. Moreover, I selected these areas with the 
CXCL4 and CXCL7 channel turned off. Therefore I was not influenced by positive staining 
for CXCL4 and CXCL7 within the synovium.  
 
6.2 Cardiovascular disease and rheumatoid arthritis 
 
Rheumatoid arthritis patients generally have a decreased life expectancy ranging from 3 to 18 
years when compared to the general population (Van Doornum, 2002). The disease, itself, not 
only affects joints, but can also affect multiple organ systems leading to extra-articular disease 
manifestations. Frequent complications arising in patients with RA include the development 
of rheumatoid nodules which are observed in 15-20% of patients, cardiovascular disease 
including atherosclerosis, pericarditis and myocarditis, respiratory disease such as pulmonary 
hypertension, pneumonia and bronchitis, and renal disease. Approximately 40% of patients 
with RA may also suffer from mental illness such as depression. Whilst in attendance at a 
conference, a question was raised regarding whether or not both CXCL4 and CXCL7 could be 
predictors of adverse cardiovascular events rather than being predictors of early disease 
outcome as both chemokines are released in huge abundance following the activation of 
platelets.  
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Cardiovascular disease is the leading cause of death in RA patients whereby it is accountable 
for 35-50% of excess mortality (Satter et al, 2003). However, although a number of risk 
factors associated with the development of cardiovascular disease are shared between patients 
with RA and the general population, such as smoking, hypertension and obesity, patients with 
RA develop cardiovascular disease almost a decade earlier. Therefore the disease, itself, 
driven by chronic inflammation or its treatment may be attributed to this earlier onset. In a 
retrospective study of an inception cohort of RA patients in Rochester, MN, patients were 
found to have a significantly increased cardiovascular disease mortality rate compared to age 
and sex matched controls. Treatment of patients with glucocorticoids was also reported to 
drive premature atherosclerosis and increase cardiovascular mortality risk.  
 
Both CXCL4 and CXCL7, as well as platelets, have been identified in atherosclerotic lesions 
(Pitsilos et al, 2003). CXCL4 was evident in human atherosclerotic carotid arteries and was 
reported to positively correlate with increasing lesion grade and clinical severity of disease. 
CXCL4 was observed in macrophages of early fatty streak atherosclerotic lesions and in foam 
cells in more advanced lesions, whereas CXCL7 was evident in advanced lesions, only. 
CXCL4 was also identified in calcified regions surrounding macrophages and in the 
neovasculature of the atherosclerotic lesion. Moreover CXCL4 has been reported to colocalise 
with oxidized LDL in foam cells (Nassar et al, 2002). Pitsilos et al (2003) identified that both 
CXCL4 and CXCL7 were not derived from newly incorporated platelets into the lesion, but 
instead from platelet secretion and retention of these chemokines in the lesions. It was 
suggested that CXCL4 may be internalised by endothelial cells and subsequently released into 
the surrounding plaque upon apoptosis or that CXCL4 may bind to the surface of monocytes 
and migrate into the vessel wall. 
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Little is known about the role of CXCL7 in atherosclerosis, however CXCL4 has been studied 
extensively and has been reported to exacerbate disease and drive its progression.  CXCL4-/- 
mice have reduced atherosclerosis and furthermore deletion of CXCL4 in ApoE-/- mice led to 
a reduction in the number of atherosclerotic lesions, thus suggesting that elimination of 
CXCL4 is atheroprotective (Sachais et al, 2007). CXCL4 is capable of forming heterodimers 
with CCL5/RANTES and as a result can trigger monocyte arrest on the endothelium. 
Although CXCL4 alone cannot affect monocyte arrest on endothelial cells, in cooperation 
with CCL5 the result is greater than the effect of CCL5 alone (Gleissner and Ley, 2007). 
CXCL4 can prevent apoptosis of monocytes and promote differentiation to macrophages that 
lack surface expression for HLA-DR. CXCL4 differentiated macrophages also fail to 
upregulate the atheroprotective enzyme heme oxygenase-1 at the RNA and protein level thus 
drive atherosclerosis (Gleissner et al, 2010).  CXCL4 can trigger phagocytosis and generation 
of ROS and may therefore trigger the uptake of oxidized LDL by macrophages thus driving 
foam cell formation. Esterification of oxidized LDL by macrophages is increased by CXCL4. 
Furthermore, CXCL4 has been shown to interfere with the binding, internalisation and 
degradation of LDL by the LDL-receptor, thus increasing the opportunity for oxidization to 
take place. CXCL4 can bind oxidized LDL and increase its binding to vascular cells and 
macrophages (Nassar et al, 2002).  
 
In this thesis, I quantified CXCL4 and CXCL7 within the plasma taken from patients enrolled 
in the BEACON cohort and healthy controls. I also quantified sGPVI as a marker of platelet 
activation in the plasma of these individuals. The high levels of CXCL4 and CXCL7 that I 
observed in my study may be indicative of over-active platelets in these patients. This was 
also indicated by the high concentrations of sGPVI observed. Although I was unable to use 
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the results to distinguish between those patients who developed early RA from those who had 
a resolving disease course, it is possible that the levels of CXCL4 and CXCL7 may be used to 
predict future cardiovascular events in this cohort. Tracing of morbidity and mortality in the 
BEACON cohort is routine, but to answer these questions will require significant time for 
follow-up in order to provide a meaningful analysis. It would be interesting to analyse the 
changes in the expression of CXCL4 and CXCL7 over time to determine whether or not they 
are predictors of adverse outcome in RA.  
 
6.3 FUTURE WORK 
 
Following on from my findings that both CXCL4 and CXCL7 are elevated in synovial 
biopsies at an early stage of disease, it would be important to validate these findings in an 
independent cohort. Moreover, a longitudinal study to monitor the expression of both 
chemokines throughout the disease would be an interesting area to explore, as well as their 
potential to predict adverse cardiovascular events in RA. However, as I used patients who 
were DMARD and glucocorticoid naïve at the time of biopsy, it would be somewhat unethical 
to deny treatment to patients over a longer period of time. Another interesting area to explore 
would be to evaluate CXCL4 and CXCL7 as predictive markers of therapeutic outcome. 
Studies have suggested thus far that increased CXCL4 expression in the serum can predict a 
poor response to infliximab, which is a monoclonal antibody used during the treatment of 
autoimmune diseases which is directed against TNFα. However as of yet, the usefulness of 
CXCL7 in predicting response to therapy has not been carried out. Moreover, another 
interesting avenue to explore would be the levels of CXCL7 in the serum of psoriatic patients. 
Although only described briefly in this thesis, I did observe an increase in serum CXCL7 in 
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psoriatic arthritis patients compared to controls and RA patients. Therefore I could study this 
further in a much larger psoriatic arthritis cohort in order to address the main questions; does 
an increase in CXCL7 correlate with the severity of psoriatic arthritis and the skin lesions 
observed, can we use the expression of CXCL7 to predict arthritis in those patients presenting 
with psoriasis, and vice versa? Previously, an increase in CXCL4 has been shown to correlate 
with systemic sclerosis which like psoriatic arthritis is also characterised by skin lesions. As 
CXCL7 exists in a number of different isoforms, it may also be interesting to determine the 
exact isoform expressed within the synovium. 
 
In order to study the functional role of both CXCL4 and CXCL7 in RA, I could utilise 
knockout mice crossed with a model for arthritis. I could also use these mice to study the 
therapeutic potential of targeting CXCL4 and CXCL7 in different models of RA. Within the 
University of Birmingham I have access to PF4-cre mice crossed with Rosa26-Stop-EYFP. In 
this model, any cells that express the PF4 transcript will be reported. A study is in place to 
induce arthritis in these mice and monitor the % EYFP cells in different leukocyte subsets at 
the peak of inflammation. Moreover, induction of systemic inflammation via injection of LPS 
and monitoring any alteration in the % of EYFP+ cells in the different leukocyte populations 
will be studied. This study will be carried out by Dr Guillaume Desanti, a post-doctoral 
researcher based at The University of Birmingham.  A group at Kings College London 
managed by Professor Bruce Hendry and colleagues have developed CXCL7/PPBP knockout 
mice for the study of renal injury, however publications describing this model are lacking. If I 
decide to study the effect of knocking out PPBP on arthritis development, then I would need 
to enquire on the possibility of housing some of these mice in Birmingham.  Unfortunately I 
would not be able to study CXCL4L1 in the same way. The gene for CXCL4L1 is expressed 
  
197 
 
in humans and primates, only. There is no mouse equivalent of the gene and animal work 
carried out at the university is limited to studies on mice, rats and rabbits. One potential way 
in which I could explore the role of CXCL4L1 would be to perform knockdown experiments 
of the CXCL4L1 gene using small interfering RNA (SiRNA). This would enable functional 
assays to be carried out to further explore the role of CXCL4L1 in angiogenesis and 
lymphangiogenesis. I may also have the potential to collaborate with Dr Helen McGetterick at 
The University of Birmingham to study the role of CXCL4L1 in angiogenesis. Here I could 
explore the effect on CXCL4L1 expression when fibroblasts are co-cultured with blood 
endothelial cells. Another interesting area to explore would be to stain tissue sections from 
different disease groups to study the pattern of CXCL4L1 expression. 
 
With regards to the validation of the In Situ Hybridization method, described in chapter 4, for 
the detection of single CXCL7/PPBP RNA molecules, I did try multiple troubleshooting 
techniques in order to validate the method. However, for CXCL7, the results so far were not 
entirely convincing. As a result, any future plans would involve stripping the protocol back to 
the beginning and attempting the optimisation for the heat pre-treatment and protease 
digestions steps again. Moreover, as I was not entirely convinced by the GAPDH expression 
across the tissue sections, largely due to its absence across large areas of tissue, I may 
therefore opt to combine multiple house-keeping genes to prepare a more robust positive 
control. Moreover in chapter 4, I studied the expression of CXCL4 and CXCL7 mRNA in 
CD14+ monocytes, and in vitro differentiated macrophages under M1, M2 and Mo-DC culture 
conditions. A further area to explore would be the different monocyte subsets, sub-grouped 
based on their CD16 expression and their regulation of CXCL4 and CXCL7. 
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Figure 8.1 Validation of the CXCL7 antibody for immunofluorescence. CXCL7 antibody 
was incubated overnight with increasing concentrations of CXCL7 peptide. The CXCL7-
peptide complex was used to stain a section of rheumatoid synovium taken from a patient 
undergoing joint replacement. The CXCL7 chemokine was successfully inhibited when 
incubated with the CXCL7 peptide. Nuclei were counterstained with Hoechst 33258 (blue). 
Images were taken at x400 total magnification using the Zeiss LSM 510-UV confocal. 
 
 
 
 
 
 
  
Section without CXCL7 peptide 0.5µg/ml CXCL7 peptide 1µg/ml CXCL7 peptide 
2µg/ml CXCL7 peptide 4µg/ml CXCL7 peptide Negative control 
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Biopsy code Age Sex Joint Disease 
duration 
(weeks) 
Diagnosis RF CCP 
H03.8 70 F Knee 1820 RA P NA 
H03.10 78 M Hip 1040 RA NA NA 
H03.11 57 M Knee 936 RA NA NA 
H03.12 69 F Knee 2288 RA N  N  
H04.5 72 F Hip 1040 RA NA NA 
H04.10 77 M Knee 1144 RA P NA 
H04.12 48 F Knee 780 RA N N 
H04.17 57 F Knee 260 RA NA NA 
H04.18 61 F Hip 832 RA N N 
H07.2 74 F Elbow 1040 RA N N 
H07.6 NA NA NA NA RA NA NA 
H13.03 71 M Elbow 780 RA P P 
H13.12 68 M MCP 21 RA p P 
 
Table 8.1 Patient clinical information collected from those with longstanding disease who had undergone joint replacement 
surgery. Synovial biopsies were used widely throughout chapter 3 and chapter 5. Abbreviations used throughout the tables; CCP, Cyclic 
Citrullinated Peptide; RF, Rheumatoid Factor; N, Negative; P, Positive; and NA, Not Available.  
 
 
  
  
234 
 
Outcome Age Sex Biopsied 
joint 
Symptom
duration 
(weeks) 
CCP RF ESR CRP Global SWJ28 TJC28 DAS28 baseline 
Early RA 50 M Knee 4 P P 31 26 28 11 13 5.70 
Early RA 70 F Knee 5 N N 68 26 96 5 4 6.04 
Early RA 48 F Knee 2 N N 4 102 16 6 8 3.46 
Early RA 59 M Knee 6 N N 14 22 54 20 4 4.98 
Early RA 74 F Knee 9 P N 20 32 62 3 3 4.42 
Early RA 51 M Knee 8 P P 61 97 75 NA NA 6.67 
Early RA 63 M Knee 8 N N 2 0 70 NA NA 2.31 
Early RA 60 F Ankle 11 P P 32 45 46 NA NA 4.32 
Early RA 44 F Ankle 5 N N 18 10 32 2 3 3.84 
Early RA 56 M MCP 10 N P 5 0 50 21 14 5.21 
Established RA 46 M Knee 150 P P 34 7 75 16 13 6.66 
Established RA 69 F Knee 52 N N 11 0 52 7 7 4.63 
Established RA 57 M Knee 14 P P 56 16 50 14 21 7.13 
Established RA 58 M Knee 16 P P 7 0 33 7 7 4.05 
Established RA 63 F Knee 26 P P 35 0 60 NA NA 5.19 
Established RA 72 M Knee 38 N N 53 43 70 16 21 7.45 
Established RA 65 F Knee 156 P P 72 81 28 12 3 5.33 
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Outcome Age Sex Biopsied 
joint 
Symptom
duration 
(weeks) 
CCP RF ESR CRP Global SWJ28 TJC28 DAS28 baseline 
Established RA 22 F Knee 52 N N 81 79 89 6 6 6.38 
Established RA 62 F Ankle 16 P P 40 5 16 2 4 4.32 
Established RA 65 M Ankle 53 N N 50 10 29 NA NA 4.95 
Established RA 60 F Ankle 45 N P 70 112 6 NA NA 5.20 
Early Resolving 32 M Knee 7 N N 10 10 35 1 1 2.94 
Early Resolving 33 M Knee 4 N N 51 14 83 9 12 6.69 
Early Resolving 74 M Knee 5 N N 45 13 55 23 0 4.78 
Early Resolving 37 F Knee 7 N N 7 0 NA 2 8 3.34 
Early Resolving 28 M Knee 6 N N 18 8 99 1 2 4.48 
Early Resolving 45 F Knee 1 N N 4 0 83 5 5 4.01 
Early Resolving 35 M Knee 2 N N 51 7 33 1 1 4.05 
Early Resolving 81 F Ankle 7 N N 60 52 50 11 16 6.73 
Early Resolving 55 M Ankle 6 N N 2 6 91 5 4 3.51 
Early non-RA 69 M Knee 7 N N 44 38 85 NA NA 5.58 
Early non-RA 41 M Knee 2 N N 50 25 50 4 2 4.79 
Early non-RA 43 F Knee 2 P N 97 70 86 10 11 7.15 
Early non-RA 39 F Ankle 8 N N 27 15 83 NA NA 4.72 
Early non-RA   34 M Ankle 9 N N 21 22 40 NA NA 3.53 
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Outcome Age Sex Biopsied 
joint 
CCP RF 
Normal 49 F Knee N N 
Normal 42 M Knee N N 
Normal 38 F Knee N N 
Normal 16 M Knee N N 
Normal 41 F Knee N N 
Normal 41 F Knee N N 
Normal 42 M Knee N N 
Normal 23 M Knee N N 
Normal 44 M Knee N N 
 
 
Table 8.2 Patient clinical information from those used during the study of the expression of CXCL4 and CXCL7 in tissue biopsies. 
*Abbreviations used throughout the tables; CCP, Cyclic Citrullinated Peptide; RF, Rheumatoid Factor; ESR, Erythrocyte Sedimentation 
Rate; CRP, C-Reactive Protein; Global, Global Arthritis Score; SWJ28, Swollen Joint Count of 28 joints; TJC28, Tender Joint Count of 28 
joints; DAS28 baseline, Disease Activity Score of 28 joints baseline; N, Negative; P, Positive; F, Female; M, Male; and NA, Not 
Available.  
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Diagnosis Symptom 
duration 
(weeks) 
CCP RF ESR CRP Global TJC 28 SJC 28 
RA 257.1 1 48.4 18 0 10 5 6 
RA 628.4 19 334 5 0 86 22 3 
RA 12.0 >340 71.1 30 0 34 3 2 
RA 42.0 1.1 0 5 8 68 8 5 
RA 57.3 1 0 NA 0 25 3 1 
RA 10.1 1 0 NA 48 59 4 1 
RA 35.1 27 39 41 8 17 8 1 
RA 7.9 0.8 29.8 8 10 82 8 5 
RA 30.7 >340 115 34 6 49 0 0 
RA 4.1 0.6 0 30 56 91 12 10 
RA 53.1 158 127 30 5 37 4 2 
RA 207.6 4.6 0 30 24 64 5 1 
Unclassified inflammatory arthritis NA 1 0 27 34 49 5 4 
Unclassified inflammatory arthritis 17.4 0.9 11.5 38 0 75 5 11 
Unclassified inflammatory arthritis 104.4 1.1 0 2 0 72 8 2 
Unclassified inflammatory arthritis 628.4 1.6 0 12 30 100 1 1 
Unclassified inflammatory arthritis 19.4 1.8 0 26 11 58 2 2 
Unclassified inflammatory arthritis 22.4 0.4 0 2 0 20 1 1 
Unclassified inflammatory arthritis 47.6 0.9 0 15 6 47 3 0 
Unclassified inflammatory arthritis 22.3 2.8 0 NA 50 36 1 0 
Unclassified inflammatory arthritis 22.3 0.5 0 0 0 30 2 2 
Unclassified inflammatory arthritis 13.6 2 29.8 43 18 24 7 1 
Unclassified inflammatory arthritis 22.0 1.5 21.5 123 132 80 1 1 
Unclassified inflammatory arthritis 16.0 1 0 NA 13 45 7 3 
Unclassified inflammatory arthritis 321.9 0.8 0 13 3 51 2 2 
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Diagnosis Symptom 
duration 
(weeks) 
CCP RF ESR CRP Global TJC 28 SJC 28 
Unclassified inflammatory arthritis 104.3 Not Done 0 2 1 18 18 7 
Unclassified inflammatory arthritis 11.7 8 33.2 8 6 51 7 5 
Psoriatic arthritis 16.1 0.9 0 16 14 79 4 0 
Psoriatic arthritis 5.7 1.2 0 40 13 53 16 15 
Psoriatic arthritis 32.9 0.4 14.2 2 0 23 7 5 
Psoriatic arthritis 102.3 0.7 0 5 0 29 2 0 
Psoriatic arthritis 51.0 Not Done 72.2 35 6 93 22 21 
Psoriatic arthritis 8.4 1.7 0 2 0 14 14 10 
Psoriatic arthritis 8.7 1 0 5 4 78 4 0 
Psoriatic arthritis 22.3 1.2 0 37 20 65 2 1 
Inflammatory arthralgia 109.3 0.9 0 2 8 11 1 0 
Inflammatory arthralgia 18.4 >340 261 26 13 50 1 0 
Inflammatory arthralgia 6.9 0.9 0 2 5 68 14 0 
Inflammatory arthralgia 12.0 227 234 2 0 5 1 0 
Inflammatory arthralgia 43.6 0.5 63 -9 0 21 1 0 
Inflammatory arthralgia 14.7 1 0 27 12 51 3 0 
Inflammatory arthralgia 39.9 1 0 2 0 49 0 0 
Inflammatory arthralgia 13.0 Not Done Not Done NA 0 58 5 0 
Inflammatory arthralgia 10.1 1.9 11 NA 6 69 4 0 
Inflammatory arthralgia 17.0 1.4 0 NA 5 59 0 0 
Inflammatory arthralgia 441.7 0.8 231 5 5 25 0 0 
Inflammatory arthralgia 42.4 0.8 0 26 NA 75 8 0 
Inflammatory arthralgia NA 1.4 0 5 7 25 5 0 
Inflammatory arthralgia 17.9 0.9 NA NA NA 70 6 0 
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Diagnosis Symptom 
duration 
(weeks) 
CCP RF ESR CRP Global TJC 28 SJC 28 
Inflammatory arthralgia 36.3 1.3 0 17 4 3 2 0 
Inflammatory arthralgia 25.1 1 NA 20 15 54 2 0 
Inflammatory arthralgia 117.6 1.3 NA -9 8 80 1 0 
Palindromic rheumatism 17.6 161 20 8 12 9 1 0 
Palindromic rheumatism 11 >340 13.1 5 18 20 0 0 
Diagnosis not given 260.9 >340 70.6 27 0 NA 15 17 
 
Table 8.3 Patient clinical information collected from those used during the plasma ELISA experiments. Abbreviations used 
throughout the tables; CCP, Cyclic Citrullinated Peptide; RF, Rheumatoid Factor; ESR, Erythrocyte Sedimentation Rate; CRP, C-Reactive 
Protein; Global, Global Arthritis Score; SWJ28, Swollen Joint Count of 28 joints; TJC28, Tender Joint Count of 28 joints; N, Negative; P, 
Positive; and NA, Not Available.  
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Line Diagnosis Site Gender RF CCP ESR CRP Age Disease 
duration 
(years) 
Disease 
duration 
(weeks) 
DAS28 SJC28 TJC28 
ST01SY Osteoarthritis Knee F NA NA 33 0 63 8 - NA NA NA 
ST02SY Osteoarthritis Knee F NA NA 32 11 67 8 - NA NA NA 
ST04SY Osteoarthritis Hip M NA NA 10 10 71 7 - NA NA NA 
ST08SY Osteoarthritis NA M NA NA NA NA 73 10 - NA NA NA 
ST09SY Osteoarthritis Knee F NA NA NA NA 72 30 - NA NA NA 
RA02SY J Rep Est RA Knee F P NA 70 46 52 20 - 4.39 2 2 
RA05SY J Rep Est RA Knee F P NA 63 62 62 20 - 6.84 11 9 
RA12SY J Rep Est RA Hip F P NA 21 21 32 3 - 4.77 14 1 
RA16SY J Rep Est RA Knee F P NA 37 33 30 15 - 6.50 19 12 
BX087 Early Resolving  Ankle M NA N 37 28 27 - 4 3.76 2 2 
BX127 Established RA Ankle F P N 70 112 60 - 45 5.20 10 5 
BX128 Established RA Wrist F P P NA NA 51 - 36 NA NA NA 
BX130 Early RA Ankle F P N NA NA 61 - 12 NA NA NA 
 
Table 8.4 Clinical information collected from patients used in Figure 5.9. Abbreviations used throughout the tables; J Rep Est RA, 
Joint replacement established RA; CCP, Cyclic Citrullinated Peptide; RF, Rheumatoid Factor; ESR, Erythrocyte Sedimentation Rate; CRP, 
C-Reactive Protein; DAS28, Disease Activity Score in 28 joints; SWJ28, Swollen Joint Count of 28 joints; TJC28, Tender Joint Count of 
28 joints; N, Negative; P, Positive; and NA, Not Available.  
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Line Diagnosis Site Gender RF CCP ESR CRP Age Disease 
duration 
(years) 
Disease 
duration 
(weeks) 
DAS28 SJC28 TJC28 
RA05SY J Rep Est RA Knee F P NA 63 62 62 20 - 6.84 11 9 
RA06SY J Rep Est RA Knee M P NA 54 75 60 30 - 6.4 11 12 
RA07SY J Rep Est RA Knee F P NA NA NA 71 - 52 NA NA NA 
RA11SY J Rep Est RA Knee F P NA NA NA 62 - 1040 NA NA NA 
RA18SY J Rep Est RA Knee M P NA 57 45 47 23 - 3.8 1 1 
BX070 Normal Knee M N N NA NA 44 NA NA NA 0 0 
BX081 Normal Knee F N N NA NA 58 NA NA NA 0 0 
BX082 Normal Knee F N N NA NA 49 NA NA NA 0 0 
BX083 Normal Knee M N N NA NA 42 NA NA NA 0 0 
BX094 Normal Knee F NA NA NA NA 46 NA NA NA NA NA 
 
Table 8.5 Clinical information collected from patients used in Figure 5.10. Abbreviations used throughout the tables; J Rep Est RA, 
Joint replacement established RA; CCP, Cyclic Citrullinated Peptide; RF, Rheumatoid Factor; ESR, Erythrocyte Sedimentation Rate; CRP, 
C-Reactive Protein; DAS28, Disease Activity Score in 28 joints; SWJ28, Swollen Joint Count of 28 joints; TJC28, Tender Joint Count of 
28 joints; N, Negative; P, Positive; and NA, Not Available.  
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ABSTRACT
Background and objectives For our understanding
of the pathogenesis of rheumatoid arthritis (RA), it is
important to elucidate the mechanisms underlying early
stages of synovitis. Here, synovial cytokine production
was investigated in patients with very early arthritis.
Methods Synovial biopsies were obtained from
patients with at least one clinically swollen joint within
12 weeks of symptom onset. At an 18-month follow-up
visit, patients who went on to develop RA, or whose
arthritis spontaneously resolved, were identiﬁed. Biopsies
were also obtained from patients with RA with longer
symptom duration (>12 weeks) and individuals with no
clinically apparent inﬂammation. Synovial mRNA
expression of 117 cytokines was quantiﬁed using PCR
techniques and analysed using standard and novel
methods of data analysis. Synovial tissue sections were
stained for CXCL4, CXCL7, CD41, CD68 and von
Willebrand factor.
Results A machine learning approach identiﬁed
expression of mRNA for CXCL4 and CXCL7 as
potentially important in the classiﬁcation of early RA
versus resolving arthritis. mRNA levels for these
chemokines were signiﬁcantly elevated in patients with
early RA compared with uninﬂamed controls.
Signiﬁcantly increased CXCL4 and CXCL7 protein
expression was observed in patients with early RA
compared with those with resolving arthritis or longer
established disease. CXCL4 and CXCL7 co-localised with
blood vessels, platelets and CD68+ macrophages.
Extravascular CXCL7 expression was signiﬁcantly higher
in patients with very early RA compared with longer
duration RA or resolving arthritis
Conclusions Taken together, these observations
suggest a transient increase in synovial CXCL4 and
CXCL7 levels in early RA.
INTRODUCTION
The rheumatoid synovium is characterised by a
complex inﬂammatory inﬁltrate, which can either
be highly structured with distinct features of lymph-
oid neogenesis or comprise a more diffuse inﬁltrate.
There is considerable evidence that cytokines pro-
duced by the synovial inﬁltrate play an important
role in the orchestration of both the development
and the resolution of synovial inﬂammation.1 Since
there is evidence that therapeutic outcome in
rheumatoid arthritis (RA) is inﬂuenced by the time
elapsed before initiation of therapy, there is a con-
siderable clinical need to diagnose patients with
early disease.2–4 Due to the important role of cyto-
kines in the regulation of the inﬂammatory inﬁltrate
and the need to understand and diagnose early RA,
this study systematically addresses the level of
mRNA expression of a wide range of cytokines in
the early stages of synovial inﬂammation.
In order to capture a population of patients in a
time frame close to the onset of clinically apparent
joint inﬂammation, patients with at least one clinic-
ally swollen joint were seen within 12 weeks of the
onset of any symptom attributed, by the assessing
rheumatologist, to an inﬂammatory arthritis. At this
time, among a range of other investigations per-
formed within the Birmingham Early Inﬂammatory
Arthritis Cohort (BEACON), ultrasound-guided
biopsies were taken. At an 18-month follow-up visit,
patients who had progressed to RA as classiﬁed
according to the 1987 American College of
Rheumatology (ACR) criteria5 or had resolving
disease were identiﬁed for this study. Furthermore,
patients from the same clinic who were disease-
modifying antirheumatic drug (DMARD) naive but
had synovitis for >12 weeks, as well as patients
attending a clinic due to mechanical joint problems
without any clinically observed inﬂammation, were
investigated as control groups.
Proﬁling of cytokine mRNA expression led to
the ﬁnding that the chemokines CXCL4 and
CXCL7 are expressed during the earliest phase of
RA, but not in patients with resolving arthritis or
established RA. We found that both chemokines,
which are classically regarded as platelet-derived
chemokines, were also expressed on macrophages
in the synovium, implicating a previously unde-
scribed role for this cell type in the earliest clinic-
ally evident stages of RA.
PATIENTS AND METHODS
Study participants
Patients with early arthritis were seen in the
BEACON cohort; details of this clinic have been
reported previously.6 Patients were eligible for the
early arthritis cohort if they had at least one clinic-
ally swollen joint, were seen within 12 weeks of the
onset of any symptom attributed by the assessing
rheumatologist to an inﬂammatory arthritis and had
not been treated with either DMARD or glucocorti-
coids prior to referral. Patients underwent a 68-joint
clinical examination.7 Patients with a joint amenable
to ultrasound-guided biopsy8 were recruited for this
study. Following the biopsy, patients were followed
Yeo L, et al. Ann Rheum Dis 2015;0:1–9. doi:10.1136/annrheumdis-2014-206921 1
Basic and translational research
 ARD Online First, published on April 9, 2015 as 10.1136/annrheumdis-2014-206921
Copyright Article author (or their employer) 2015. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. 
group.bmj.com on April 10, 2015 - Published by http://ard.bmj.com/Downloaded from 
for up to 18 months. Patients were identiﬁed for inclusion in the
study if they were classiﬁed as having RA according to 1987 ACR
criteria,5 or a resolving arthritis deﬁned as the absence of clinic-
ally apparent synovial swelling at ﬁnal assessment with no
DMARDs or glucocorticoids having been used for the previous
three months. A small number of patients developed chronic
inﬂammatory diseases of the joint other than RA (table 1). As a
control group, we included patients with RA with disease dur-
ation (deﬁned as the time from the onset of any symptom attribu-
ted by the assessing rheumatologist to an inﬂammatory arthritis)
of >12 weeks who fulﬁlled the 1987 ACR criteria5 at the time of
biopsy. Similarly to patients with early arthritis, those with RA of
>12 weeks’ duration were all DMARD and glucocorticoid naive
and synovial tissue was obtained by ultrasound-guided biopsy. As
a further control group, we included ‘uninﬂamed controls’ who
underwent knee arthroscopy because of unexplained joint pain.
None of these subjects showed inﬂammatory or degenerative
joint pathology upon physical examination or arthroscopy. All
researchers involved in the investigation of biopsies either at
mRNA or protein level were blinded to patient outcome
throughout the study.
Ultrasound-guided synovial biopsy
Prior to biopsy, joints were assessed using a Siemens Acuson
Antares scanner (Siemens, Bracknell, UK) and multifrequency
(5–13 MHz) linear array transducers; for details, see Filer et al.7
Ultrasound-guided biopsy was used to collect tissue from mul-
tiple regions within knee, ankle or metacarpophalangeal (MCP)
joints in which there was evidence of grey-scale synovitis.
Ultrasound guidance was used to introduce a single portal
through which tissue was sampled using custom manufactured
2.0 mm cutting-edged forceps or a 16 g core biopsy needle
(MCP joint).9 Frozen blocks were assembled for processing
from six individual biopsies in order to overcome synovial het-
erogeneity.8 10–12
Synovial tissue cytokine mRNA real-time PCR analysis
TaqMan low-density real-time PCR arrays (Applied Biosystems,
Paisley, UK) were designed to determine expression of 117 cyto-
kines and cytokine-related molecules (for full details, see online
supplementary table S1). RNA was extracted from synovial
tissue sections using an RNeasy RNA extraction kit (Qiagen,
Crawley, UK). RNA from synovial tissue used in the low-density
array for genes with non-intron spanning primers was treated
with DNase (Qiagen). A reaction mixture containing RNA,
QuantiTect-RT Master Mix (Qiagen) and QuantiTect Reverse
Transcriptase (Qiagen, Crawley, UK) was added to a TaqMan
low-density array microﬂuidic card. Six times more RNA was
loaded into microﬂuidic cards designed for weakly expressed
genes and genes with non-intron spanning primers (see online
supplementary table S1). Reverse transcription and real-time
PCR was performed in a 7900HT Real-Time PCR System
(Applied Biosystems). Relative gene expression (RQ) was
expressed as 2−ΔCt, where ΔCt represents the difference in Ct
between glyceraldehyde-3-phosphate dehydrogenase and the
target gene. Validation experiments established the reproducibil-
ity of quantitation and a combination of positive controls from
anti-CD3/anti-CD28-activated lymphocytes and commercially
available control mRNA from human cell lines representing dif-
ferent tissues (Stratagene) were used to ascertain that all cyto-
kines listed could be detected.
GMLVQ analysis of cytokine mRNA proﬁles
Cytokine mRNA data were log-transformed and all zero values
were replaced by 0.00002, the smallest non-zero expression
value in the data. This yielded 117 log-transformed expression
values per patient. These data were analysed by applying a com-
bination of principal component analysis and learning vector
quantisation (LVQ), a distance-based classiﬁcation technique,
which determines class representatives from a set of example
data in an iterative training process. Example data corresponded
to the individual cytokine proﬁles observed within the four
classes of patients. Matrix relevance LVQ identiﬁes a suitable
distance measure, which is discriminative with respect to the dif-
ferent classes. The speciﬁc technique used was generalised
matrix relevance LVQ (GMLVQ), a variant that optimises the
distance measure with respect to its discriminative power.13
Further details on this methodology can be found in online sup-
plementary method 1.
Immunoﬂuorescence
Frozen sections from synovial biopsies taken from patients with
resolving arthritis, early RA and established RA were stained
with antibodies speciﬁc for CXCL4 (Abcam, UK) or CXCL7
Table 1 Demographic and clinical characteristics of study participants used for cytokine and chemokine mRNA real-time PCR low-density arrays
Uninflamed Resolving arthritis Early RA Established RA
Number 10 9 17 12
Symptom duration (weeks); median (IQR) na 5 (2–9) 6 (4–9) 38 (27–52)
Female; n (%) 5 (50) 3 (33) 12 (71) 6 (50)
Age years; median (IQR) 43 (37–48) 40 (30–69) 53 (48–59) 60 (48–67)
RF and/or anti-CCP positive; n (%) na 0 (0) 8 (47) 7 (58)
Global disease-related variables
CRP; median (IQR) na 10 (8–22) 12 (5–32) 17 (7–52)
ESR; median (IQR) na 24 (8–48) 25 (14–58) 28 (12–55)
DAS28; median (IQR) na 4.1 (3.4–4.6) 4.7 (4.2–6.0) 5.4 (4.7–6.6)
Biopsied joint-related variables
Joint biopsied
Ankle; n (%) 0 (0) 3 (33.3) 4 (24) 2 (17)
Knee; n (%) 10 (100) 6 (66.6) 10 (59) 10 (83)
MCP joint; n (%) 0 (0) 0 (0) 3 (18) 0 (0)
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; na, not available;
RF, rheumatoid factor.
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(Novus Biologicals, UK), and CD41 (Dako, UK), CD68
(Thermo Scientiﬁc Pierce, UK) and von Willebrand factor
(vWF) (Dako, UK). Staining with isotype-matched, species-
matched and concentration-matched negative controls was per-
formed in parallel. Secondary antibodies used were goat antirab-
bit Chromeo 494 (Abcam, UK), Cy3-conjugated streptavidin
( Jackson Immunoresearch, USA), goat antimouse Alexa Fluor
488 ( Jackson Immunoresearch, USA) and goat antimouse Cy5
(Southern Biotechnology, USA). Immunoﬂuorescence was visua-
lised using a Zeiss LSM 780 Zen Confocal and analysed using
Zeiss imaging software (Zeiss, Germany). Five to six 2×2 tile
scans were taken from each section at ×400 total magniﬁcation.
Regions were drawn around tissue; areas with folding or bleed-
ing into tissue caused during biopsy collection/processing were
excluded from analysis. As readout, pixels per unit area were
calculated.
RESULTS
Study participants
Details of study participants used for cytokine mRNA proﬁling
and immunoﬂuorescence studies are shown in tables 1 and 2,
respectively. The symptom durations of patients with early arth-
ritis highlight that this population was captured very soon after
the onset of their clinically apparent disease (median 5 weeks
for those with resolving disease and 6 weeks for those with
early RA in the patients who provided samples for cytokine
mRNA proﬁling; median 6 weeks for those with resolving
disease and 7 weeks for those with early RA in the patients who
provided samples for immunoﬂuorescence studies).
Synovial cytokine mRNA expression proﬁles in early arthritis
The mRNA expression of a panel of 117 cytokines and related
molecules was assessed in synovial biopsies using low-density
real-time PCR arrays. Subject groups investigated were patients
with resolving arthritis (n=9), patients with very early RA
(n=17), patients with established RA (>3 months’ symptom
duration; n=12) and uninﬂamed control subjects (n=10).
Twenty-two genes were identiﬁed as being differentially
expressed between subject groups by Kruskal–Wallis and Dunn’s
post-test analysis, shown in ﬁgure 1A. Eighteen of these genes
were more highly expressed in patients with established RA
compared with the uninﬂamed controls. Of interest, both
CXCL4 and CXCL7 mRNA levels were found to be signiﬁcantly
elevated in patients with early RA compared with uninﬂamed
controls, and showed a trend towards higher expression in early
RA compared with patients with resolving arthritis. Intriguingly
there was also a trend towards higher expression in early RA
compared with established RA, suggesting an increase in CXCL4
and CXCL7 levels in the early phase of disease in patients whose
arthritis persisted versus those whose arthritis resolved. No sig-
niﬁcant differences were observed in CXCL4 and CXCL7
expression between cyclic citrullinated peptide (CCP)-positive
and CCP-negative patients in either the early RA or established
RA groups (see online supplementary ﬁgure S2). When cytokine
and chemokine mRNA expression was ranked by their difference
in expression between resolving arthritis and early RA groups,
CXCL4 and CXCL7 were ranked highly in showing differential
expression between the two groups (ﬁgure 1B).
Machine learning classiﬁcation selection of differentiating
cytokines and chemokines
We applied a novel strategy of multivariate analysis to test
whether combinations of gene expression signals rather than
individual cytokine mRNA signals could distinguish synovium
from patients with self-limiting arthritis from those with early-
stage RA. Matrix relevance GMLVQ analysis was applied to
the cytokine mRNA data to achieve classiﬁcation of samples by
determining a discriminative distance measure that characterises
differences between subject groups. For classiﬁcation of the
established RA and uninﬂamed groups, analysis of the obtained
relevance matrix revealed that the 10 most informative
genes in discriminating patients with established RA from unin-
ﬂamed controls were CXCL7, CXCL4, IL1B, MST1, CCL20,
IL8, LGALS12, LTA, CXCL13 and OSM (ﬁgure 2A). Receiver-
operating characteristic (ROC) analysis was used to assess the
performance of classiﬁer models for group classiﬁcation. For
the established RA and uninﬂamed group classiﬁcation,
GMLVQ yielded an area under the curve (AUC) of 0.996
(ﬁgure 2B). For classiﬁcation of the early RA and resolving
arthritis groups, the 10 most informative genes corresponded
to CXCL7, CXCL4, MST1, CCL20, LGALS12, IL8, IL1B,
CXCL1, LTA and IL1RN (ﬁgure 2C). ROC analysis yielded
Table 2 Demographic and clinical characteristics of study participants used for detection of CXCL4 and CXCL7 by immunofluorescence
Resolving arthritis Early RA Established RA Early non-RA
Number 9 10 11 5
Symptom duration (weeks); median (IQR) 6 (3–7) 7 (4.8–9.3) 45 (16–53) 7 (2–8.5)
Female; n (%) 3 (33) 5 (50) 6 (55) 2 (40)
Age, years; median (IQR) 37 (33–65) 58 (50–65) 62 (57–65) 41 (37–56)
RF and/or anti-CCP positive; n (%) 0 (0) 4 (40) 6 (55) 1 (20)
Global disease-related variables
CRP; median (IQR) 8 (3–13.5) 26 (7.5–58) 10 (0–79) 25 (18.5–54)
ESR; median (IQR) 18 (5.5–51) 19 (4.75–39.25) 50 (34–70) 44 (24–73.5)
DAS28; median (IQR) 4.1 (3.4–5.7) 4.7 (3.8–5.8) 5.2 (4.6–7.5) 4.8 (4.1–6.4)
Biopsied joint-related variables
Joint biopsied
Ankle; n (%) 2 (22) 2 (20) 3 (27) 2 (40)
Knee; n (%) 7 (78) 7 (70) 8 (73) 3 (60)
MCP joint; n (%) 0 (0) 1 (10) 0 (0) 0 (0)
Early non-RA group: psoriatic arthritis n=2, sarcoidosis n=1, ankylosing spondylitis n=1, unclassified n=1.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; na, not available;
RF, rheumatoid factor.
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an AUC of 0.764 (ﬁgure 2D). In both cases, CXCL4
and CXCL7 played dominant roles in terms of discriminative
power.
CXCL4 and CXLC7 protein expression in synovial tissue
Since cytokine mRNA proﬁling suggested an upregulation of
CXCL4 and CXCL7 expression in patients with early RA, we
Figure 1 Cytokine and chemokine mRNA expression in synovial biopsies from uninﬂamed controls and patients with resolving arthritis, early
rheumatoid arthritis (RA) and established RA. (A) Synovial tissue sections were assessed from uninﬂamed controls (n=10) and patients with
resolving arthritis (n=9), early RA (n=17) and established RA (n=12). Data for genes for which the Kruskal–Wallis and Dunn’s post-test showed
signiﬁcant difference between the four groups are shown. * p<0.05, ** p<0.01, ***p<0.001. (B) Cytokine and chemokine genes were ranked by
difference in mRNA expression between resolving arthritis and early RA groups. Means of each group are represented in the heat map. Green
represents low and red high relative expression (z-score of mean expression levels).
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next sought to test whether expression of these chemokines was
also elevated at the protein level. CXCL4 and CXCL7
were stained in synovial tissue sections from patients with
resolving arthritis (n=9), early RA (n=10) and established RA
(n=11), and staining was visualised by immunoﬂuorescence.
Representative images of staining of CXCL4 and CXCL7 in the
synovium are shown in ﬁgure 3A, B. Synovial tissue sections
were co-stained for CD68 to identify macrophages, CD41 to
identify platelets and vWF to identify vascular endothelial cells.
Both CXCL4 and CXCL7 were found to be expressed in the
synovium of all subject groups examined. However, expression
of both CXCL4 and CXCL7 was signiﬁcantly elevated in
patients with early RA compared with patients with resolving
arthritis (CXCL4 and CXCL7; p<0.05) and patients with estab-
lished RA (CXCL4 and CXCL7; p<0.05; ﬁgure 3C), which
supported the ﬁndings made at the mRNA level. Quantiﬁcation
of protein levels of CD41, which is speciﬁcally expressed by pla-
telets, did not show signiﬁcant differences (data not shown).
The groups of patients investigated in the cytokine mRNA pro-
ﬁling and those tested for immunoﬂuorescence studies were par-
tially overlapping. Protein data from seven patients who were
not investigated in the mRNA study also showed a higher level
of CXCL4 and CXCL7 protein expression in the patients with
early RA compared with those with established disease (see
online supplementary ﬁgure S3A and B). A small number of
patients developed chronic inﬂammatory joint diseases other
than RA (table 2). Their CXCL4 and CXCL7 levels are shown
in online supplementary ﬁgures S3C, D.
In the synovium of all subject groups studied, CXCL4 and
CXCL7 staining was found to co-localise with CD68 staining,
indicating an association of both of these chemokines with
macrophages (ﬁgure 4A, B). As expected, CXCL4 and CXCL7
staining was also observed on CD41-expressing platelets
(ﬁgure 3). To further investigate this ﬁnding, synovial tissue
samples were stained for vWF and expression of CXCL4 and
CXCL7 was quantiﬁed inside and outside of the vasculature.
Quantiﬁcation of positive pixels showed that CXCL4 and
CXCL7 were found predominantly outside the vasculature
(ﬁgure 5A, B). In addition, the speciﬁcity of the CXCL7 staining
was conﬁrmed by inhibition of staining with preincubation of the
antibody with recombinant CXCL7 (see online supplementary
ﬁgure S1).
Figure 2 Generalised matrix relevance learning vector quantisation-based discrimination of subject groups (A) All 117 cytokine/chemokine genes
used to classify uninﬂamed controls versus patients with established rheumatoid arthritis (RA). The 10 genes most informative in discriminating
groups are indicated. (B) Receiver-operating characteristic (ROC) characteristics of the obtained classiﬁers for uninﬂamed controls and patients with
established RA. (C) Classiﬁcation cytokine mRNA signals in resolving arthritis versus patients with early RA. The 10 genes most informative in
discriminating groups are indicated. (D) ROC characteristics of the obtained classiﬁers for patients with resolving arthritis and early RA. AUC, area
under the curve.
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DISCUSSION
In this study, we have identiﬁed two chemokines, CXCL4 and
CXCL7, which are expressed in the earliest clinically apparent
stage of RA. They were predominantly detected on macrophages
inﬁltrating the synovium, indicating a previously undescribed
role for this cell type in contributing to RA pathogenesis in the
very early phase of disease.
Macrophages are found in large numbers throughout the
rheumatoid synovium. Type A synoviocytes are macrophage-
derived cells that constitute part of the healthy synovial lining
while large numbers of activated macrophages are found in the
inﬂammatory inﬁltrate in the sublining and at the pannus–
cartilage interface. The origin of these cells is a matter of
debate; they could derive from the proliferation of tissue-based
macrophages or from circulating monocytes entering from the
blood stream.14–17 Macrophages are important contributors to
inﬂammation and joint destruction due to their production of
proinﬂammatory mediators and tissue-degrading enzymes.
Figure 3 Immunoﬂuorescence staining of CXLC4 and CXCL7 in synovial tissue sections. (A) Synovial tissue staining of CXCL4 (red), CD68 (blue),
CD41 (green) and von Willebrand factor (vWF) (orange). (B) Synovial tissue staining of CXCL7 (red), CD68 (blue), CD41 (green) and vWF (orange).
Nuclear counterstain is shown. Images are representative of early rheumatoid arthritis (RA) synovium (n=10). No staining was observed using
isotype and concentration-matched negative controls. Images were taken at ×40 magniﬁcation. (C) Quantiﬁcation of CXCL4 and CXCL7 staining,
calculated as the number of pixels per μm2 over 6× 2×2 tile scans at ×40 magniﬁcation, in synovial tissue sections from patients with resolving
arthritis (n=9), early RA (n=10) and established RA (n=11). Patients with early RA showed a signiﬁcantly higher level of CXCL4 (p<0.05) and CXCL7
(p<0.05) compared with patients with resolving arthritis and established RA. Kruskal–Wallis and Dunn’s post-test; * p<0.05, ** p<0.01.
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Furthermore, the number of synovial macrophage has been
found to correlate with joint erosion in RA while changes in the
numbers of CD68+ macrophages correlate with therapeutic
success of a range of therapies.18–20
CXCL4 is chemotactic for neutrophils, ﬁbroblasts and mono-
cytes, prevents monocyte apoptosis, induces differentiation of
monocytes into macrophages and enhances monocyte phagocyt-
osis and oxygen radical production.21–24 CXCL7 is involved in
neutrophil chemotaxis and activation, and activates connective
tissue cells.25 The functions described for CXCL4 and CXCL7
suggest that in RA these chemokines could not only exacerbate
synovial inﬂammation but also promote its chronicity by attract-
ing monocytes to the inﬂamed tissue and activating them fol-
lowing recruitment to the synovium. Our ﬁnding that CXCL4
and CXCL7 are highly expressed during the ﬁrst 12 weeks of
synovitis in patients who develop RA but are found at lower
levels in longer duration RA may reﬂect local pathological
changes occurring during this critical phase, which has been
described as the therapeutic ’window of opportunity’. A similar
phenomenon was recently reported by van Bon et al,26 who
demonstrated high levels of CXCL4 expression in patients at an
early stage of systemic sclerosis.
Previous studies have suggested roles for CXCL4 and CXCL7
in RA. Elevated levels of CXCL7 have been reported in the
serum, synovial ﬂuid and synovial tissue of patients with
RA.27 28 While CXCL7 promotes angiogenesis, CXCL4 has an
antiangiogenic effect.29 The elevated expression of the angio-
static chemokine CXCL4 during the early phase of disease may
reﬂect an attempt to prevent or minimise the ﬁrst signs of angio-
genesis that takes place in the RA synovium.
In our study, CXCL4 and CXCL7 expression in the synovium
was found to be predominantly localised to CD68+ macro-
phages, with less co-localisation observed with platelets. Where
CXCL4 and CXCL7 expression was seen to co-localise with pla-
telets in the synovium, this was mainly conﬁned to vessel
thrombi. The genes for CXCL4 and CXCL7 are located in a
Figure 4 Co-localisation of CXCL4 and CXCL7 with CD68-positive cells. (A) Synovial tissue staining of CXCL4 (red) and CD68 (blue) and (B)
staining of CXCL7 (red) and CD68 (blue) showed co-localisation of both cytokines with macrophages. Image representative of rheumatoid arthritis
synovium (n=10).
Figure 5 Expression of CXCL4 and CXCL7 in the synovium is predominantly found outside the vasculature. Staining of CXCL4 and CXCL7 in
synovial tissue sections was quantiﬁed inside and outside of the vasculature, as assessed by co-staining with von Willebrand factor. Expression of
both chemokines was signiﬁcantly elevated outside the vasculature. RA, rheumatoid arthritis. Kruskal–Wallis test, Dunn’s post-test; *p<0.05,
***p<0.001.
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gene cluster comprising several CXC chemokines in a locus on
chromosome 4,30 31 which was once considered to be
megakaryocyte-speciﬁc. However, other studies have reported
that expression of these chemokines is not restricted to the
megakaryocyte lineage. A recent study using a PF4-Cre mouse
model reported that CXCL4 could be produced by both
myeloid and lymphoid lineages, with CXCL4 transcripts
detected in adult haematopoietic stem cells.32 In a similar
reporter gene model, CXCL4 expression was shown in mature
murine macrophages.33 Furthermore, Schaffner et al34 reported
expression of CXCL4 by human monocytes and found that
CXCL4 expression was upregulated upon monocyte activation.
Intriguingly, a recent study reported CXCL4 expression by acti-
vated T cells that limited Th17 differentiation.35 Monocytes
have been described to constitutively transcribe and translate
CXCL7, which is processed intracellularly into several deriva-
tives known to have signalling and effector functions.36
Together this evidence is supportive of our ﬁnding that CXCL4
and CXCL7 is associated with and may be produced directly by
macrophages in the synovium during very early RA.
Interest in chemokines in RA has been revived by ﬁndings
such as detection of citrullinated chemokines in RA synovial
ﬂuid that have enhanced chemotactic activity37 and the prospect
of using antichemokine targeting for therapeutic purposes.38 39
We have interpreted the high levels of CXCL4 and CXCL7
found in early RA compared with resolving arthritis or estab-
lished RA to represent a transient upregulation of these cyto-
kines based on a cross-sectional analysis of samples; it would be
interesting to conﬁrm the transient nature of this upregulation
in a longitudinal study. However, the ethical implications would
make an observational study of the evolution of synovial tissue
pathology from early to established RA in the absence of
therapeutic intervention impossible to conduct in patients. In
the future, it will be important to investigate whether the pro-
duction of CXCL4 and CXCL7 observed in the synovium in
early RA is reﬂected by elevated levels in plasma samples. Future
use of these chemokines as biomarkers for prediction of pro-
gression to RA will depend on replication in other independent
cohorts.
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